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Abstract 
In this work, trans-diazido Pt(IV) complexes with general formula 
[Pt(N3)2(OH)(OCOR)(pyr)2] (where OCOR is a carboxylate axial ligand) and 
[Pt(N3)2(OH)2(L1)(L2)] (where L1 and L2 are aromatic N-heterocyclic ligands) 
have been synthesised and characterised. The chemical and photochemical 
properties of these complexes, as well as their photobiological behaviour, have 
been studied in order to check their potential as photoactivatable anticancer drugs. 
Four trans-diazido Pt(IV) complexes with general formula trans, trans, trans-
[Pt(N3)2(OH)(OCOR)(pyr)2] (OCOR= succinate, 4-oxo-4-propoxybutanoate, N-
methylisatoate and succinate-(RGD)f peptide ligands) have been obtained by axial 
derivatisation of one hydroxido ligand from trans, trans, trans-
[Pt(N3)2(OH)2(pyr)2]. The crystal structures of three axially-derivatised complexes 
have been determined by X-ray diffraction. Photoirradiation studies have shown 
an improved photoactivity of the carboxylate versus the dihydroxido complexes at 
the longer wavelengths. Release of the axial ligands was observed in the studied 
complexes. This fact is especially relevant in the case of the Pt(IV)-(cRGD)f 
complex, where the RGD was incorporated as a tumour cell targeting moiety. 
DFT-TDDFT calculations performed on the complex trans, trans, trans-
[Pt(N3)2(OH)(Succ)(pyr)2] showed dissociative transitions at longer wavelength, 
which could explain the photolability observed in these carboxylate derivatives. 
Studies of photoactivation of the diazido Pt(IV) complexes in the presence of 5’-
GMP indicate the formation of a mono-GMP Pt(II) adduct as main photoproduct, 
therefore DNA could be considered a potential target site for these anticancer 
compounds. Additionally, EPR studies showed that azidyl radical release was 
observed when complexes bearing the succinate and 4-oxo-4-propoxybutanoate 
ligands were irradiated with green light. No such result was obtained for the 
dihydroxo precursor showing that these complexes could be phototoxic with 
longer wavelength light activation.  
Seven trans-diazido Pt(IV) complexes, trans, trans, trans-
[Pt(N3)2(OH)2(L1)(L2)] (where L1 and L2 are pyridine, 2-picoline, 3-picoline, 4-
picoline, thiazole or 1-methylimidazole ligands), have been obtained by oxidation 
of the corresponding trans-[Pt(N3)2(L1)(L2)] precursor. The X-ray crystal 
vii 
 
structures have been determined for four Pt(IV) diazido complexes from this 
family of compounds. Photoirradiation studies indicate that the incorporation of a 
sterically demanding ligand, e.g. trans, trans, trans-[Pt(N3)2(OH)2(2-pic)(pyr)], 
greatly enhances the photoactivity in these complexes. DFT-TDDFT calculations 
are in agreement with these results, since higher intensity transitions were 
observed for such complex at longer wavelength. 
Phototoxicity studies carried out on A2780, A2780cis and OE19 cell lines 
with the trans, trans, trans-[Pt(N3)2(OH)2(pyridine)(n-picoline)] family concluded 
that steric hindrance close to the platinum centre does not favour phototoxicity. 
Most of the complexes were equally potent in cisplatin resistance against the 
ovarian cancer cell line (A2780cis), except [Pt(N3)2(OH)2(3-pic)2] and 
[Pt(N3)2(OH)2(4-pic)2] which exhibited some cross resistance. All of the 
complexes tested in both OE19 and A2780 cell lines have shown less sensitivity 
to OE19 than to A2780. Studies in S. pombe yeast strains (WT and ΔRad3) with 
trans, trans, trans-[Pt(N3)2(OH)2(pyr)2] suggest that DNA is potentially an 
important target for this type of compounds, although other targets are not 
excluded. Furthermore, live-cell confocal microscopy was performed on A2780 
cells treated with the complex trans, trans, trans-[Pt(N3)2(OH)2(pyr)2] and 
irradiated with a low dose of blue light. The cell death, monitored by propidium 
iodide uptake, was captured occurring 2 h 30 min post activation. 
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1.1 Cancer  
There are more than 200 types of cancer which have as a common characteristic 
the uncontrolled cell growth. These are generated from a series of errors in vital 
signalling pathways which eventually generate a survival advantage over 
neighbouring cells. Subsequent cell division leads to a modified group of cells 
(cancer) which divide autonomously since they do not obey to any anti-growth 
signals. This uncontrolled cell growth allows the formation of tumours, which 
together with the capacity to spread across different tissues and organs, can be 
fatal.
1
 Statistics show that more than 1 in 3 people will develop some form of 
cancer in their lifetime, indicating an enormous prevalence.
2
 It is the leading cause 
of death in developed countries and the second cause of death in developing 
countries.
3
  
At the moment there are three main streams for the treatment of cancer: surgery 
(removal of solid tumour when localized in a specific tissue), radiotherapy 
(radiation with X-ray beam) and chemotherapy (use of antiproliferative drugs). 
Amongst the drugs used in the last category, platinum drugs are used to treat over 
40% of all cancer patients.
4,5
 For this reason, new and more advanced treatments 
involving platinum and other metallodrugs are likely to be greatly beneficial in 
enhancing the survival chances of cancer patients.  
1.2 Cisplatin 
Cisplatin (cis-[PtCl2(NH3)2], CDDP) was the first example of a platinum 
anticancer drug. Its antiproliferative effects were first reported by Rosenberg et al. 
in 1968.
6,7
 The drug was approved for clinical use by the FDA (Food and Drug 
Administration) in 1978, leading to an enormous improvement of survival rates of 
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testicular cancer from 10% to greater than 90%. Currently, it is routinely used for 
the treatment of bladder, advanced cervical cancer, non-metastatic non-small cell 
lung, ovarian carcinoma,  malignant mesothelioma, head and neck squamous cell 
carcinoma and testicular cancer.
8
 
After cisplatin is administered (in a saline solution), via blood perfusion, it 
remains in the neutral form due to high Cl
-
 concentration in the blood stream 
(>100 mM) which suppresses hydrolysis of the chlorides. Cellular uptake occurs 
through passive and active transport (partly via copper transporters).
9
 Once inside 
a cell, where the chloride concentration drops significantly (ca. 20 mM), aquation 
occurs, leading to DNA binding (Figure 1.1).  
It is widely accepted that the main target of cisplatin is cellular DNA to which it 
can bind to two proximal nucleobases forming intra and interstrand crosslinks. 
Most crosslinks are 1,2-GpG intrastrand (60-65%), whereas 1,2-ApG intrastrand 
account for another 20-25%. Less frequent are the 1,3-GpXpG intrastrand 
crosslinks (where there is another base between the two platinated guanines), the 
G-G interstrand crosslinks as well as monofunctional adducts.
10,11
 Formation of 
the 1,2-intrastrand crosslinks can kink the DNA structure, inhibiting DNA 
replication and transcription. These platinum-DNA lesions can be recognized by a 
number of nuclear proteins such as High Mobility Group-domain (HMG) proteins 
that protect them from nucleotide excision repair upon binding, finally leading to 
cell death.
9
 Recently, Lippard et al. illustrated that interstrand crosslinks, although 
low in abundance, have profound effects since they can inhibit transcription as 
efficiently as 1,2-intrastrand cross links and also inhibit DNA-histone sliding thus 
evading cellular repair.
12,13
 This suggests that this kind of lesion might have a 
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greater role in the antiproliferative capacities of cisplatin than previously 
suspected.  
Other pathways might also be responsible for the cytotoxicity of the drug. CDDP 
causes an increase in the levels of ROS (Reactive Oxygen Species). This effect is 
caused by the reaction of cisplatin with thiols (–SH containing molecules), which 
maintain the redox homeostasis within the cell.
14
 Furthermore, CDDP is able to 
block the enzyme Thioredoxin Reductase (TrxR), responsible for the reduction of 
disulfide bonds, and can alter the mitochondrial functioning, causing NADPH 
depletion, thus leading to an increase in OH· and O2·
-  
species.
15
 
 
Figure 1.1: Various pathways of cisplatin: uptake, aquation and inactivation 
pathways. Image modified from that in reference 9. 
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1.3 Cisplatin drawbacks and development of second and third generation 
Pt(II) agents 
Despite the clinical success of the drug, there are many disadvantages associated 
with cisplatin. One of the main drawbacks of CDDP, and other Pt(II) drugs, is the 
development of resistance, which can be inherent or acquired. The former is a 
result of spontaneous mutations occurring during cell division as part of intrinsic 
genetic instability and the latter is a result of initial exposure to the 
chemotherapeutic agent.
15
 The three main causes of acquired resistance are as 
follows:  
(a) Decreased drug uptake and/or increased efflux. It is generally accepted that 
active transport (e.g. via copper transporter) plays a major role in cisplatin uptake 
(Figure 1.1). Downregulation of these proteins or upregulation of the efflux 
proteins (e.g. ATP7A/B) leads to decreased sensitivity to the drug.
16,17
  
(b) Increased DNA repair (especially nucleotide excision repair which is the main 
repair mechanism for 1,2-GG intrastrand crosslinks) or bypassing DNA-Pt 
adducts during replication leads to a decrease in apoptotic response.
10
  
(c) Increased drug deactivation through elevated cellular amounts of glutathione 
and/or metallothioneins. The high affinity of platinum for sulphur makes the drug 
reactive towards the sulphur-containing molecules in the cell (e.g. GSH). 
Formation of the inactive adducts prohibits the drug from reaction with the DNA. 
Furthermore cisplatin produces serious side effects, including nephrotoxicity, 
nausea, renal toxicity, vomiting, hair loss and asthenia.
18
 Ultimately the 
therapeutic window is narrowed, thus making necessary the development of 
alternative treatments. Lastly cisplatin is not orally bioavailable and it needs to be 
administered intravenously.
8
  
Chapter 1: Introduction 
 
6 
 
Other strategies for the development of new Pt drugs have also been explored 
leading to the discovery of the second (changing the leaving group) and third 
generation (changing ammines) anticancer drugs. From all the newly-tested 
complexes, carboplatin, oxaliplatin, nedaplatin, heptaplatin and lobaplatin (Figure 
1.2) have found clinical approval, from which the former two are globally 
employed whereas the latter three are mainly used in Asia.
19
 Carboplatin is used 
for the same spectrum of cancers as cisplatin, but with the advantage of fewer side 
effects, whereas oxaliplatin responds to a different spectrum of cancers and has 
found a main applicability in colorectal cancer.
10
 Nevertheless, these platinum 
drugs still suffer from disadvantages, mainly the development of resistance and 
severe dose limiting side-effects.
5
   
 
Figure 1.2: Pt(II)-anticancer drugs approved for clinical use. 
 
Other strategies to potentiate platinum drugs are: increase delivery of the drugs to 
cancer cells via targeting, combination therapy, use of platinum resistance 
modulators or the development of new drugs that lack cross-resistance.
10
 
 
Chapter 1: Introduction 
 
7 
 
1.4 Non-conventional Pt(II) complexes 
The aforementioned Pt(II) complexes exert their mode of action by the formation 
of coordination bonds with the DNA, which are mainly 1,2-intrastrand 
crosslinks.
18
 In this section the mode of action of non-conventional Pt(II) drugs 
will be described, with a main focus on the monofunctional and trans-Pt(II) 
complexes.  
The term monofunctional implies that the complex can bind to DNA through only 
one coordination site (Figure 1.3 A). Although some monofunctional complexes, 
such as [Pt(NH3)3Cl]
+ 
and [Pt(dien)Cl]
+
 are inactive, it is believed this inactivity is 
because they fail to alter DNA synthesis via inhibition of DNA polymerase,
20
 
Hollis and co-workers reported that replacement of one chloride with a N-
heterocyclic ligand (pyridine, purine, pyrimidine, aniline) could afford 
compounds showing significant cytotoxicity.
21
 Further studies by Lippard et al. 
illustrated that the complex cis-[Pt(NH3)2(pyr)Cl]
+
, pyriplatin, is able to stall RNA 
polymerase II and has a different spectrum of activity than cisplatin.
22
 This 
molecule is uptaken by cells via Organic Cation Transporters (OCTs 1 and 2) and 
forms monofunctional adducts which are able to stall RNA polII.
9, 23
 These 
adducts can be repaired via NER mechanism (similarly to cisplatin) but less 
efficiently.
24
 The interesting properties of pyriplatin spurred on the synthesis of 
other monofunctional complexes, of which phenanthriplatin (Figure 1.3 B) was 
found to be the most promising, with a 4-40 fold lower IC50 compared with 
cisplatin or oxaliplatin.
25
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Figure 1.3: (A) Scheme illustrating the monofunctional DNA adduct formed by 
pyriplatin, with green and cyan representing the nondamaged and damaged 
strands, respectively. Taken from reference 26. (B) Structure of phenanthriplatin, 
developed by Lippard et al. 
 
Similarly to the monofunctional Pt(II) complexes, trans-Pt(II) complexes were 
also thought to be inactive according to the initial structure-activity relationships 
due to inability to form 1,2-intrastrand crosslinks.  
The mechanism of action for trans complexes follows the same principle as for 
the cis compounds, in which aquation of the chlorides needs to occur. Hydrolysis 
of the first chloride is fast in comparison to the second, as it is opposite to H2O, 
which has a weak trans effect.   
Replacement of one or both ammines with iminoethers, aliphatic amines or 
heterocyclic aliphatic amines (Figure 1.4) generates a wide variety of trans 
(A) 
(B) 
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antitumor complexes which display cytotoxicity in cisplatin-resistant cell 
lines.
27,28
 
 
Figure 1.4: Examples of trans-[PtCl2(L)(L)’] containing iminoether, aliphatic 
heterocyclic amines and aromatic amines which show in vivo efficacy.
29,30,31
 
 
These complexes display a different mode of DNA binding than transplatin, but 
also differences amongst themselves, depending on the type and the steric bulk of 
the ammine. For example, trans-[PtCl2(NH3)(thiazole)] generates an almost equal 
number of monofunctional, interstrand and intrastrand crosslinks,  but the 
piperidine and piperazine complexes produce more intrastrand crosslinks. The use 
of two iminoether ligands, on the other hand leads to mainly monofunctional 
adducts.
28
 In the case of trans-[Pt(pyridine)2Cl2], which can be considered as a 
prototype of trans complexes with planar aromatic ligands, it was shown that it is 
very efficient in forming interstrand crosslinks, despite the steric bulk created by 
the two pyridine ligands.
32
  
The interstrand crosslinks formed by these kinds of complexes are usually 
between two adjacent GC base pairs, resembling those formed by cisplatin, 
whereas transplatin’s interstrand adducts are formed between G-C adjacent pairs 
(Figure 1.5).  
Chapter 1: Introduction 
 
10 
 
Depending on the adduct type, protein recognition (e.g. by the HMG-group 
family) can be different, which ultimately affects downstream effects (e.g. repair).  
 
Figure 1.5: Types of interstrand DNA cross links formed by transplatin (left), 
cisplatin (middle) and trans complexes with a planar aromatic amine, using trans-
[PtCl2(NH3)(isoquinoline)] as an example. Taken from reference 28. 
1.5  Pt(IV)-prodrugs 
A different strategy used for the production of drugs which could potentially 
decrease the side effects shown by the conventional Pt(II) drugs is the 
development of Pt(IV) prodrugs. A prodrug is a “derivative of a drug that is 
metabolized or activated in the body to release or generate the active drug”.33 The 
status of Pt(IV) prodrugs can be justified by the fact that these complexes enter 
the cells as Pt(IV) and reduction to Pt(II) is essential before any substitution 
reaction takes place.
34,35
  
The kinetic inertness exhibited by Pt(IV) complexes renders them less prone to 
undergo reactions on route to the tumour, enabling a higher therapeutic index.
35
 
The presence of two additional ligands compared to Pt(II) also allows 
modification of important chemical properties of the drug (e.g. lipophilicity, 
aqueous solubility, reduction potential)
36
 and can be used for the incorporation of 
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targeting features such as nanoparticles and peptides. Furthemore, there is also the 
capability of a dual mode of action by the incorporation of biologically active 
axial ligands which can be released in the cell upon reduction.
9
 
Four Pt(IV) drugs have so far entered clinical trials (Figure 1.6): iproplatin, 
tetraplatin, satraplatin and LA-12. The first two have been abandoned. Iproplatin 
showed less cytotoxicity than cisplatin and tetraplatin was too toxic
36
, whereas 
satraplatin is now being trialled for combination therapy.
37
 LA-12 is currently 
under phase I clinical trials.
38
 
 
Figure 1.6: Pt(IV) complexes that have entered clinical trials. 
 
Although the examples discussed above entail chemical activation, of special 
interest is the use of light to photoactivate a prodrug, which is the main concept 
behind photodynamic therapy.  
1.6 Photodynamic therapy (PDT)  
PDT is a clinical treatment for cancer based on the administration of a 
photosensitizer and subsequent activation using light at a wavelength where the 
compound absorbs. This in effect excites the photosensitizer in a higher electronic 
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state, causing Type I and Type II reactions. The former entails a redox reaction 
with subsequent formation of radicals and the second involves energy transfer to 
ground state molecular oxygen (
3
O2) to produce the highly reactive 
1
O2 (singlet 
oxygen).
39
 This species is toxic to cells and causes death via oxidative stress 
mechanisms, DNA damage, protein destruction and cell lysis.
40,41
 The short life 
time of singlet oxygen in water (3 μs) and the maximum diffusion distance of up 
to 100 nm within a cell, gives rise to localized cellular damage.
42
 Further to this 
mechanism of action, PDT can damage the vasculature associated with the tumour 
and also trigger an immune response.
40
  
The photosensitizer ideally should be activated by longer wavelength light for 
deeper penetration into the tissue, have good aqueous solubility, no dark toxicity, 
preferential accumulation in the cancer tissue, and finally a long enough half-life 
in the blood to reach the tumour cells in adequate concentrations.
43,44
 Most of the 
photosensitizers are highly conjugated macrocycles (e.g. porphyrins, chlorins, 
bacteriochlorins, phthalocyanines, naphtlaocyanines), although research on metal-
based photosensitizers has shown that they are already promising candidates for 
PDT.
45
 Notable examples (Figure 1.7) include aluminium sulfonated 
phthalocyanine (Photosense), which is approved for clinical use in Russia,
46
 the 
Motexafin Lutetium (Lu-trin or Lu-Tex) and the palladium bacteriopheophorbide 
(Tookad soluble), both of which are evaluated as a treatment for prostate 
cancer.
47,43
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Figure 1.7: PDT agents containing metals which are either used clinically (A, 
Motexafin Lutetium) or under clinical evaluation (B, aluminium sulfonated 
phthalocyanine and C, palladium bacteriopheophorbide). 
 
The medical benefits of PDT for the treatment of cancer and pre-cancerous 
conditions are the follows: (a) There is little effect on the non-living connective 
tissue, allowing healing without a risk of the mechanical integrity of hollow 
organs.
48
 (b) There are no total-dose limitations, as in the case of radiotherapy.
43
 
(c) It allows excellent spatial control therefore avoiding damage to healthy cells. 
PDT’s main drawbacks lie in the fact that it is oxygen-dependent and oxygen is 
scarce in hypoxic tumour environments.
49
 Furthermore, porphyrin aggregation,
50
 
poor-solubility
51
 and photosensitivity after treatment
52
 are some other 
disadvantages associated with the current-porphyrin based PDT.  
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1.7 Light Delivery 
Although light penetration into a specific tissue is dependent upon the competitive 
absorption of endogenous chromophores (e.g. melanin and haemoglobin), the 
optimum range is 620 nm – 850 nm. Light in the range of 600-700 nm penetrates 
50-200 % deeper than in the 400-500 nm, therefore is preferentially used in the 
clinic (Figure 1.8).
45
 However, shorter wavelength of light can be used if the 
target lesion is thin and the tissue surface is easily accessible.
43
  
Figure 1.8: Light penetration through the tissue. Adapted from reference 53. 
 
LED lights are used for dermatological purposes and recent advances in laser 
technology have enabled physicians to perform PDT in internal organs (e.g. lungs, 
brain, bladder, cervix and colon) via the use of optical fibres to deliver laser 
light.
43,54
 The use of advanced high power and tightly focused femtosecond laser 
systems may also enable PDT via two photon excitation in the future. This 
phenomenon is the near-simultaneous absorption of two photons, typically above 
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600 nm, to achieve excitation at shorter wavelength (approximately half).
55
 As a 
result, metal complexes with the ability to absorb two photons (usually large with 
highly conjugated donor and acceptor ligands) can be activated with longer and 
clinically relevant wavelengths. In a recent report, Zhao et al. presented the first 
example of a Pt(II) complex containing the π-conjugated ligand 4-[2-(4-
methoxyphenyl)ethynyl]pyridine for which activation with laser pulses between 
600 – 740 nm yielded the same photoproducts as UV activation.56 Furthermore, 
research has been carried out on the development of upconversion nanoparticles in 
PDT. A photosensiziter which is activated with UV or short visible wavelength is 
loaded onto the nanoparticle which is composed of material capable of photon 
upconversion (usually lanthanides, such as NaYF4: Yb, Er 
57
) and upon irradiation 
with near-infrared light, shorter wavelength light is produced which is able to 
activate the photosensitizer coated on the outer shell of the NP.
58
  
1.8 Photophysical and photochemical properties of metal complexes59,60, 61,62  
Photochemistry is concerned with the effects of light in chemical systems and will 
be discussed here with respect to metal coordination compounds.  Absorption of a 
photon by a molecule can cause excitation if the energy gap between the excited 
and the ground state matches the energy of the photon. The possibility of an 
electronic transition occurring depends on the transition dipole which in turn is 
dependent on the two following selection rules.  
(a) Spin selection rule: transitions with a change of multiplicity are not 
allowed (ΔS = 0). This selection rule can be relaxed by the coupling of the 
spin and orbital angular momenta. Heavier atoms have a greater spin-orbit 
coupling.  
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(b) Laporte selection rule: in a centrosymmetric molecule the only allowed 
transitions are those accompanied by a change in parity (e.g. g ↔ u). This 
rule can be relaxed when the complex’s symmetry departs from the perfect 
centrosymmetry, through natural asymmetry or through distortions 
occurring during vibrations.  
The fact that these transitions are forbidden suggest that experimentally they will 
occur with low probability, hence the extinction coefficients are small. 
 
Absorption of radiation by a molecule can lead to the population of singlet excited 
states, which then follow various deactivation pathways, as illustrated in the 
Jablonski diagram (Figure 1.9). When the population of higher electronic states 
(e.g. S1, S2) occurs, then return to a lower singlet level can occur without radiation 
via internal conversion, vibrational relaxation, quenching or via a radiative 
process, fluorescence. Otherwise, intersystem crossing can lead to population of a 
triplet state which can give rise to phosphorescence (radiative process) upon 
return to the ground state (S0). Phosphorescence has a longer life time than 
fluorescence (10
-3–1 s vs 10-9–10-6 s),41 as the former is a spin forbidden process. 
A decrease in the intensity of fluorescence is commonly observed when transition 
metals are in close proximity to the fluorophore because they increase the rate of 
Intersystem-Crossing to the triplet state due to an increase in the spin-orbit 
coupling. This radiationless process competes with the S1→S0 transition, 
responsible for fluorescence.
63
 
The deactivation of an excited state often does not go through a physical process 
(e.g. luminescence) but rather causes a chemical change (e.g. isomerisation, 
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dissociation, redox, substitution). Nevertheless, the population of the triplet state, 
occurring through intersystem crossing from the singlet state, is an important step 
that dominates a lot of the routes of electronic excitation. 
 
Figure 1.9: A Jablonski diagram to summarise all potential deactivation pathways 
of complex in an excited state. Reproduced and modified from reference 64.  
 
Prior to discussing the various types of the excited states in a d
6 
metal complex, it 
is important to describe the typical molecular orbital diagram for this class of 
compounds. In an octahedral d
6
 metal complex (e.g. Pt
IV
), the splitting of the 
orbitals is such that the dxy, dyz, dxz are lower in energy than the dz2 and dx
2
-y
2 
orbitals, as described by crystal field theory. The energy of the ligand orbitals is 
lower than the metal orbitals and therefore the lower energy bonding orbitals are 
ligand centred, whereas the lowest energy antibonding orbitals are predominantly 
metal-based.  
The excited state reactivity of a metal complex, as induced by light, is 
summarized by the following (Figure 1.10). 
1) Metal-centred transitions (d-d transitions). These are Laporte forbidden 
(g↔g transitions), hence they give rise to weak absorption band (ε ~ 1-
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1000 M
-1
cm
-1
. Such transitions typically lead to the occupation of 
antibonding orbitals, often leading to bond elongation and ligand 
substitution.  
2) Charge transfer transitions (ligand-to-metal, metal-to-ligand or to-solvent) 
are fully allowed, giving rise to intense absorption bands. A MLCT may 
result if the metal is electron rich and the ligand has low lying empty 
orbitals. A LMCT occurs when the ligand is easy to oxidize and the metal 
easily reduced. A LMCT leading to a chemical change can cause change in 
the oxidation state of the metal, as well as ligand release by a homolytic 
bond cleavage to liberate radicals.  
3) Ligand-centred transitions mainly occur in aromatic ligands with extended 
π and π* orbitals and they are allowed by both spin and Laporte selection 
rules.  
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Figure 1.10: A simplified MO diagram of an octahedral d
6
 complex, assuming 
strong crystal field splitting. The bonding orbitals π1 and π2 are predominantly 
ligand in character, whereas the t2 are metal in character. The blue arrows 
represent electrons with the associated spin in the ground state, whereas the 
coloured arrows represent electrons involved in a transition. In the singlet and 
triplet states the spins are up (↑↑↑↑) or down (↓↓↓↓), respectively. Reproduced 
and modified from Farrer et al.
44
 
1.9 Non-platinum metal-based photoactivated drugs 
Many transition metals (e.g. Ti, Cr, Mn, Cu, Co, Pd, Ir, Fe, V) show medically 
interesting photochemical properties which have been studied. A few notable 
examples are the oxovanadium(IV) curcumin complex [VO(cur)(dppz)Cl] and the 
Fe(L)(cat)NO3, where L= 9-[(2,2’-dipicolylamino)methyl]anthracene and cat= 
catecholate. The former was shown to have a lower IC50 than the FDA approved 
PDT agent photofrin when irradiated with visible light (400-700 nm) and its 
efficacy is thought to be due to its DNA photocleavage ability.
65
 The latter 
complex can induce near IR-light induced apoptotic cell death. The anthracenyl 
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ligand is responsible for the fluorescent and intercalative abilities of the complex, 
whereas the catecholate ligand provides IR absorption.
66
  
Ru(II) and Rh(III) complexes have been studied the most over the years. A very 
prominent family is that compromising Ru-polypyridyl complexes which not only 
show intercalative properties via the ligand but also because the photoexcitated 
state is a strong oxidant, capable of oxidizing DNA nucleobases.
67
 Especially 
when tridentate ligands (e.g. 2-pyridyldipyrido-[3,2-a;2’,3’-c]phenazine) were 
employed, quantum yields of singlet oxygen production were exceptionally 
high.
68
 Ru-polypiridyl complexes which contain monodentate ligands can also 
exhibit ligand release of one or two ligands which is exploited for the uncaging of 
bioactive molecules (e.g. amino acids, nucleotides, neurotransmitters and genetic 
inducers). The photosubstitution in these complexes is enabled by the population 
of a d-d state from the 
3
MLCT, a transition which is temperature dependent.
69
 
Light-induced ligand substitution and subsequent nucleobase binding was also 
shown by Sadler and coworkers in the case of Ru(II)-arene complexes containing 
a pyridine monodentate ligand.
70
 Furthermore, the use of polyazaaromatic ligands 
(e.g. 1,4,5,8,9,12-hexaazatriphenylene (HAT) and 1,4,5,8-tetraazaphenanthrene 
(TAP)) lead to formation of covalent adducts with nucleobases through a radical 
recombination process which is lethal for the cell.
71
 Finally, the nitrosyl bound 
Ru(II) complexes can also undergo ligand release but through a different 
mechanism (via oxidation to Ru(III)).
72
 
Rh(III) complexes with polypiridyl or phenathranoline ligands can also cause 
DNA cleavage on light activation. A notable example, which uses a more 
sterically demanding chrysi ligand (chrysi = 5,6-chrysenequinone diimine) is 
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[Rh(bpy)2(chrysi)]
2+
, complex developed by Barton et al., which can specifically 
bind to DNA base mismatches.
73
  
1.10 Photoactivity of Pt(II) complexes 
Up until now most of the photochemistry of platinum evolved around luminescent 
Pt(II) complexes, which have been explored thoroughly due to their useful 
photophysical properties. Their high efficiencies, long lifetimes of the emissive 
state enabled this type of complexes to be used in applications such as 
chemosensors,
74
 photocatalysis,
75
 light emitting diodes
76
 and photovoltaic 
devices.
77
 
More recently, Pt(II) agents were also found to be phototoxic when coordinated to 
appropriate ligands. Studies carried out with transplatin (Figure 1.11, complex A) 
showed that upon irradiation with UVA, an enhancement in the toxicity (2-fold) 
was observed. This was attributed to the loss of chloride ligands and the formation 
of bifunctional DNA interstrand crosslinks which are unable to form in the dark.
78
 
A recent study has shown that a similar effect can be caused by UV irradiation of 
carboplatin, where a 10-fold increase in cytotoxicity and faster DNA binding 
kinetics was induced.
79
 
Brunner and co-workers, in an attempt to combine the advantages given by the 
preferential cellular accumulation of porphyrins in cancer cells with the cytotoxic 
activity of Pt(II), attached poly(ethyleneglycol)-derivatized hematopoprhyrins to 
Pt(II) (Figure 1.11, complex B). The phototoxicity results showed that most of the 
complexes exhibited both cytotoxicity and phototoxicity (λ = 600-730 nm, 10 
min), towards human cancer cells with a few exceptions which showed promising 
light-induced efficacy.
80
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Franz et al. reported that the attachment of a photosensitive nitrophenyl group to a 
tetradentate ligand backbone with two pyridyl and two amide nitrogen donor sites 
makes the Pt(II) complex photolabile (Figure 1.11, complex C). Bond breakage 
occurs, accompanied by release of a Pt(II) complex prone to ligand substitution 
reactions as well as other nitroso side-products when exposed to UV light for a 
short time. The cytotoxicity of the complex was low in the dark and decreased to 
68% upon irradiation.
81
  
Chi-Ming Che et al. also has reported luminescent cyclometalated Pt(II) 
complexes with thiophene,
82
 mono
83
 or bidentate (N-heterocyclic carbenes)
84
 
ligands. These complexes exhibit high emission quantum yields which enable 
their tracking inside a cell, via fluorescence microscopy. In the first two reports, 
although the complexes were very potent, they produced only a small increase in 
cytotoxicity when irradiated with visible light (~6 fold, Figure 1.11, complexes D 
and E), whereas in the latter case it was improved 30-fold in some cases (Figure 
1.11, complex F). These compounds tend to accumulate in cytoplasmic structures 
(e.g. endoplasmic reticulum and mitochondria) rather than the nucleus, which can 
indicate a different mode of action than traditional anticancer Pt drugs (usually 
targeting nuclear DNA).  
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Figure 1.11: Selected complexes showing enhancement in cytotoxicity when 
irradiated with UV (A and C) or visible light (B and D-F). 
 
Finally, a few dinuclear complexes of Pt(II) have been reported in recent years 
which exhibit promising photosensitizer characteristics. Monti et al. reported 
complexes with a dichloridopyrido Pt(II) moiety attached externally to the 
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porphyrazine macrocycle, where the central cavity was occupied with either 
Zn(II), Mg(II) or Pd(II). They were shown to generate singlet oxygen efficiently 
in DMF (λ > 600 nm) and also to bind to G-quadruplex structures.85 Brewer et al. 
reported a Ru(II)-Pt(II) dinuclear complex, where the dichloro-platinum moiety is 
attached on a dpp ligand, where dpp=2,3- bis(2-pyridyl)pyrazine)). The other 
ligands on the ruthenium centre were the widely used phenanthronile ligands. 
Irradiation at long wavelength (λ > 600 nm) causes a MLCT excitation to the 
ruthenium which is transferred to PtCl2 site, causing hydrolysis of the chlorides 
and DNA binding.
86
 
 
1.11 Photoactivity of Pt(IV) complexes 
The phototochemical properties of Pt(IV) were documented early on, when it was 
shown that [PtCl6]
2-
 can be reduced to metallic Pt or [PtCl4]
2-
 with low-energy 
visible light.
87
 More recently, Lippert et al. reported that Pt
IV
 2,2-bipyridine 
complexes, e.g. mer-[PtCl3(2,2-bpy)(MeNH2)],  can undergo photoreduction (λ > 
300 nm) to produce the Pt(II) fragment  [PtCl(2,2-bpy)(MeNH2)] accompanied by 
the loss of HOCl or Cl2 which possibly originate from the reductive elimination of 
the axial chlorido ligands. Surprisingly, the same result is obtained when the 
complex is heated at 50 
o
C  for 24 h, showing the thermolability of the 
complexes.
88
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1.11.1 Pt(IV)-diiodo and Pt(IV)-diazido complexes 
A controlled localized reduction to a cytotoxic component is extremely beneficial 
to healthy cells which are prone to rapid division, such as bone marrow, GI-tract 
and skin, since these cells are particularly sensitive to chemotherapy.
38
 
Pt(IV) complexes, contrary to the Pt(II), are less prone to substitution reactions 
and therefore the selection of appropriate ligands can render them stable in the 
presence of high amounts of reducing agents and also create photolability.  
The first generation of Pt(IV) photoactivatable anticancer drugs were diiodo 
complexes (Figure 1.12), with the general formula of trans, cis-[Pt(X)2I2(en)], 
where en = ethylenediamine and X = Cl
-
, OH
-
, acetate or methylsulfonate.
89
 The 
ethylenediamine ligand was chosen in order to avoid photoisomerisation reactions 
which could lead to the formation of a trans-Pt(II) photoproduct which is not able 
to form the lethal intrastrand DNA cross-links.
89
 The choice of iodides as the 
reducing ligands was made because they are weak field ligands and thus the 
LMCT transition occurs at low energy in the visible region. Indeed, the UV-Vis 
spectrum of the iodo complexes bears a tail which extends up to 500 nm.
90
  
 
Figure 1.12:  First generation photoactivatable Pt(IV) drugs with iodidos as the 
reducing ligands, developed by Berdnaski et al.
54
  
Chapter 1: Introduction 
 
26 
 
CT-DNA binding studies illustrated that the most promising complex was C in 
Figure 1.12 as complexes A and D could form adducts in the dark, whereas 
photolysis of B led to no platination. Instead complex C led to 65% platination 
only after irradiation.
90
   
Nevertheless, cytotoxicity studies on these complexes showed no significant 
difference between light and dark toxicity. This might be attributable to the facile 
reduction of the complexes by thiols within the cellular environment.
90,91
 
Photochemical reduction of platinum(IV)-azide complexes was documented early 
on, by Vogler and co-workers who showed that trans-[Pt(CN)4(N3)2]
2-
 was 
converted to [Pt(CN)4]
2-
 upon excitation with UV (300 nm) via a simultaneous 
two-electron reduction process without a Pt(III) intermediate.
92
 Furthermore, they 
showed that [Pt
II
(N3)4]
2-
 is also photolabile being reduced to metallic platinum 
leading to the production of nitrogen and azide.
93
 Following this, the Sadler group 
developed a second generation of Pt(IV) photoactivatable drugs containing azides 
instead of iodides (Figure 1.13). 
 
Figure 1.13: Pt(IV)-diazido complexes developed by Sadler and co-
workers.
54,94,95
 
 
Complexes A and B in Figure 1.13 were the first synthesized and have been 
studied extensively. Initial experiments monitored by UV-Vis showed that A 
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decomposed more slowly than B under UV irradiation. This could be rationalized 
by the fact that the LMCT band of B is shifted towards the visible region by 29 
nm and also the extinction coefficient is greater.
96
 Another advantage of B over A 
is the higher aqueous solubility. However irradiation studies followed by 
1
H and 
2D [
1
H, 
15
N] HSQC NMR spectroscopy, showed slow photoreactivity of this class 
of compounds since reduction to Pt(II) was seen only after 60 min of irradiation 
with UVA light. Instead photosubstitution/ photoisomerisation Pt(IV) products 
were possibly formed. Interestingly, irradiation of B in the presence of 5’-GMP (2 
molar equivalents) led to the formation of trans-[Pt
II
(NH3)2(5’-GMP-N7)2] 
adducts and reduction to Pt(II) occurred at a faster rate than in the absence of 
nucleotides. Futhermore, complex A was shown to generate equivalent nucleotide 
crosslinks when irradiated with visible light in presence of 5’-GMP or 
d(guanosinylphosphoguanosine) as those formed by cisplatin.
97
 These results 
demonstrated for the first time the photoreduction of Pt(IV) to Pt(II), and also that 
the stereochemistry of the amines is retained after reduction to Pt(II) and 
subsequent binding to biomolecules.  
The photochemical decomposition pathways of A and B were studied extensively 
by Ronconi et al via 
14
N and 
15
N NMR.
98,99,100
 It was discovered that the 
photodecomposition pathways of the two isomers are similar in the major 
products formed but that the experimental conditions under which the irradiation 
experiments were carried out affected the photoproducts: in PBS, azide release 
was observed, whereas in acidic conditions, N2 was the major product. However 
in both conditions, O2 and free ammonia were detected (indicating ammine 
release), although amine bound Pt(II) was also detected, accompanied by an 
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increase in pH. It was postulated that the photodecomposition to Pt(II) could 
involve also the formation of highly reactive Pt(IV)-nitrene intermediates, 
indicating a complex mechanism of photodecomposition of this class of 
compounds.  
Although neither complexes A or B (Figure 1.13) possess dark toxicity, the trans 
isomer was slightly more active than the cis counterpart under irradiation (IC50 
156 μM vs 176 μM in HaCaT cell line, UVA irradiation for 50 min).96 Changes in 
the nuclear morphology of 5637 human bladder cells were also followed for 
complex A by phase-contrast and fluorescence microscopy illustrating that cells 
did not undergo the typical apoptotic changes (e.g. budding and cellular 
fragmentation). Treated cells rather ballooned and lost contact with neighbours as 
well as suffering disintegration of the nuclei. Furthermore, a distinctive 
mechanism of cell death from cisplatin became obvious.
101
  
Complex C (Figure 1.13) which incorporates a pyridine in place of an ammine 
ligand was significantly more potent than A and B, when irradiated with UV light 
(IC50s 6.1 and 1.9 μM in HaCaT and A2780 cell lines, respectively).
94
 Photolysis 
experiments showed that reduction to Pt(II) occurred in the presence of 
biomolecules (e.g. 5’-GMP) to produce trans-[Pt(NH3)(py)(5’-GMP-N7)2] and  
trans-[Pt(N3)(NH3)(py)(5’-GMP-N7)]. Studies to elucidate the mechanism of 
action were performed for complex C by Berdnaski et al. showing that an elevated 
amount of ROS was generated after irradiation with UVA light (30 min).
102
 
Treatment of HL60 (human promyleotic leukaemia cells) with the complex C did 
not yield morphological changes (Figure 1.14) that resembled those triggered by 
cisplatin or etoposide, which are apoptotic agents. The lack of activation of 
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caspase 3 or 7, combined with changes in the levels of key autophagic proteins 
(e.g. LC3, p62), led to postulated autophagy as the possible mechanism of cell 
death.
103
 
 
Figure 1.14: Phase contrast images of HL60 cells treated for 48 hours with 
untreated control (a), 68 μM of complex C activated with UVA light (b), 0.74 μM 
of cisplatin (c) and  0.74 μM etoposide (d).103 
 
The success of complex C spurred on the synthesis of trans, trans, trans-
[Pt(N3)2(OH)2(L)(L’)] complexes which when compared to their cis analogues 
they were found to be more phototoxic.
104
 This systematic study produced the first 
structure-activity relationship for Pt(IV)-diazido complexes.  
Replacement of aliphatic amine with pyridine (complex D, Figure 1.13) resulted 
in photocytotoxicity (IC50 8.4 μM in OE19) with blue light (420 nm). As in the 
case of complex C irradiation with blue light in the presence of 5’-GMP resulted 
in the formation of mono and bis-5’-GMP adducts.95 EPR studies illustrated the 
evolution of azide radicals and their role in the cytotoxicity of this class of 
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complexes was shown by the reduction in potency when IC50 studies were carried 
out in the presence of the radical quencher tryptophan.
105
 Azidyl radicals can 
cause oxidation reactions of tryptophan and tyrosine
106
 thus potentially damaging 
proteins and other biomolecules. 
These complexes are thought to have a dual mode of action (Figure 1.15) with 
azidyl radicals playing a primary role in the cytotoxicity. However binding to 
biomolecules is also significant. DNA binding studies of complex D demonstrated 
the formation of 1,3-intrastrand crosslinks as the major adduct (51%) but 
monofunctional lesions can form to a greater extent than cisplatin (37% vs 2%). 
Pracharova et al. also postulated that interaction of the pyridine ligand with the 
DNA duplex may play an important role for activity. Moreover, stalling of RNA 
polymerase II (responsible for transcription) is also a significant factor which can 
contribute to the cytototoxicity of this complex.
107
 This result also parallels the 
report by Lippard et al. in which an X-ray crystal structure of RNA polII stalled 
by a monofunctional platinum-DNA adduct with pyriplatin. The structure showed 
that a pyridine ligand located in cis position to NH3 can fit into the RNA polII 
active site and subsequently cause blockage of the translocation of the enzyme 
from this  position.
26
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Figure 1.15: Mechanism of action of Pt(IV)-diazido complexes were L and L’ are 
N-aromatic ligands. The scheme shows that cell death can be produced by 
oxidative stress caused by the generation of radicals and also by the platination of 
biomolecules, such as DNA and proteins. 
 
All of these compounds were found to be stable in the dark in the presence of 
cellular concentrations of reducing agents such as GSH and ascorbate which is a 
desirable feature for photoactivatable drugs.
108
 Together with the fact that the 
mechanism of action is oxygen-independent and the generally high aqueous 
solubility of these prodrugs, these complexes are potential candidates for 
photoactivated chemotherapy (PACT).  
1.12 Aims  
The aims of this thesis are the following.  
 Synthesis and characterisation of novel complexes with planar aromatic 
ligands which can potentiate the phototoxicity of the Pt(IV)-diazido 
complexes without compromising the lack of dark toxicity.  
Chapter 1: Introduction 
 
32 
 
 Synthesis and characterisation of Pt(IV)-diazido complexes with 
derivatization of the axial ligands so as to provide targeting and imaging 
features. 
 Studies of the photochemistry of the new complexes, especially on the 
biologically relevant wavelengths, and elucidation of photoproduct 
pathways.  
 Cellular studies in mammalian cells for the determination of phototoxicity, 
cell uptake as well as the employment of novel methods (confocal 
microscopy and survival in yeast cells) which can enable the determination 
of the mechanism of action.  
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This chapter describes the main techniques used in this thesis. Specific 
experimental parameters and settings used on various instruments are given.  
2.1 Nuclear Magnetic Resonance spectroscopy (NMR) 
1
H, 
13
C and 
195
Pt NMR spectra were acquired at 298 K on Bruker AV-400 (
1
H: 
399.10 MHz), Bruker DPX-400 (
1
H: 400.03 MHz) or Bruker AVIII-600 (
1
H: 
600.13 MHz) spectrometers. Samples were prepared by the addition of the 
appropriate solvent (0.6 mL) in 5 mm NMR tubes. 1D 
1
H-NMR spectra were 
recorded using standard pulse sequences. Typically the data were acquired with 
128 or 16 transients into 32 k data points over a spectral width of 14 ppm. The 
1
H-
NMR chemical shifts were internally calibrated with the residual peaks of solvent 
CHD2COCD3 (δ = 2.05 ppm), CHD2OD (δ = 3.31 ppm), DMSO-d6 (δ = 2.50 
ppm) or added 1,4-dioxane (δ = 3.75 ppm) in the case of D2O.
1
 2D spectra were 
recorded using standard pulse-pulse sequences. All the novel Pt(IV) complexes in 
this thesis were characterized with 
13
C-NMR spectroscopy. The pulse sequences 
used were jmod (J Modulation) and PENDANT (Polarization ENhancement 
During Attached Nucleus Testing). In both cases, the peaks for –CH2 or 
quaternary carbons appear to be inverted relative to those for –CH or CH3 groups. 
The signals of quaternary carbons were generally of low intensity.
2
 
COSY (Correlation spectroscopy) spectra were recorded to identify pairs of nuclei 
which are coupled through bonds. Typically they were acquired using 8 transients 
into 1024 data points. [
1
H,
 13
C] HSQC (Heteronuclear Single-Quantum 
Correlation) 2D spectra were used for the assignment of 
13
C NMR peaks. The 
spectra were acquired with 32 transients and the time domain was 1024 or 2048.  
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The 
195
Pt-NMR spectra were typically obtained with pulse sequence zg (non-
proton decoupled), with a relaxation delay (D1) of 0 s, using a 2 k or 65 k time 
domain and 20 k transients. The spectra were externally referenced with K2PtCl6 
(15 mM in D2O). 
Water suppression was used when samples were prepared in aqueous solution. To 
minimise the large residual water peak, the HOD signal was suppressed by 
irradiating at the frequency of water in between pulse sequences.  
The labelling of the atoms for the assignment of the 
1
H and 
13
C-NMR signals 
shown in the characterisation data (Chapters 3 and 4) are included in the 
Appendix.  
2.2 Mass Spectrometry  
2.2.1 Electrospray mass spectrometry (ESI-MS) 
Positive-ion ESI spectra were obtained by preparing the samples in CH3OH or 
H2O and infusing into the mass spectrometer (Bruker Esquire 2000 Trap 
Spectrometer or Agilent 6130 single Quad) , using  an automatic sample delivery 
system. The mass spectra were recorded with a scan range of m/z 500-1000 for 
positive ions. Data were processed using Data Analysis version 3.3 (Bruker 
Daltonics). The detection of platinum-containing species was aided by the 
distinctive isotopic distribution pattern of platinum. Platinum has 6 stable 
isotopes: 
190
Pt (0.0014 %), 
192
Pt (0.782 %), 
194
Pt (32.967 %), 
195
Pt (33.832 %), 
196
Pt (25.242 %), 
198
Pt (7.163 %).  Figure 2.1 illustrates the isotopic distribution 
pattern for platinum.  
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Figure 2.1: Isotopic distribution of platinum. 
 
2.2.2 LC-MS (Liquid Chromatography-Mass Spectrometry) 
LC-MS analysis was carried on a Dionex 3000RS UHPLC coupled with a Bruker 
MaXis Q-TOF mass spectrometer. An Agilent Zorbax Eclipse instruments plus 
column (C18, 100 x 2.1 mm, 1.8 µm) were used. Mobile phases consisted of A, 
water with 0.1% formic acid and B, acetonitrile with 0.1% formic acid. A gradient 
of 5% B to 100% B in 15 minutes was employed with flow rate at 0.2 mL/min, 
UV detection was made at 254 nm. The mass spectrometer was operated in 
electrospray positive mode with a scan range 50 – 2,000 m/z. Source conditions 
are, end plate offset at -500 V; capillary at -4500 V; nebulizer gas (N2) at 1.6 bar; 
dry gas (N2) at 8 L/min; dry temperature 180 °C. Ion tranfer conditions were: ion 
funnel RF at 200 Vp/p; multiple RF at 200 Vp/p; quadruple low mass set at 55 
m/z; collision energy at 5.0 ev; collision RF at 600 Vp/p; ion cooler RF at 50-350, 
Vp/p; transfer time set at 121 µs; pre-pulse storage time 1 µs. Calibration was 
done with sodium formate (10 mM) through a loop injection of 20 μL of standard 
0 
20 
40 
60 
80 
100 
In
te
n
si
ty
 
Chapter 2: Experimental Methods 
 
44 
 
solution at the beginning of each run. The spectra were processed with Bruker 
Daltonics Data Analysis.  
2.2.3 ICP-MS (Inductively coupled plasma mass spectrometry)  
ICP-MS was carried out on an Agilent 7500 Series spectrometer. Data acquisition 
was carried out on ICP-MS Top (version B.03.05) and analysis on Offline Data 
Analysis (version B.03.05). The standards were prepared from a stock of 1000 
ppm Pt solutions obtained from Sigma Aldrich, in 5% HNO3 with miliQ water at 
the following concentrations: 200, 50, 10, 5, 1, 0.5, 0.2, 0.05, 0.01 ppb.  
2.3 HPLC (High Performance Liquid Chromatography)  
HPLC was mainly used for purity assessment of the novel complexes synthesized. 
Specific conditions can be found in Chapters 3 and 5 and in all of the cases 
performed on Agilent 1200 system, with a C18 column.  
2.4 X-Ray crystallography 
X-ray diffraction data were collected and solved by Dr Guy Clarkson at the 
University of Warwick.  
Diffraction data were collected by the use of Mo Kα radiation at a wavelength of 
λ=0.71073 Å on an Oxford Diffraction Gemini four-circle system with Ruby CCD 
area detector. The crystals were held at the following temperatures: 100 K, 150 K 
and 568 K (refer to specific values for each compound in Chapters 3 and 5) with 
the Oxford Cryosystem Cryostream Cobra. The structures were solved by direct 
methods using SHELXS (Sheldrick, 1990) (TREF) with additional light atoms 
found by Fourier methods. Hydrogen atoms were added at calculated positions 
and refined using a riding model. Anisotropic displacement parameters were used 
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for all non-H atoms except the OH; H-atoms were given isotropic displacement 
parameters equal to 1.2 (or 1.5 for OH and methyl hydrogen atoms) times the 
equivalent isotropic displacement parameter of the atom to which the H-atom is 
attached.  
ORTEP diagrams were used to illustrate the ellipsoid form of the crystal 
structures and Mercury to generate the intermolecular interactions as well as the 
packing diagrams.  
The formula used to assess whether bond distances are statistically different was 
the following:  
Bond difference > 3σ, where 
σ = √( σ1
2
+ σ2
2
), where σ1 and σ2 are the bond length standard deviations 
 
2.5 UV-VIS spectroscopy 
UV-Vis absorption spectra were recorded on a Varian Cary 300 UV-Vis 
spectrophotometer in 1 cm path-length quartz cuvettes, purchased from Starna 
Scientific. Before the measurement of each spectrum, a blank of the solvent was 
recorded for reference. The spectral width was from 200-800 nm, the bandwidth 
was 1.0 nm and the scan rate was set to 600 nm/min. Typically, the volume used 
was 450 μL. The spectra were processed using UV-Winlab software for Windows 
XP. Extinction coefficients were determined using the Beer-Lambert law (A = εcl, 
where ε is the extinction coefficient M-1/cm-1, c the molar concentration and l the 
path length in cm). Pt concentrations for determination of extinction coefficients 
were measured by ICP-MS.  
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2.6 pH measurements 
pH measurements for the pKa analysis in Chapter 5 were recorded at ambient 
temperature directly in the NMR tube with a pocket ISFET pH meter (Minilab 
Series), which is a solid state electrode. The meter was calibrated using standard 
buffer solutions (pH 7.00, pH 4.01, pH 10.01), as supplied by the provider 
(Minilab).  
2.7 Irradiation methods and devices 
Photoactivation of Pt complexes were carried out at 293 K. The light sources used 
were the following: (a) LZC-ICH2 photoreactor (Luzchem Research Inc.) 
equipped with a temperature controller and 3 UVA lamps (Hitachi, λmax = 361 
nm) or 6 Luzchem LZC-420 lamps (λmax = 420 nm) with no other sources of light 
filtration. (b) LED light sources (BASETech model no. SP-GU10 230V~50 Hz 
1.3-2.1 W) with λmax = 463 nm or 515 nm. (Refer to Appendix for the output 
spectra). (c) KiloArc
TM
 broadband arc lamp monochromator, which was supplied 
with the appropriate filters to cut-off any unwanted lower wavelength light.  
 
 
 
 
 
 
 
 
(A) 
(A) 
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Figure 2.2: Light sources used in this thesis: A) LZC-ICH2 photoreactor 
(Luzchem Research Inc) equipped with 420 nm bulbs and a temperature 
controller. (B) KiloArc monochromator (C) Irradiation of a sample in a UV-Vis 
cuvette with the green LED (517 nm) fitted into a GU-10 device. 
 
2.8 Light measurements 
The light intensity used to irradiate samples was measured with an International 
Light Technologies Powermeter (ILT1400-A) equipped with SEL 033 detector 
and either a UVA/TD filter (315-390 nm) for UVA irradiations or a flat response 
visible filter F/W (400-1064 nm) for visible wavelengths. The output spectrum for 
each of the light sources discussed above was measured using the Ocean Optics 
USB4000-UV-Vis spectrophotometer.  
The determination of the light dose in the experiments was calculated by the 
equation:  
Dose (mJ cm
-2
) = Time (s) × Irradiance (mW cm
-2
) 
(B) 
(C) 
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2.9 EPR (Electron Paramagnetic Resonance)3 
The EPR spectra were recorded on a Bruker EMX (X-band) spectrometer (for 
more details refer to Chapter 3).  
2.10 DFT and TDDFT calculations 
Calculations were carried out in collaboration with Dr Luca Salassa, CIC 
biomaGUNE, Spain.  
All calculations were performed with the Gaussian 03 (G03) program
4
 employing 
the DFT method, with the PBE1PBE
5
 functionals. The LanL2DZ basis set
6
 and 
effective core potential were used for the Pt atom and the 6-31G**+ basis set
7
 was 
used for all other atoms. Geometry optimizations for complex 4 and complex 4-
deprotonated (Chapter 3) and complex 18 (Chapter 4) in the ground state (S0) and 
lowest-lying triplet state (T1) were performed in the gas phase and the nature of all 
stationary points was confirmed by normal mode analysis. For the T1 geometries 
the UKS method with the unrestricted PBE1PBE functional was employed. The 
conductor-like polarizable continuum model method (CPCM)
8
 with water as 
solvent was used to calculate the electronic structure and the excited states of 
complex 4 and complex 4-deprotonated in solution (H2O). Thirty-two singlet 
excited states with the corresponding oscillator strengths were determined with a 
Time-dependent Density Functional Theory (TD-DFT)
9, 10 
calculation. 
2.11 Cell culture 
The A2780 human ovarian cell line was obtained from the ECACC (European 
Collection of Animal Cell Culture, Salisbury, UK). Cells used for the uptake 
experiment were maintained in RPMI 1640 media, which was supplemented with 
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10% foetal calf serum (FCS), 1% L-glutamine and 1% penicillin / streptomycin. 
All cells were grown at 310 K in a humidified atmosphere containing 5% CO2.  
For the determination of phototoxic activity, cells were maintained in RPMI 
medium containing 10% FCS, in an antibiotic free culture in a humidified 
atmosphere, containing 5% CO2 and mycoplasma free.  
2.12 Photo-dark toxicity testing 
The photo-dark toxicity testing was carried out in collaboration with Dr Julie 
Woods, University of Dundee, Scotland.  
The complexes were prepared in Earl’s balanced salt solution just before use and 
filtered. Irradiations were performed using a bank of 2 × 3 ft TL03 (Philips; λmax: 
420 nm) light sources filtered to attenuate wavelengths below 400 nm. Irradiance 
was measured with an International Light meter, fitted with the appropriate 
detector and diffuser and calibrated using a double grating spectroradiometer 
(Bentham, UK) in the UKAS accredited optical physics laboratory (Photobiology 
Unit, Dundee). The delivered dose was 5 J/cm
2
. The experiments were controlled 
for test compound and irradiation. The cytotoxicity was measured using the 
neutral red assay 96 or 72 hours after light exposure (i.e. recovery period). The 
IC50 was determined by curve fitting (Graphpad). Goodness of fit was assessed by 
R
2 
values and the 95% confidence interval. All cell experiments were performed 
in duplicate/ triplicate and repeated independently a minimum of two times.  
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2.12.1 Neutral Red assay 
Upon cell uptake Neutral red (Figure 2.3) accumulates in lysosomes. The low pH 
in the lysosomal matrix of live cells causes the dye to becomes charged, allowing 
it to be retained in this organelle.
11
 The dye is then extracted from the cells upon 
solubilisation and thus can be quantified.  
The protocol used for this assay was the following. A stock solution of neutral red 
was prepared in water (4 mg/mL) and diluted 80-fold in the cell culture medium 
(e.g. RPMI). Prior to addition to the cells, the solution was heated to 37 
o
C and 
filtered (no. I Whatman paper). The growth medium was removed from the cells 
and the neutral red dye (100 μL) was added and the cells are incubated for 3 hours 
in the dark. Upon removal of the dye, the cells were rinsed with PBS (100 μL) and 
then the plates were shaken for 15 min with PBS (200 μL) for solubilisation. The 
dye concentration was quantified by measuring the absorbance at 450 nm. 
 
Figure 2.3: Chemical structure of 3-amino-7-dimethylamino-2-methylphenazine 
hydrochloride, is the dye used in the neutral red assay.  
 
2.12.2 MTT assay 
MTT (4, 5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide) assay can also be 
used to assess cell viability in phototoxicity experiments. The basis of this assay is 
that when the dye is uptaken by live cells, cytoplasmic and mitochondrial 
enzymes reduce the dye to the formazan form which is purple (Figure 2.4).
12
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MTT (50 μL of 1 mg/ mL stock solution prepared in PBS) was added to all the 
treated and control cells. Plates were incubated for 3 hours at 37 
o
C to allow 
uptake of the dye. Following this step, the medium was removed and the plates 
were frozen at -20 
o
C for 48 h. DMSO (150 μL) was added to solubilise the dye 
and the plates were placed on the shaker for 15 minutes to ensure a homogeneous 
solution.  The reading was made using a plate reader at 570 nm, with a reference 
reading at 690 nm.   
 
 
Figure 2.4: MTT assay reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium, which is yellow, to form the purple formazan.  
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3.1 Introduction 
In recent years efforts have been made for the development of Pt(IV) prodrugs, 
which could improve the pharmacological profile of the platinum drug family due 
to their kinetic inertness and the various modification possibilities that they offer.
1
 
Amongst the 30 platinum compounds that have entered clinical trials, only three 
of them were Pt(IV): tetraplatin, iproplatin and satraplatin. (Chapter 1, Figure 
1.6). The satraplatin-related compound LA-12 is still under clinical investigation.
2
 
Satraplatin was certainly the most promising Pt(IV) prodrug, but unfortunately 
there has been no significant increase of survival rates when compared to standard 
cisplatin treatment.
3,4
 Numerous strategies have been applied to transform the 
successful Pt(II) compounds into Pt(IV) prodrugs, which would exert their 
cytotoxic effect by the reduction into Pt(II) in the blood plasma or tissue. Pt(IV) 
analogs of carboplatin, picoplatin, oxaliplatin and cisplatin have been produced 
and they showed interesting antiproliferative properties.
5-8
 The Pt(IV) compounds 
are octahedral complexes, which upon reduction produce Pt(II) square-planar 
complexes.  
By convention, axial ligands are normally considered to be those which lie above 
and below the plane of the amines.
1
 The type of axial ligands in Pt(IV) prodrugs 
has always been of great interest as they affect many properties of the drug such 
as lipophilicity, stability, reduction rate as well as a second cytotoxic effect upon 
release. The work of Wee Han Ang et al., is a representative example of the full 
exploitation of the axial ligands.
7
 By utilizing sequential acylation, Pt(IV) 
complexes with asymmetric axial ligands were produced. This enabled the 
introduction of lipophilic and hydrophilic substituents, leading to the regulation of 
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the pharmacological and cytotoxic properties of the prodrug.
7 
Furthermore, 
mitaplatin which is a cisplatin derivative containing two dichloroacetate axial 
ligands, can exert its pharmacological effect in a dual mode upon reduction to 
Pt(II) inside the cell: the first by DNA platination via cisplatin, and the other by 
the release of DCA (dichloroacetate) ligands. DCA alters the mitochondrial 
membrane potential gradient in cancer but not normal cells. As a consequence, 
cytochrome c is released and apoptosis inducing factor is translocated to the 
nucleus.
9 
The axial ligands of Pt(IV) complexes normally act as leaving groups upon 
reduction to Pt(II), although this rule must be handled with care.
10
 The reduction 
potential of Pt(IV) can be greatly affected by the nature of the axial ligands. In 
general, based on half-wave reduction potentials, the order by which reduction is 
facilitated is I
- 
> Cl
- 
> OAc
- 
> OH
-
.
11 
This correlates with the rate of reduction in 
the presence of a biological reducing agent (e.g. ascorbic acid or glutathione). An 
example of a result of such study is illustrated in Table 3.1, which shows values of 
half-wave reduction potentials in a series of Pt(IV) complexes.
12
 However, a 
recent finding by Hambley et al. contradicts this expected trend: for Pt(IV) 
analogues of oxaliplatin (i.e. a complex with coordination sphere N2O2), the 
fastest rate of reduction does not correlate with the most positive reduction 
potential, with the dihydroxo compound being reduced significantly faster than 
the dicarboxylated compound.
13
 This indicates that the coordination sphere of the 
Pt(IV) plays a crucial role in the reduction mechanism of the complexes by 
biological reductants and therefore predicting the ease of reduction of Pt(IV) 
prodrugs is not straightforward.  
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Table 3.1: Variation of half-wave reduction potential for Pt(IV) complexes with 
axial ligand. 
 
Complex X Reduction Potential (mV) 
 
-Cl
- 
-260 
-OAc
- 
-635 
-OH
- 
-880 
 
A fundamental step in the development of Pt(IV) drugs is the carboxylation of the 
hydroxyl groups, which greatly facilitates subsequent modification. Hydroxyl 
groups are common axial ligands because oxidation of the Pt(II) to Pt(IV) can be 
carried out through the use of hydrogen peroxide. Carboxylation by acetylation of 
a dihydroxo Pt(IV) was first reported by Giandomenico et al.
14, 15
 In a later 
development it was shown that functionalisation of the hydroxides can be 
achieved using cyclic anhydrides, which yields a free carboxylic acid for further 
functionalisation.
16
 This was first utilized by Lippard’s group to bind estrogen 
derivatives to oxoplatin, as it was established that estrogen-receptor-positive cells 
are sensitized to cisplatin, due to shielding of the Pt-DNA crosslinks.
17
 
Furthermore, more functionalities were attached such as peptides (e.g. RGD, 
NGR) which can recognize the integrins on the surface of tumour endothelial cells 
(found in angiogenic tumours) and regions of inflammation.
18
 Chlorotoxin (which 
targets glioma, prostate, lung and melanoma cell lines), TAT peptide (a cell 
penetrating peptide which facilitates cellular uptake) and also analogues of 
somatostasin and neurotensin (peptides whose receptors are upregulated in 
various tumours) are more examples of peptides which have been coupled to 
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cisplatin or oxaliplatin Pt(IV) derivatives via a carboxylic acid axial ligand.
19, 20, 21
 
In most cases the cytotoxicity of the peptide derivative is increased compared to 
the Pt(IV) precursor but not necessarily greater than that of the Pt(II) parent 
compound.
19-21
 Nevertheless, tumour cell targeting could give a significant 
advantage in terms of selectivity of the drug towards cancerous versus healthy 
tissue. More sophisticated carriers exploiting the concept of passive targeting 
include carbon nanotubes to which the Pt(IV) prodrug is anchored via covalent 
linkage, or through hydrophobic interactions and enclosure within gold 
nanoparticles have also been investigated.
22
  
Very little work has been carried out with regard to modification of the axial 
ligands of Pt(IV)-azido photoactivatable complexes. Since their mechanisms 
include photoreduction to Pt(II), their importance from a structure-activity 
relationship point of view is unquestionable. Early work on diiodo-Pt(IV) 
complexes (Figure 3.1) demonstrated that changing from dihydroxo to diacetato 
axial ligands affects the photochemistry of the compound. For example 
photoirradiation studies followed by NMR showed that complex A undergoes 
photosubstitution instead of reduction and thus cannot bind to 5’-GMP whereas B 
is able to (Figure 3.1).
23
 Also photolysis of A did not show any measurable calf 
thymus-DNA platination whereas photolysis of B resulted in 65%.
24
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Figure 3.1: Diiodo-Pt(IV) complexes differing in the axial ligands. Complex A 
does not show evidence of DNA platination upon UV irradiation unlike 
compound B.  
 
Computational work carried out by Sadler et al.
25
 systematically studied the effect 
that various ligands or substituents would have on the UV-visible electronic 
absorption properties and photochemistry of trans-Pt(IV) compounds, including 
the modification of the axial ligands. Changing the OH
-
 axial ligand to I
-
 or to 
OAc
-
 critically influences the electronic transitions of the complex. Time-
dependent density functional theory (TDDFT) calculations demonstrated that 
replacing both OH
-
 with OAc
-
 extends the strongest absorption band as well as the 
tail of the absorption spectrum to longer wavelengths. This is achieved by 
lowering the energy of the LUMO and LUMO+1, therefore lowering the energy 
gap between the HOMO and LUMO. However it was anticipated that this 
modification could also lead to more facile reduction within the cell under dark 
conditions.
25
 
The work in this chapter investigates the effect of axial ligand modifications on 
the photochemistry and photobiology of trans-Pt(IV) azido compounds. It 
describes the synthesis, characterisation, photoirradiation and biological studies of 
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the following novel compounds (Figure 3.2): trans, trans, trans-
[Pt(N3)2(pyr)2(OH)(succ)] (Complex 4), trans, trans, trans-
[Pt(N3)2(pyr)2(OH)(Succ-Pr)] (Complex 5), trans, trans, trans-
[Pt(N3)2(pyr)2(OH)(N-MI)] (Complex 6), in comparison with reference trans, 
trans, trans-[Pt(N3)2(OH)2(pyr)2] (Complex 3). The incorporation of cancer-cell 
targeting features is also presented and discussed.   
 
Figure 3.2: Complexes synthesized and studied in this chapter. 
 
3.2 Experimental  
Caution! Heavy metal azides are known to be shock sensitive detonators. 
Although no problems were encountered during this work, platinum azide 
compounds should be handled with care. Any syntheses or handling of platinum 
azide complexes was carried out under faint lighting conditions.  
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3.2.1 Materials 
All materials were used as obtained from commercial sources unless otherwise 
stated. K2PtCl4 was purchased from Precious Metal Online. Pyridine, HCl and all 
solvents for common use were analytical reagent grade and were bought from 
Fisher Scientific and used as supplied. AgNO3, NaN3, H2O2 (30%), succinic 
anhydride, 1,1'-carbonyldiimidazole (CDI), N-methylisatoic anhydride (N-MIA), 
5’-guanosine monophosphate and glutathione were purchased from Sigma 
Aldrich. 5,5-dimethyl-pyrroline N-oxide (DMPO) was bought from Enzo Life 
Sciences. PBS was purchased from Sigma Aldrich as tablets and one tablet 
dissolved in water (200 mL) yields a solution of 0.01 M phosphate, 0.0027 M 
KCl, 0.137 M NaCl at pH 7.4. Distilled water was purified using a Milipore water 
purification system. Water used in ICP-MS was purified using Purelab UHQ 
water purification system.  
3.2.2 Methods and Instrumentation 
3.2.2.1 HPLC purity test 
The purity of the compounds was determined on an Agilent 1200 system with a 
VWD and 100 μL loop. The column was an Agilent ZORBAX Eclipse Plus C18, 
with dimensions of 250 × 4.6 mm
2
 and a 5 μm pore size. The injected volume was 
at 45 μL with needle washes. The mobile phase used was H2O 0.1 % TFA / ACN 
0.1% TFA. The flow rate was set to 1 mL/min and the method used is depicted in 
Table 3.2.  
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Table 3.2: HPLC method for purity tests on complexes. Solvent B is ACN (0.1% 
TFA) and solvent A is H2O (0.1% TFA).  
Time 
(min) 
%B 
0 10 
30 80 
40 80 
41 10 
55 10 
 
Complexes 4 and 5 were dissolved in water and complex 6 in 10% MeOH/ 90% 
H2O. The concentration used was 60 μM.  
3.2.2.2 Extinction coefficient determination 
The extinction coefficient was estimated as described in Chapter 2 (section 2.6). 
The solvent used for 4, 5 and compound 3 was H2O; 95% H2O / 5% DMSO (v/v) 
was used for 6 due to the poor solubility of the complex. The extinction 
coefficients for complexes 3 and 4 at longer wavelengths were measured using 
higher concentrations. 
3.2.2.3 pKa measurement  
The pKa
*
 (pKa from D2O measurements) of complex 4 (1.1 mM) was determined 
by following the changes in the chemical shifts of the pyridine protons, according 
to changes in pH
*
. The pH
*
 was measured as described in Chapter 2 and it was 
adjusted to the desired value by using 0.01 M, 0.05 M, 0.1 M KOD and 0.1 M, 
0.05 M, 0.001 M DClO4 solutions. 
1
H-NMR spectra were recorded at 25 
o
C on a 
600 MHz NMR spectrometer. Dioxane was used as a chemical shift reference.  
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3.2.2.4 Electron Paramagnetic Resonance 
The EPR spectra were recorded on a Bruker EMX (X-band) spectrometer by 
Jennifer S. Butler at the University of Warwick. A cylindrical TM10 mode cavity 
(Bruker 4103 TM) was used and samples were placed in spectrosil quartz tubes of 
inner diameter 1.0 mm and outer diameter of 1.2 mm (Wilmad Labglass) sealed 
with J-Blue Tac. The tube was placed inside a larger quartz tube so the sample 
could be more accurately positioned inside the resonator. Using the y-incremental 
sweep mode of 24 with an accumulation of 10 scans in the X dimension, selected 
key parameters applied during the experiment were the following: modulation 
amplitude 2.0 G, microwave power 0.63 mW, modulation amplitude 0.2 mT, 
receiver gain 1.0×10
4
, sweep gain 41.94 s. The green LED (517 nm) was placed at 
a distance of 8.5 cm from the tube in the EPR cavity. The irradiation lasted for 35 
minutes and the spectra represented are at 7 minute intervals. The spin adduct 
concentration was determined using a calibration curve (SigmaPlot) obtained 
from standard solutions of 4-hydroxy-2,2,6,6-tetramethyl-piperidine-1-oxyl 
(Tempol) in the corresponding solvent and the processing was carried out using 
Bruker WINEPR software.  
3.2.2.5 Computational details 
DFT and TDDFT calculations were carried out, as described in Chapter 2 (section 
2.10).  
3.2.2.6 Cell uptake studies 
A2780 cells were seeded at a density of 5×10
5 
cells/mL in each well and were 
allowed to adhere for 36 h. Before the drugs were added, the cells were washed 
with PBS (1 mL). The stock concentration of the drugs was confirmed via ICP-
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MS analysis before exposure to the cells to mitigate any discrepancies in the 
added drug. The drugs (20 μM, 2 mL in PBS) were added and cells and incubated 
for 1 hour in the dark at 37 
o
C. Following the uptake of the drug, the cells were 
washed with PBS (1 mL) and a solution of trypsin/ EDTA (2%) was added (0.5 
mL) and incubated at 37 
o
C for 3 minutes, then neutralized with cell culture 
medium-RPMI (2 mL). Cells were transferred into falcon tubes and broken into a 
single cell suspension via vigorous pipetting to enable counting followed by 
addition of more RPMI (2 mL) to dilute the cells. Cells were counted in duplicate 
and an average was taken. Then, they were centrifuged at 1000 rpm at 22 
o
C
 
for 5 
minutes. The supernatant was removed and the cells were resuspended in PBS (1 
mL) for a further wash. The cell pellet was kept at -20 
o
C until the Pt content was 
analysed via ICP-MS. Digestion of the cell pellet was carried out overnight in 
concentrated nitric acid (73%) at 70 
o
C. The resulting solutions were diluted to 
5% v/v HNO3, using doubly ionised water and then filtered through an inorganic 
membrane filter to remove any insoluble cell debris. The platinum content was 
measured by ICP-MS, as described in Chapter 2 (section 2.2.3). Temperature-
dependent cell uptake experiments were performed for complexes 3 and 6, at 4 
o
C, 25 
o
C and 37 
o
C, after 1 h of drug exposure in the dark. Concentration-
dependent cell uptake experiments were performed at concentrations of 5, 10, 20, 
40 and 60 μM for complexes 3 and 6, after 1 h of incubation in the dark. Each 
experimental condition was carried out in triplicate. 
3.2.2.7 Fluorescence measurements  
Fluorescence measurements for complex 6 were performed on a Jasco FP-6500 
spectrofluorimeter at a concentration of 26 μM in H2O and using quartz cuvettes 
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with 1 cm path length. Spectra were acquired using the following parameters: 
excitation wavelength at 320 nm, excitation and emission slits at 10 nm and 5 nm 
respectively. The response was set to medium and the scanning rate to 200 nm/ 
min.  
3.2.2.8 Synthesis and characterisation 
Complexes 1, 2 and 3 have been synthesized as reported previously with an 
agreement in the characterization data.
26
 
3.2.2.8.1 trans-[PtCl2(pyr)2] (1) 
K2PtCl4 (4 g, 9.64 mmol) was dissolved in H2O (100 mL) and pyridine was added 
(15 mL, 193 mmol, 20 eq). The solution was stirred at 85 
o
C for 1.5 h after which 
point it became transparent. The solution was allowed to cool down and the 
solvent was rotary-evaporated to dryness to yield a white solid which was washed 
with diethyl ether for the removal of excess pyridine. HCl (2 M, 100 mL) was 
added and the solution was heated at 75 
o
C overnight to give trans-[PtCl2(pyr)2] as 
a yellow solid which was filtered off and washed with ice-cold water, ethanol and 
diethyl ether (Yield = 3.75 g, 8.86 mmol, 92%). 
1
H-NMR (acetone-d6, 400 MHz, ppm): δ= 8.87 (dd,
 3
J1H1H= 6.83 Hz, 
3
J195Pt1H = 
31.07 Hz, 4Ho), δ= 8.02 (t, 3J1H1H = 7.70 Hz, 2Hp), δ= 7.52 (t, 
3
J1H1H = 7.46, 
4Hm). 
3.2.2.8.2 trans-[Pt(N3)2(pyr)2] (2) 
This complex was prepared as previously reported.
26
 Trans-[PtCl2(pyr)2] (1) (3.75 
g, 8.85 mmol) was suspended in water (500 mL), AgNO3 (3.008 g, 2 eq) was 
added and the reaction was stirred at 60 
o
C overnight. The grey precipitate was 
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filtered through celite over a frit to obtain a pale yellow solution which was then 
further passed through an IM filter. Then NaN3 (5.75 g, 10 eq) was added and the 
reaction was stirred overnight at room temperature. The yellow precipitate was 
filtered and washed with ice-cold water, ethanol and diethyl ether (3.48 g, 90%). 
The solid was recrystallised from pre-warmed pyridine at 40 
o
C at a ratio of 1 
g/37 mL of pyridine and following hot filtration it was allowed to crystallise at -
20
o
C. The yellow solid was filtered, washed and dried under vacuum (Yield = 
2.44 g, 70%). 
1
H-NMR (acetone-d6, 400 MHz, ppm): δ = 8.86 (dd, 
3
J1H1H = 6.76 Hz, 
3
J195Pt1H = 
37.30 Hz, 4Ho), δ = 8.13 (tt, 3J1H1H = 7.67 Hz, 
4
J1H1H = 1.38 Hz, 2Hp), δ = 7.67 (t, 
3
J1H1H = 7.15 Hz, 4Hm). 
3.2.2.8.3 trans, trans, trans-[Pt(N3)2(OH)2 (pyr)2] (3) 
The title product was obtained by oxidation of trans-[Pt(pyr)2(N3)2], 2. Trans-
[Pt(N3)2(pyr)2] (2.00 g, 4.56 mmol) was suspended in H2O2 (160 mL, 30%) and 
allowed to react at 45 
o
C for 4 hours, producing a yellow solution. This was 
filtered (IM) and transferred to a larger flask to which H2O (340 mL) was added. 
The solution was lyophilized, yielding a yellow solid which was recrystallised 
from 2:1 ethanol/ methanol and the product precipitated by addition of diethyl 
ether at -20 
o
C. The solid was filtered and dried under vacuum (Yield = 1.6 g, 
80%).  
1
H-NMR (D2O, 400 MHz, dioxane, ppm): δ= 8.80 (dd, 
3
J1H1H = 6.68 Hz, 
3
J195Pt1H 
= 26.88 Hz, 4Ho), δ= 8.28 (tt, 3J1H1H =7.78 Hz, 
3
J1H1H =1.30 Hz, 2Hp), δ= 7.82 (t, 
3
J1H1H = 7.11 Hz, 4Hm). 
ε294 nm =17467 M
-1
cm
-1
, ε260 nm =12297 M
-1
cm
-1
 (H2O). 
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3.2.2.8.4 trans, trans, trans-[Pt(N3)2(OH)(Succ)(pyr)2] (4) 
Carboxylation of one of the axial ligands was prepared by modification of a 
published method.
27
 Trans, trans, trans-[Pt(N3)2(pyr)2(OH)2] 3 (0.150 g, 0.318 
mmol) was dissolved in anhydrous DMSO (1.8 mL) under N2, in the presence of 
activated molecular sieves. Succinic anhydride (1.1 eq, 0.035 g) was added and 
the reaction stirred in the dark at 40 
o
C for 48 h. The suspension was filtered and 
water (~2 mL) was added. The yellow solution was allowed to stand at room 
temperature until a crystalline solid precipitated (3–4 hours). The remaining 
solution was decanted and the crystalline precipitate was washed with diethyl 
ether and then filtered (Yield = 0.096 g, 52%). Crystals suitable for single-crystal 
X-ray diffraction were obtained by slow diffusion of water into the DMSO 
reaction mixture at room temperature.  
1
H-NMR (D2O, 600 MHz, pH 5.18, ppm): δ= 8.77 (dd, 
3
J1H1H=5.78 Hz, 
3
J195Pt1H= 
11 Hz,4H, Ho), δ=8.27 (t, 
3
J1H1H= 7.64 Hz, 2H, Hp), δ=7.80 (t, 
3
J1H1H= 7.04 Hz, 
4H, Hm,), δ=2.58 (t, 
3
J1H1H= 6.90 Hz, 2H, H1), δ=2.48 (t, 
3
J1H1H= 6.90 Hz, 2H, H2). 
13
C-NMR (MeOD-d4, 150 MHz, ppm): δ=178.7, (Ca), δ=177.57 (Cd), δ=150.89, 
Ce), δ=143.15 (Cg), δ=127.37 (Cf) 
195
Pt-NMR (D2O, 129 MHz): δ= 1059 ppm. 
ESI-MS: [M+Na] 
+ 
(m/z) Calc., 594.0; Found, 593.9. 
ε299 nm =17251 M
-1
cm
-1
, ε260 nm = 11584 M
-1
cm
-1
 (H2O). 
3.2.2.8.5 trans, trans, trans-[Pt(N3)2(OH)(Succ-Pr)(pyr)2] (5) 
Trans, trans, trans-[Pt(N3)2(OH)(Succ-Pr)(pyr)2] 4 (0.100 g, 0.176 mmol) was 
pre-dried using P2O5 and then dissolved in dry DMF (1 mL) under argon. A stock 
solution of CDI (1,1'-carbonyldiimidazole) in DMF (0.194 M) was prepared under 
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dry conditions and 1.2 mL was added (1.2 eq) to the solution of the platinum 
complex and allowed to stir at 50 
o
C for 20 minutes, under continuous purging 
with argon. Then, sodium propanolate (2 mL), formed by the dissolution of 
sodium metal (0.02 g) in absolute propanol (20 mL), was added and the reaction 
carried out at room temperature for 48 hours. DMF was removed under vacuum 
and the crude product was purified by column chromatography (eluent: EtOAc: 
MeOH, 11:1). After solvent removal from the combined fractions, the solid was 
recrystallised from DCM/diethyl ether (Yield = 0.060 g, 56%). Crystals suitable 
for X-ray crystallography were grown by slow evaporation from water at ambient 
temperature.  
1
H-NMR (D2O, 600 MHz, dioxane, ppm): δ=8.76 (dd, 
3
J1H1H =5.64 Hz, 
3
J195Pt1H 
=25.40 Hz, 4H, H6), δ=8.28 (t, 
3
J1H1H =7.73 Hz, 2H, H7), δ=7.81 (t, 
3
J1H1H =7.14 
Hz, 4H, H8), δ=3.95 (t,
 3
J1H1H =6.72, 1H, H3 ), δ=2.64, 2.63 (m, 2H, H1,2), δ=1.54 
(s, 
3
J1H1H =7.28 Hz, 1H, H4), δ=0.84 (t, 
3
J1H1H =7.50 Hz, 1H, H5). 
13
C-NMR (D2O, 150 MHz, dioxane, ppm): δ=179.29 (Cd), δ=176.22 (Ca), 
δ=149.84 (Ch), δ=143.31 (Cj), δ=127.64 (Ci), δ=67.90 (Ce), δ=31.78 (Cb), δ= 
30.88 (Cc), δ=21.91 (Cf), δ=10.17 (Cg). 
195
Pt-NMR (D2O, 107 MHz, dioxane): No signal was obtained with ns = 32768, 
sw = 902.14, o1p = 1000 .  
ESI-MS: [M+Na] 
+ 
(m/z) Calc. 636.1; Found, 636.2. 
ε300nm =16565 M
-1
cm
-1, ε260 nm =10602 M
-1
cm
-1
 (H2O). 
3.2.2.8.6 trans, trans, trans-[Pt(N3)2(OH)(N-MI)(pyr)2] (6) 
Trans, trans, trans-[Pt(N3)2(pyr)2(OH)2] 3 (0.086 g, 18.25 mmol) was dissolved in 
anhydrous DMSO (2 mL) and N-methylisatoic anhydride (0.162 g, 91.23 mmol, 5 
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mol eq) was added. The reaction was carried out for 72 h at 40 
o
C under nitrogen 
with an outlet to allow the release of CO2(g). The isolation of the product was 
achieved by the addition of water (10 mL) at which point the compound 
precipitated. For the removal of excess ligand, repeated washing with diethyl 
ether was necessary and carried out via centrifugation (Yield = 0.020 g, 18%). 
Crystals suitable for X-ray diffraction were grown by slow evaporation of a 
solution in DCM/MeOH at ambient temperature. 
1
H-NMR (DMSO-d6, 500 MHz, ppm): δ= 8.86 (dd, 
3
J1H1H =5.54 Hz, 
3
J195Pt1H 
=27.00 Hz, 4H, H7), δ=8.30 (t, 
3
J1H1H =7.56 Hz, 2H, H9), δ=7.88 (m, 5H, 4H8, H4), 
δ=7.62 (q, 3J1H1H=5.07 Hz, 1H, H5), δ=7.26 (t, 
3
J1H1H =7.78 Hz, 1H, H3), δ=6.53 
(d, 
3
J1H1H =7.53 Hz, 1H, H1), δ= 6.51 (t, 
3
J1H1H = 7.53 Hz, 1H, H2), δ= 3.88 (d, 
2
J195Pt1H = 14.8 Hz, H10), δ= 2.70 (d, 
3
J1H1H= 5.00 Hz, 3H, H6). 
13
C-NMR (DMSO-d6, 125 MHz, ppm): δ=171.26 Ca, δ= 150.82 Cc, δ= 149.73 Cb, 
δ=149.38 Ci, δ=142.18 Ck, δ=132.86 Cg, δ=132.09 Cf, δ=126.42 Cj, δ=113.74 Cd, 
110.00 Ce, δ=29.07 Ch. 
195
Pt-NMR (DMSO-d6,107 MHz,): δ= 990 ppm. 
ESI-MS: [M+H] 
+ 
(m/z) Calc. 605.1; Found, 605.1. 
ε302  nm =18325 M
-1
cm
-1
, ε260 nm =19169 M
-1
cm
-1
 (5% DMSO/95% H2O). 
3.2.2.8.7 N-Methylisatoic acid (N-MIA) (L1) 
The open form of the N-methylisatoic anhydride was prepared by the hydrolysis 
and decarboxylation of N-methylisatoic anhydride.
28
 N-MI anhydride (1.2 g, 6.77 
mmol) was dissolved in a solution of KOH, 2 M (15 mL) and allowed to react for 
4 h at 100 
o
C. The clear solution was then allowed to cool down at room 
temperature and then the pH was adjusted to 6-7 by the addition of HCl (3 M). 
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The white precipitate formed was isolated and dried under vacuo (Yield = 0.17 g, 
19%). This compound was air sensitive therefore it was stored under nitrogen 
after preparation.  
1
H-NMR (75% MeOD-d4/25% D2O, 400 MHz, ppm): δ= 8.45 (d, 8.29 Hz, H1), δ= 
7.39 (t, 7.74 Hz, H2), δ= 6.78 (d, 8.21 Hz, H3), δ= 6.66 (t, 7.57 Hz, H4), δ= 2.87 (s, 
-CH3). 
ESI-MS: [M+Na]
+ 
(m/z) Calc. 174.0; Found, 174.0, [M+K] 
+ 
(m/z) Calc. 190.0; 
Found, 190.0. 
3.2.2.8.8 Trans, trans, trans-[Pt(N3)2(OH)(Succ-(RGD)f)(pyr)2] (7) 
The Pt(IV)-(RGD)f complex, compound 7 (Figure 3.3) was prepared, purified and 
provided by Dr Vicente Marchan’s group at the University of Barcelona, using 
complex 4 as starting material. The synthetic route was similar to that reported 
previously for coupling RGD peptide to [(η6-p-cym)Ru(bpm)(H2O)]
2+ 
complex.
29
  
In summary the peptide was assembled on a 2-chlorotrityl chloride resin using 
standard Fmoc/tBu protection scheme on the amino group of the amino acids to 
form the linear peptide with sequence of H2N-Asp(OtBu)-D-Phe-Lys(Alloc)-
Arg(Pbf)-Gly-resin, where OtBu, Alloc and Pbf are the side chain protecting 
groups. Cleavage from the solid support was undertaken with acetic acid/ 
tetrafluoroethylene (TFE)/ dichloromethane and cyclization was carried out with 
benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP). 
Then the Alloc protecting group from the side chain of lysine was removed with 
Pd(PPh3)4 and phenylsilane. The free amino group allows the attachment of the 
polyethylenglycol spacer. The protecting groups of Arg and Asp residues were 
removed with concentrated TFA in the presence of cation scavengers 
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(triisopropylsilane and water) and then the peptide was purified by reversed-phase 
HPLC. Attachment of complex 4 to the peptide was carried out with the HATU/ 
DIEA coupling reagents and the Pt(IV)-c(RGD)f complex was purified by 
reversed-phase HPLC. The purity of the Pt-peptide complex was found to be 96% 
by HPLC.  
 
7 
Figure 3.3: Pt(IV)–(cRGD)f peptide conjugate, complex trans, trans, trans-
[Pt(N3)2(OH)(pyr)2(Succ-(RGD)f)], 7. This complex was formed by the 
attachment of the peptide to complex 4.  
 
3.3 Results 
The compounds were characterised by 
1
H, 
13
C, 
195
Pt-NMR and mass 
spectrometry. In this section the assessment of compounds (in terms of purity), the 
X-ray crystallography, the stability and the aqueous solubility of the complexes 
will be presented. Furthermore, irradiation studies, which were followed by UV-
Vis, EPR, NMR and mass spectrometry were carried out on complexes 3, 4, 5 and 
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6 to determine the rate of photodegradation as well as the nature of various 
photoproducts. Moreover, phototoxicity studies and cell uptake studies were 
carried out to examine in more detail the pharmacological properties of those 
novel potential anticancer drugs.  
3.3.1 HPLC purity test 
The purity of the complexes was determined via HPLC chromatography. The 
wavelength used for detection was set to 254 nm, which falls in the appropriate 
range to detect many organic and inorganic impurities. With the assumption that 
the same extinction coefficient applies for all platinum compounds separated, the 
percentage purity was calculated by the integration of the peaks using the Agilent 
ChemStation. The HPLC traces for the three novel compounds are presented in 
Figure 3.4. Complexes 4, 5 and 6 have purities of 94%, 96% and 94%, 
respectively.  
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Figure 3.4: HPLC chromatographs for A) complex 4, B) complex 5, C) complex 
6. The conditions for the chromatographs are described in section 3.2.2.1. The Y 
axis is absorbance at 254 nm (omitted for clarity).  
 
3.3.2 X-ray diffraction 
This section of the chapter is focused on the bond lengths and angles of the three 
novel complexes as well as the intermolecular interactions, such as hydrogen 
bonding and π-π stacking. It is of interest to assess the type of interactions Pt(IV)-
azido complexes can have on a supramolecular level, involving their ligands. 
These interactions can influence the various contacts a molecule can develop with 
biomolecules (e.g. transporters, enzymes, nucleic acids) which could then have an 
effect on biological activity.   
A hydrogen bond, according to a IUPAC definition published in 2011
30
 is an 
intermolecular or intramolecular attraction between a donor, X–H and an acceptor 
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Y–Z, in which X is more electronegative than H and Y is an electron-rich region 
(e.g. a lone pair of electrons or a π-bonded pair of Y–Z). An ideal hydrogen bond 
forms an angle of 180
o
 and the more linear, the stronger the bond is. Furthermore, 
a common empirical rule dictates that a strong H-bond can only exist when the 
H···Y bond distance is less than the sum of the Van der Waals radii of the atoms 
involved.
30
 Hydrogen bonds can be classified as strong, medium or weak. As a 
general consideration the bond length between the donor and the acceptor can be 
used: below 1.5 Å, from 1.5-2.2 Å and from 2.2 to 3.2 Å are considered to be 
strong, moderate and weak, respectively.
31
  
Two aromatic rings can form an electrostatic attraction between them, which is  
referred to as -  stacking. The orientation of this interaction can vary between 
face-to-face stacking, face-slipped packing or a T-shaped interaction. The last two 
orientations are a result of a π-σ attraction.32 In the structures within this chapter, 
the only entities that could potentially form any π-π intermolecular interaction are 
the pyridine ligands or the aromatic ligands in compound 6. Pyridine is a 
polarized molecule because of the electronegative nitrogen atom causing a 
positive net charge on the carbon atoms of the aromatic ring. In theory this could 
lead to a strong -  attraction, as -deficient rings are known to form stronger 
interactions than -rich rings. The distances between centroids (Ct) of aromatic 
rings establishing a -  interaction can lie up to 3.8 Å and acquire an angle of 
20
o
.
32
 The C–H···π bond is normally shorter (~3.0 Å) and, similarly to a hydrogen 
bond, linearity in the edge-to-face interaction gives rise to a stronger bond.
33
 
Single crystals suitable for X-ray diffraction studies were  
obtained for complexes trans, trans, trans-[Pt(N3)2(OH)(succ)(pyr)2] 4, trans, 
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trans, trans-[Pt(N3)2(OH)(Succ-Pr)(pyr)2] 5 and trans, trans, trans-
[Pt(N3)2(OH)(N-MI)(pyr)2] 6 as described in section 3.2.2.8. The ORTEP 
diagrams of the molecular structures are shown in Figure 3.5 A, B and C, 
respectively. Crystallographic data of complexes 4, 5 and 6 are summarized in 
Table 3.3. Selected bond distances and angles are listed in Table 3.4 including 
data for the precursor Pt(IV) complex trans, trans, trans-[Pt(N3)2(OH)2(pyr)2] 3 
for comparison.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
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Figure 3.5: ORTEP diagrams of the complexes reported in this chapter: A) trans, 
trans, trans-[Pt(N3)2(OH)(Succ)(pyr)2] 4; B) trans, trans, trans-
[Pt(N3)2(OH)(Succ-Pr)(pyr)2] 5; and C) trans, trans, trans-[Pt(N3)2(OH)(N-
MI)(pyr)2] 6. The ellipsoids are set to 50% probability level. All hydrogen atoms 
have been omitted for clarity, except for the axial hydroxide ligand.  
 
(B) 
(C) 
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Table 3.3: Crystallographic data for complexes 4, 5 and 6.  
 
Complex 4 5 6 
Empirical formula C14H16N8O5Pt C17H22N8O5Pt C18H19N9O3Pt 
Formula weight 571.44 613.52 604.51 
Crystal 
description 
Colourless block Colourless block Brown block 
Crystal system Triclinic Monoclinic Monoclinic 
Crystal size/ mm 0.40x0.10 x 0.10 0.40 x 0.08 x 0.08 0.30x 0.18 x 0.12 
Space group P-1 C2/c P2(1)/c 
a/ Å 8.4300(2) 27.4103(18) 7.5372(2) 
b/ Å 10.5284(2) 12.5601(7) 35.8705(8) 
c/ Å 11.9980(4) 13.6542(8) 8.1728(2) 
α/(°) 86.002(2) 90 90 
β/(°) 70.799(3) 115.8(9) 109.178(2) 
γ/(°) 68.795(2) 90 90 
Volume/ Å
3 936.07(4) 4252.4(4) 2086.99(9) 
Z 2 8 4 
Dcalc/gcm
-3 2.027 1.917 1.924 
F(000) 548 2384 1168 
µcalcd /mm
-1
 7.540 6.646 6.764 
T/ K 268(2) 150(2) 150(2) 
Max θ /° 30.65 31.50 32.36 
Reflections 
collected/unique 
[Rint] 
17109/5253 
[0.0377] 
14991/6340 
[0.0385] 
32557/7050 
[0.0333] 
Goodness-of-fit on 
F
2
 
1.061 1.007 1.400 
Data/restraints/ 
parameters 
5253/17/259 6340/14/284 7050/0/287 
Final R indices 
[I>2σ(I)] 
R1= 0.0189, 
wR2= 0.0469 
R1=0.0332, 
wR2= 0.0581 
R1=0.0411, 
wR2= 0.0596 
R indices (all data) R1= 0.0204 
wR2= 0.0461 
R1= 0.0545 
wR2= 0.0506 
R1= 0.0488 
wR2= 0.0586 
Largest diff. peak 
and hole (eÅ
-3
) 
1.178 and -1.399 1.843 and -2.190 1.807 and -3.397 
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Complex 4 crystallized in the triclinic space group P-1 with two molecules within 
a unit cell. Complexes 5 and 6 both crystallized in the monoclinic system, space 
groups C2/c and P2(1)/c respectively, including eight molecules of complex in the 
unit cell in case of compound 5 and four molecules of complex in the unit cell of 
compound 6. 
Compounds 4, 5 and 6 are neutral mononuclear Pt(IV) complexes showing a 
distorted octahedral geometry with a [N4O2] hexacoordinated environment around 
the Pt(IV) ion. The three complexes differ in one of the oxygen donor ligands 
coordinated in axial positions. In all of them the equatorial plane is defined by 
four nitrogen atoms from two pyridine molecules trans to each other (N1 and N2) 
and two azido anions trans (N3 and N6), whereas an oxygen atom (O2) from a 
hydroxido ligand is located in an axial position. The sixth position is occupied by 
an oxygen atom (O1) from a monoanionic and monodentate ligand: a succinate 
anion in 4, a 4-oxo-4-propoxybutanoate anion in 5 and a N-methylisatoate anion 
in the case of 6. 
The distortion from ideal octahedral geometry is shown by the axial bond angles 
between Pt(IV) ion and the donor atoms in trans (e.g. O2–Pt–O1 174.22(8)o in 
complex 4) with values smaller than 180
o
. These angles are slightly smaller in 
comparison with the values found in the fully symmetrical precursor 3 (Table 
3.4). Such an effect is observed in all the three complexes described in this section 
and can be attributed to the steric hindrance caused by the bulky oxygen-
coordinated ligands. Along the N1–Pt–N2 axis in complex 4, a greater distortion 
from the octahedral geometry than the corresponding angle in the other two 
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complexes is apparent, which can be attributed to the C–H···  interaction between 
the pyridine rings found in complex 4 but absent in 5 and 6. 
 
Table 3.4: Selected bond distances (Å) and angles (
o
) for complexes 4, 5, 6 and 
the precursor complex 3.
26
 
Bond (Å)/ Angle (
o
) 4 5 6 3 
Pt–O1 2.021(2) 2.056(2) 2.029(2) 1.990(3) 
Pt–O2 1.984(2) 1.971(3) 1.978(2) 2.027(3) 
Pt–N1 2.039(3) 2.032(3) 2.026(3) 2.047(3) 
Pt–N2 2.033(3) 2.037(3) 2.036(3) 2.047(3) 
Pt–N3 2.050(3) 2.057(3) 2.053(3) 2.043(3) 
Pt–N6 2.041(3) 2.052(3) 2.037(3) 2.047(3) 
N6–N7 1.209(4) 1.217(5) 1.214(4) 1.215(4) 
N7–N8 1.139(4) 1.150(5) 1.148(4) 1.139(4) 
N3–N4 1.198(4) 1.208(5) 1.210(4) 1.218(5) 
N4–N5 1.133(4) 1.151(5) 1.141(4) 1.146(5) 
N6–Pt–N3 175.19(10) 178.48(12) 178.01(12) 176.86(12) 
N7–N6–Pt 121.8(2) 115.92(2) 116.1(2) 118.0(3) 
N4–N3–Pt 118.1(2) 115.7(3) 116.9(2) 120.3(2) 
N1–Pt–N2 176.83(8) 178.48(12) 178.47(11) 179.09(12) 
O2–Pt–O1 174.22(8) 175.51(10) 176.50(11) 179.58(11) 
N3–N4–N5 174.2(4) 175.1(4) 175.3(4) 175.3(4) 
N6–N7–N8 172.9(3) 173.8(4) 175.0(4) 174.4(4) 
 
Complex 3 has been reported previously
26
 and has been included in Table 3.4 for 
comparison purposes, as it is the precursor of the rest of the complexes. The bond 
distances between Pt(IV) and pyridine nitrogen atoms (Pt–N1 and Pt–N2) of 4, 5 
and 6 have no significant difference when compared within the same complex or 
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between the aforementioned complexes. The only exception is the bond with the 
pyridine ligand Pt–N1 (1.978(2) Å) in complex 6, which shows a shorter distance 
than Pt–N2.  
The Pt–N (azido) distances for trans-azido, trans-hydroxo compounds with one 
pyridine or substituted pyridine ring, are reported to be between 2.026 Å and 
2.069 Å.
34
 The azide anion – although symmetrical with both N=N bonds being of 
equal distance – adopts a resonance structure with one bond slightly longer than 
the other, when it is bound to a metal ion.
35
 Therefore it is reasonable that the N6–
N7 (or N3–N4) bonds, involving coordinated donor atoms, are larger than the N7–
N8 (or N4–N5) bonds. The Pt–N3 and Pt–N6 bond lengths do not have significant 
differences between them and fall within the expected range for Pt-azido 
complexes. The exception is complex 6 for which there is a significant difference 
between Pt–N3 (2.053(3) Å) and Pt–N6 (2.037(3) Å) bond distances.  
A special remark needs to be made with regard to the Pt–O bond as these are the 
first reported examples of Pt–azido compounds with asymmetric axial ligands. 
The more closely related compound is trans, trans, trans-[Pt(N3)2(OAc)2(pyr)2] 
which shows a Pt–O bond length of 2.001 Å.36 Therefore the bond distances in 4, 
5 and 6, ranging from 1.971(3) Å to 2.056(2) Å, are close to the expected value. 
There is a significant difference in the bond distances between the two Pt–O axial 
bonds in each complex. In all the cases the Pt–O bond for the carboxylate is 
longer than the Pt–O bond for the hydroxido ligand, perhaps indicating a higher 
potential lability of this bond. Complex 3 which was also included in Table 3.4 is 
a symmetrical molecule and therefore no difference in the bond distances would 
be expected in solution. Nevertheless, a significant difference between both axial 
Chapter 3: Axial ligand derivatisations 
 
80 
 
Pt–OH bonds is also observed for compound 3 (Pt–O1 1.990(3) Å and Pt–O2 
2.027(3) Å). The existence of hydrogen bond interactions could have some effect 
on the bond distances between the oxygen donor atoms and the metal centre. Thus 
the significant length difference observed in the two Pt–O axial bonds of the 
symmetric compound 3 (vide supra) is related to its packing arrangement, with 
one of the hydroxido ligands being involved in two hydrogen bonds (as a donor 
and acceptor) with another hydroxide and an azide of a neighbouring molecule, 
whereas the second hydroxido acts only as a donor. This appears to weaken 
slightly the former Pt–OH bond. For this reason, a comparative analysis of 
intermolecular interactions in complexes 4, 5, 6 with those in precursor 3 is 
interesting in order to explain such effects. 
The intermolecular attractions which dictate the packing of complex 4 are shown 
in Figure 3.6 and consist of classical hydrogen bonds as well as some weak -  
and C–H···  interactions.  
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Figure 3.6: Intermolecular interactions of complex 4. Classical H-bonds are 
denoted in pink whereas -  interactions are shown in green. Bond distances are 
expressed in Å.  
 
Each molecule in the unit cell is able to participate in three intermolecular 
hydrogen bonds: two are established with an adjacent molecule through the 
interaction of the hydroxido ligand and the azide nitrogen atom (O2–H2···N3, O2–
H2···N6 2.12 Å), while the third hydrogen bond interaction involves the OH group 
of the succinate ligand and the oxygen atom from the hydroxido belonging to a 
third molecule of complex (O–H5···O2, 1.706 Å). Based on the distance, both 
hydrogen bonds can be considered strong, but the interaction with the succinate is 
considerably stronger.  
Additionally, the pyridine rings of complex 4 interact via two different 
intermolecular forces: a C–H···  interaction between the ortho hydrogen of a 
pyridine ring and the -cloud of another pyridine ring from a neighbouring 
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molecule (Ct1···H15, 3.025 Å), and also a very weak -  stacking interaction 
between two pyridines with a centroid-centroid distance of 3.950 Å (Ct2-Ct3) 
(Figure 3.6). 
Interestingly, in complex 5 the azide ligands are not involved in any hydrogen 
bonding. Each molecule establishes two intermolecular hydrogen bonds between 
the carbonyl group of the 4-oxo-4-propoxybutanoate ligand and the hydroxido 
group of a nearby molecule (O2–H2···O2 1.972 Å) as shown in Figure 3.7. 
Moreover, complex 5 shows a -  stacking interaction between pyridine rings 
(3.551 Å) in the crystal packing, which is stronger in comparison with that found 
for complex 4. 
 
Figure 3.7: Intermolecular interactions of complex trans, trans, trans-
[Pt(N3)2(OH)(Succ-Pr)(pyr)2] complex 5. Hydrogen bond and -  stacking 
interactions are denoted with purple and green colours, respectively. Bond 
distances are expressed in Å. 
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In complex 6, each molecule in the crystallographic unit cell is hydrogen-bonded 
via an azide nitrogen atom (N5) and the hydroxido group (O2–H2) to another 
neighbouring molecule (Figure 3.8). The strength of this bond can be considered 
as medium to weak as it is only 2.288 Å. It must be noted that the azido ligand in 
complex 6, which participates in an intermolecular hydrogen bond shows weaker 
bond with the Pt(IV) ion than the second azide ligand. Moreover, this is the only 
complex for which a strong intramolecular hydrogen bond interaction is observed. 
In this case the H-bond involves the carbonyl and the NH group of the 
coordinated N-methylisatoate anion (N-H10···O3 1.096 Å), which also dictates the 
spatial orientation of the ligand.  
 
Figure 3.8: Intermolecular and intramolecular hydrogen bond interactions for 
complex trans, trans, trans-[Pt(N3)2(OH)(N-MI)(pyr)2] 6. Bond distances are 
expressed in Å. 
 
3.3.3 Aqueous solubility and stability in the dark 
The aqueous solubility of novel compounds is important as it greatly influences 
the mode of drug administration. The solubility of the compounds was determined 
as a saturated solution in water (for complex 4 and 5) and in 5% DMSO/ 95% 
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H2O (for complex 6). The concentration of the latter compound was determined 
by ICP analysis of the platinum content (see Chapter 2 for details). The results are 
summarized in Table 3.5, in which complex 3 is also included for completion.  
 
Table 3.5: Solubility of 3-6 at room temperature (ca. 20 
o
C).  
Complex 
Solubility  
(mM) 
Solvent 
3
 34.0
a
 H2O 
4 2.0 H2O 
5 1.5 H2O 
6
 0.064 5% DMSO/95% H2O 
 
a
 From reference 36 
 
Before cell testing experiments are carried out, it is important to ensure the 
stability of the compound in the biological media, so as to verify the state of the 
compound before the photoactivation step. Drug exposure according to the 
protocol of cytotoxicity measurement of Pt(IV) compounds is 1 hour followed by 
irradiation. Therefore there needs to be stability in an aqueous solution in the dark 
for a minimum of 1 hour. Furthermore, it is of interest to check whether there is 
rapid reduction of the compound in the presence of a biological reducing agent 
such as glutathione. For these reasons, the stability of complex 4 was tested in the 
presence of 2 mol eq of reducing agent GSH in PBS for 24 hours at 37 
o
C, in the 
dark, as a model for the reactivity of this series of complexes. 
1
H-NMR data show 
(Figure 3.9) that there is very little oxidation of GSH (~4 %, as quantified by 
NMR) over this period when compared to the GSH control. 
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Figure 3.9: 
1
H-NMR with water suppression of (A) GSH (3.8 mM) in 10 %D2O/ 
90% H2O (PBS) after incubation at 37 
o
C for 24 h in the dark (B) Complex 4 (1.9 
mM) plus 2 eq of GSH, in 10% D2O /90 % H2O PBS (pH 7.4) at t= 24 h after 
incubation at 37 
o
C in the dark. The NMR spectra show the region where the GSH 
peaks fall (see discussion). The small peak at 3.3 ppm is assigned to GSSG
37
 
(originating from GSH oxidation) which integrates to 4%. The asterisk in 
spectrum B indicates peaks for the complex. The peak at 2.7 ppm is a trace of 
DMSO.  
 
 
Compound 5 contains an ester bond, which might hydrolyse in water, and 
therefore it was important to check its stability in the dark in aqueous media. As 
shown in Figure 3.10, the compound is relatively stable as no change was 
observed within 3 days, but a new product formed by the second week after 
incubation at 37 
o
C. 
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7.47.67.88.08.28.48.68.89.09.2 ppm
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: 
1
H-NMR of compound 5, in PBS (D2O), at two different time points 
after incubation in the dark at 37 
o
C. The aromatic region of the NMR spectra 
corresponds to the pyridine ligands. Peaks at δ= 8.76 ppm, 8.28 ppm, 7.81 ppm 
are assigned to Hortho, Hpara, Hmeta, respectively. After two weeks the emergence of 
another species becomes evident.  
 
The stability of complex 6 was assessed by UV-Vis spectroscopy, since its 
aqueous solubility was too low for NMR experiments. The compound was 
incubated at 37 
o
C in the dark. Also in this case, very little change was observed 
after 1 h 40 min (Figure 3.11), which suggests that the compound was stable 
enough for cell line testing.  
t=0 days 
t=2 weeks 
t=3 days 
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Figure 3.11: UV-Vis spectra for complex 6 in 95% H2O and 5% DMSO at t=0 h 
and after 1 h 40 min of incubation at 37 
o
C in the dark.  
 
3.3.4 pKa
*
 study for complex 4 
To understand the speciation of the succinato complex 4 under physiological 
conditions, the pKa of the carboxyl group was determined according to the method 
described in section 3.2.2.3. Changes in pH* resulted in the shift of the ortho 
protons of the pyridine ligands as well as the protons of the succinate ligand. 
However, peaks for the latter merged to one peak at low pH* and therefore the 
change in the shift of the pyridine protons was used to examine all the pH* range. 
The data (Figure 3.12) were fitted to the Henderson-Hasselbach equation using 
Origin 8.5 which yielded the value of pKa
*
 of 5.07. It is well established that the 
binding affinities of D
+ 
and H
+ 
are different and therefore it would result in 
different acidities. pKa
* 
can be converted into the pKa value using the relationship: 
pKa= pKa
*
× 0.929 + 0.42 
38
, which results in a pKa of 5.13. 
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Figure 3.12: The change in chemical shift for the ortho protons of pyridine in 
complex 4 with respect to changes in pH*. The sample was dissolved in D2O (1.1 
mM) and the pH* was adjusted as described in section 3.2.2.3. The data were 
fitted to the Henderson-Hasselbach equation (red curve), with an r
2
= 0.99, giving 
a pKa
*
 of 5.07.  
 
3.3.5 Extinction coefficient studies 
Characterisation of the absorption profile of photoactivatable metal complexes is 
of crucial interest in the investigation of their properties. Through UV-Vis studies 
it is possible to obtain information about electronic transitions and excited states 
that can be generated upon light irradiation. Such states are involved in the 
chemical change of the complex into the generation of biologically active 
photoproducts. On this basis, the extinction coefficients of complexes 3-6 in water 
were determined, as described in Chapter 2 (section 2.5) and spectra are plotted in 
the same graph for comparative purposes in Figure 3.13. Complex 4 contains a 
carboxylic acid ligand and therefore it is interesting to determine the extinction 
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coefficient for the two different states of the coordinated ligand: protonated and 
deprotonated. As it was shown in section 3.3.4, the pKa of complex 4 was found 
to be 5.13, hence the extinction coefficient was measured at both low and high pH 
(3.2 and 8.3) at ca 20 
o
C. The absorbance was identical indicating no pH 
dependence of the extinction coefficient. The determination of the extinction 
coefficient at longer wavelength for complexes 3 and 4 was achieved by the use of 
higher concentrations (1.4 mM and 0.95 mM for 3, 0.87 mM and 0.57 mM for 4) 
and this is illustrated in the inset graph of Figure 3.13.  
 
Figure 3.13: Comparison of the UV-Vis spectra of complexes 3-6. The inset 
shows expansions at longer wavelength, determined using more concentrated 
samples (0.87 mM for 4 and 1.4 mM for 3). 
 
 
The wavelengths corresponding to the maximum absorption of those compounds 
follow the order of: 6 > 5 > 4 > 3, as the values are 302 nm, 300 nm, 299 nm, 294 
nm, respectively. The difference between UV-Vis spectra of these complexes is 
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that in the case of complex 6, a shoulder appears at ca. 350 nm which is due to the 
presence of the aromatic ligand.  
3.3.6 Photoirradiation studies followed by UV-Vis  
The photoreactivity of compounds 3, 4, and 6 was followed by UV-Vis 
spectroscopy at frequent time points after irradiation of aqueous solutions of the 
compounds (ca. 60 μM) with green light (517 nm LED, 29 mW/cm2) at ambient 
temperature (ca 20 
o
C). The photoreactivity of complex 3 has been reported 
before
26
 but it was also examined here as a control compound. Green light was 
used, as it is clinically more preferable (see Chapter 1). Furthermore, complex 4 
was also irradiated with blue (463 nm, 59 mW/cm
2 
) and green light (550 nm, 
filtered below 530 nm with GG530, 4 nm slits, 2.5 mW/cm
2 
), as shown in Figure 
3.19 and Figure 3.20, in order to investigate the effects of shorter and longer 
wavelengths.  
 
Figure 3.14: Change in the UV-Vis spectrum over time of complex 3 (60 μM, 
H2O) upon irradiation with green light (517 nm). The arrow shows the decrease in 
absorbance of the absorption maximum, at 296 nm, with respect to time. 
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Figure 3.15: Change in the UV-Vis spectrum of complex 4 (60 μM, H2O) upon 
irradiation with green light (517 nm). 
 
Figure 3.16: Time dependent change in the UV-Vis spectra of complex 5 upon 
irradiation with green light (517 nm).  
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Figure 3.17: Time dependent change in the UV-Vis spectra of complex 6 (ca 60 
μm 5% DMSO, 95% H2O) upon irradiation with green light (517 nm).  
 
 
 
0 200 400 600 800
40
60
80
100
 Complex 4
 Complex 5
 Complex 6
 Complex 3
N
o
rm
a
li
s
e
d
 a
b
s
o
rb
a
n
c
e
Time (min)
Figure 3.18: Plot of the decrease in intensity of the N3→Pt band (up to 38%) of 
compounds 3-6 versus time, when irradiated with green light (517 nm). The data 
were fitted to the equation y=y0+Ae
Rox.  
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Figure 3.19: Time dependent change in the UV-Vis spectra upon irradiation of 4 
(ca 50 μM) with blue light, 463 nm. The fast degradation of the complex is 
illustrated by the short half-life of 10 min, which was extrapolated by fitting an 
exponential function (red line, r
2
=0.99).  
 
 
Figure 3.20: Time dependent change in the UV-Vis spectra upon irradiation of 
complex 4 with a low dose of 550 nm light (2.5 mW/cm
2
). The spectra show very 
minimal change.  
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In Figure 3.14 -Figure 3.17, the change of the UV-Vis spectrum is recorded at 
different irradiation times (therefore different doses of green light). As with all of 
the Pt(IV)-diazido complexes, a decrease in the intensity of the azido-Pt charge-
transfer band (i.e. the main UV band in the absorption spectrum of complexes at 
ca. 300 nm) is observed due to the loss of an azide. The maximum for each of the 
graphs was normalized so that the first spectrum (t=0 h, i.e. before the irradiation) 
has a normalized absorbance of 100%. Then by considering only the degradation 
of up to ca. 38%, the points were fitted to an exponential curve (y=y0+Ae
Rox) 
using Origin 8.5, for determination of half-life, a method used previously.
39
 The 
graphs are plotted comparatively and illustrated in Figure 3.18. The half-lives of 
3, 4, 5, and 6 upon irradiation with green light were found to be 634 min, 220 min, 
169 min, and 214 min, respectively. This shows that the photodegradation of 3 
occurs 2.9 times more slowly than compound 4, 3.7 times slower than compound 
5, and 3.0 times slower than compound 6. 
When compound 4 was irradiated with a high dose of blue light, the photoreaction 
was very fast with a half-life of 10.4 min (Figure 3.19). However when the 
compound was irradiated with the longer wavelength light (550 nm) little change 
was observed over the course of 4 hours (Figure 3.20).  
3.3.7 Photoirradiation followed by EPR 
DMPO is a widely used trapping agent which has been employed for the detection 
of O-, N-, S- and-less frequently- for C-centred radicals.
40
 It has been used 
previously for the successful detection of azidyl and hydroxyl radicals.
41, 42
 On 
this basis, it was chosen as a suitable spin trap for the Pt(IV)-azido complexes and 
was used to follow the irradiation of compounds 3-6. Free azidyl radicals have a 
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very short life time (10
-5
-10
-6 
s), therefore it is difficult to directly detect them 
without a spin trap.
43
 
The yield of DMPO-N3 adduct formation was determined by the double 
integration of the EPR signals and quantified with respect to Tempol at each time 
point upon irradiation with green LED light (517 nm, 33 mW/cm
2
) of the 
compounds 3, 4, and 5 (1 mM, in PBS) in the presence of DMPO (2 mM). As a 
control, the EPR spectra were recorded in the dark and no azide radical trapping 
was observed. Comparing the DMPO-N3 yields at various time points (0, 7, 21, 
28, 35 min) during the irradiation of compounds 3, 4 and 5, it becomes evident 
that the two compounds with the two carboxylates can produce radicals when 
irradiated with green light whereas the dihydroxido compound 3 did not give rise 
to radical signal.  
Also, the compounds were studied for their ability to yield azidyl radicals in DMF 
(75%) which is a suitable solvent for all complexes allowing a comparative study 
(Figure 3.22). The yield was estimated at various time points during the 
irradiation (0, 7, 14, 21, 28, 35 min) and follows a similar trend as in the buffered 
solution, with compounds 4 and 5 giving rise to larger EPR signals than 
compound 3. Compound 6 gave an unexpected result, as the yield of azidyl 
radicals was as low as that found for compound 3. To rationalize the effect of the 
N-MI ligand on the yield of azidyl radicals, complex 3 (2 mM, 75% DMF/ 25% 
H2O) was irradiated (463 nm, 64 mW/cm
2
) in the presence of N-MIA (1 or 2 mol 
eq, 2 mM or 4 mM) and DMPO (2 eq, 4 mM) and the yield was measured at 
various time points (Figure 3.23).  
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Figure 3.21: Time dependent trapping of azidyl radicals upon continuous 
irradiation of three Pt(IV) diazido compounds (1 mM in PBS) with green light 
(517 nm, 33 mW/cm
2
): compound 4 (black squares), compound 5 (red circles and 
reference compound 3 (blue triangles).  
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Figure 3.22: [DMPO-N3] signal which was obtained upon irradiation with green 
light (517 nm, 33 mW/cm
2
, 14 min) of complexes 3-6 (2 mM) in the presence of 
DMPO (2 mol eq, 4 mM) in DMF/H2O (75%/25%, v/v).  
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Figure 3.23: [DMPO-N3] signal upon continuous irradiation (463 nm) of complex 
3 (2 mM) alone (black squares) or in the presence of 1 and 2 eq of the N-MI 
ligand (red and blue triangles-overlapped) in DMF/ H2O (75%/ 25%).  
 
 
3.3.8 NMR irradiation studies 
NMR is a powerful tool for the study and characterisation of photoreactions and 
has been used effectively in the past to characterise photoproducts of Pt(IV)-
diazido photoreactions.
23, 44-46
 1D 
1
H, 
195
Pt, 
14
N as well as 2D 
15
N-
1
H HMBC are a 
few NMR techniques which have been used to elucidate the complicated 
photodissociation pathways of these compounds. Moreover it has been shown that 
the photoproduct production is dependent on: a) the ligands (aliphatic vs aromatic 
amines),
47, 26
 b) wavelength of irradiation, c) concentration, d) solvent 
composition, and e) presence of other molecules with affinity for platinum. Point 
(d) became evident in the reports by Ronconi et al as it was shown that in an 
acidic environment, the decomposition of trans, trans, trans-
[Pt(N3)2(OH)2(NH3)2] gave rise to the evolution of much more dinitrogen 
compared to when the irradiation was carried out at neutral pH.
45
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become evident in many reports for which the presence of a reactive molecule 
prohibits the formation of a precipitate during the reaction. Precipitates formed 
during the irradiations can be difficult to analyse due to its extreme insolubility in 
various solvents but are believed to consist of Pt-hydroxo bridged species.
44
 
Since Pt compounds can readily bind to nucleic acids or proteins once inside the 
cell, it is important to carry out the photoirradiation studies in the presence of 
biomolecules. For this reason, compounds 4 and 6 (containing aliphatic and 
aromatic carboxylate ligands respectively) were irradiated in the presence of 
guanosine monophosphate (5’-GMP), using a wavelength of irradiation at 463 nm 
(or 420 nm) to ensure a fast reaction. Additionally, the use of the fluorophore N-
MIA as coordinating ligand in complex 6, allowed the photostability of this 
complex to be followed by fluorescence emission spectroscopy.  
 
3.3.8.1 Photoirradiation studies of complex 4 trans,trans,trans-
[Pt(N3)2(OH)(Succ)(pyr)2] 
 
Complex 4, as compounds 3, 5 and 6, was found to be stable in the dark, as shown 
in section 3.3.3. The release of the axial ligand upon irradiation is a characteristic 
outcome for such compounds together with the release of azide, as observed 
previously for trans, trans, trans-[Pt(N3)2(OAc)2(pyr)2].
36
  
Indeed, the release of the succinate ligand upon irradiation at 463 nm for 10 
minutes was confirmed by adding an aliquot of succinic acid to the irradiated 
solution of 4. Figure 3.24 shows the 
1
H-NMR spectrum before and after the 
irradiation of complex 4. The singlet peak at 2.4 ppm corresponds to the released 
succinate. No bound succinate is observed after 10 minutes of irradiation with 
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blue light (463 nm, 64 mW/cm
2
). The aromatic area shows a mixture of pyridine-
containing photoproducts. The photoreaction was studied more extensively in the 
presence of GMP (2 mol eq). 
 
Figure 3.24: 
1
H-NMR spectrum of 4 (1.5 mM, PBS/ D2O) (A) in the dark and (B) 
after 10 minutes of irradiation with 463 nm light (38400 mJ/cm
2
). The NMR 
spectra were referenced with dioxane and the release of succinate becomes 
evident. The region labelled with a square in (B) indicates the pyridine-bound 
photoproducts. 
 
In order to follow the photoreaction, NMR studies were carried out after the 
irradiation of the complex in the presence of 5’-GMP (1.5 mM complex 4, and 3 
mM GMP in PBS). Figure 3.25 shows the speciation at different doses of blue 
light (463 nm) and also the result of an irradiation with slightly shorter 
wavelength (420 nm). The 
1
H-NMR spectra  show the presence of two main 
products which are labelled by a circle and rhombus, the former product being 
assigned to the mono-azido GMP adduct, trans-[Pt(N3)(GMP)(pyr)2].  
Chapter 3: Axial ligand derivatisations 
 
100 
 
 
 
 
 
 
 
Figure 3.25: 
1
H-NMR (500 MHz, D2O, dioxane) and 
195
Pt-NMR (129 MHz) 
spectra of complex 4 and GMP (2 mol eq) in PBS (pH 7.4) at the following 
conditions: A) Dark, B) irradiation with 463 nm, 10233 mJ/cm
2
, C) irradiation 
with 463 nm, 35400 mJ/cm
2
, D) irradiation with 463 nm, 70800 mJ/cm
2
, E) 
irradiation with 420 nm, 30510 mJ/cm
2
. The circle and the rhombus signals 
denote the evolution of the two main photoproducts; F) Signal of 
195
Pt-NMR at -
2210 ppm showing the formation of trans-[Pt(N3)(5’-GMP)(pyr)2].  
 
 
(F) 
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Compound 3 was also photoirradiated in order to be compared with compound 4. 
Interestingly the photoproducts are very similar, but one important difference is 
the speed of the reaction: In the case of compound 3, 10 minutes of irradiation 
resulted in only 9 % of 5’-GMP binding whereas compound 4 gave rise to 23% 
(Figure 3.26), with the same power. Signals relative to the Pt-bound 5’-GMP were 
assigned and quantified (by the NMR H’1 integration) only in the case of trans-[Pt 
(N3)(GMP)(pyr)2], as this is the main photoproduct. This assignment is confirmed 
by the LC-MS studies (section 3.3.9.1) and also by the chemical shift of the signal 
in the 
195
Pt-NMR spectrum which was previously reported for this species.
26
 The 
other GMP photoproducts are too weak to be integrated accurately.  
 
Figure 3.26: 
1
H-NMR spectrum of A) Compound 4 (1.5 mM, PBS (D2O) plus 
GMP (2 mol eq), and B) Compound 3 (1.5 mM, PBS/ D2O) plus 5’-GMP (2 mol 
eq) after 10 minutes of irradiation with 463 nm (64 mW/cm
2
). The signals denoted 
with circles and squares represent the mono-GMP adduct (trans-[Pt 
(N3)(GMP)(pyr)2]) and starting materials, respectively.  
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With the aim of following the kinetics of the photodissociation in the presence 
and absence of 5’-GMP, the release of succinate was monitored by irradiating a 
sample of complex 4 (1.5 mM, PBS, pH* 7.4) in the presence and absence of 
GMP (2 mol eq). The release of succinate was estimated by following the 
photoreaction by 
1
H-NMR and the percentage of release was plotted and fitted to 
the exponential function: y=y0+Ae
Rox (Figure 3.27). It was shown that the 
photoreaction proceeds three times faster in the absence of 5’-GMP.  
 
 
Figure 3.27: Time dependent release of succinate upon irradiation with blue light 
(463 nm, 64 mW/cm
2
) of 4 (1.5 mM, PBS, D2O, pH* 7.4) in the presence (blue) 
and absence (red) of GMP (2 mol eq, 3 mM). Black dots denote the experimental 
data whereas the blue and red lines denote the fitted exponential function (r
2
=0.98 
for red and r
2
= 0.996 for blue).  
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3.3.8.2 Photoirradiation studies of complex 6 trans, trans, trans-
[Pt(N3)2(OH)(N-MI)(pyr)2] 
 
Photoirradiation studies of compound 6 were carried out in the presence of 5’-
GMP. The poor aqueous solubility of 6 prevented a study by 
1
H-NMR to be 
carried out in water. Therefore a mixture of 75% MeOD and 25% D2O (v/v) was 
used. Irradiation of 6 at 420 nm for 40 min resulted in a colour change from 
yellow to brown. This is likely due to the release of the axial ligand (N-MIA), as 
will be shown in the following sections. Furthermore, a change in the pH had 
occurred after the irradiation as a shift of the peaks (including the water peak) is 
observed (Figure 3.28). Accurate pH* measurement was not possible due to the 
high percentage of methanol. This effect prohibited a direct comparison of the 
chemical shift between the free N-MIA ligand (synthesized in section 3.2.2.8.7) 
and the photoproducts. Irradiation of compound 6 with blue light (420 nm, 45 
min, 11.3 mW/cm
2
) did not result in the complete photodissociation of the 
complex, as there was still present 35% of bound N-MI ligand as well as 13% of 
another species containing this ligand (Figure 3.28 B). In the aromatic region, the 
evolution of a pyridine-containing species was observed which constitutes the 
main photoproduct of this reaction. Strikingly, irradiation of 6 (1.5 mM) with a 
very low dose of UVA light (1440 mJ/cm
2
) resulted in the complete 
photodissociation of the complex, as it is shown by the presence of only one 
ligand methyl peak, which can be assigned to the free N-MIA ligand. One of the 
main photoproducts in this case was interestingly found to be free pyridine, which 
was proved by spiking the sample with pyridine (Figure 3.28 D). Irradiation with 
420 nm resulted in only a small release of pyridine; however higher doses of light 
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would result in the complete photodissociation of the complex and an even larger 
amount of pyridine release. Interestingly, irradiation with either 420 nm or UVA 
light did not result in the production of a 5’-GMP adduct. With the purpose of 
establishing whether this is an effect of the compound or the solvent, the 
previously studied complex 3, trans,trans,trans-[Pt(N3)2(OH)2(pyr)2], was also 
irradiated under the same solvent conditions, i.e. 75% MeOD, 25% D2O. The 
results show that 5’-GMP adducts formed in a small percentage (see small adducts 
at 5.8 ppm) when the compound was irradiated with either 420 nm or UVA light 
(Figure 3.29).  
 
 
Figure 3.28:
 1
H-NMR spectra (500 MHz, ns = 256) of complex 6 and 5’-GMP (2 
mol eq) in MeOD (75%) and D2O (25%) (v/v) at the following conditions: A) 
Dark, B) 420 nm, 30510 mJ/cm
2
, C) UVA, 1440 mJ/cm
2
,
 
D) Sample C spiked 
with pyridine. 
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Figure 3.29: 
1
H-NMR spectra of complex 3 (1.5 mM, MeOD (75%) /H2O (25%)) 
and 5’-GMP (2 mol eq) at A) Dark, B) irradiation with 420 nm, 30510 mJ/cm2 C) 
irradiation with UVA, 1440 mJ/cm
2
. The dots signify the release of free pyridine 
ligand.  
 
The incorporation of the fluorescent ligand, N-methylisatoaic acid in its 
deprotonated form provides the possibility of complex 6, trans, trans, trans-
[Pt(N3)2(OH)(N-MI)(pyr)2] to be studied with fluorescence emission spectroscopy  
by excitating the sample at 320 nm. Compound 6 has a strong absorption band at 
300 nm (Figure 3.13). Therefore exciting the compound at 320 nm can potentially 
cause the photodissociation of the compound and release of the axial ligand N-
MIA. Each measurement (200 nm/min, 377 nm spectral range) resulted in light 
exposure for 113 seconds, which was enough to generate structural changes in the 
compound without any further irradiation (Figure 3.30). The fluorescence spectra 
show a maximum at 420 nm (hence emission in the blue region). With the aim of 
identifying whether the increase in fluorescence is due to the release of the ligand, 
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the fluorescence of free N-MIA ligand was recorded; the fluorescence maximum 
was almost identical for both compounds.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.30: Fluorescence emission of the free N-MIA ligand (0.26 μM, 5% 
DMSO/95% H2O) and the increase in fluorescence emission of complex 6 (26 
μM, 5% DMSO/95% H2O) upon consecutive measurements, by excitation at 320 
nm. The irradiation times (in seconds) were determined by the scanning rate and 
the spectral range. 
 
3.3.9 High resolution LC-MS studies  
Liquid chromatography coupled to mass spectrometry is a useful technique for the 
separation and identification of photoproducts. HPLC coupled to mass 
spectrometry was used previously by Bednarski et al. to identify the 
photoproducts from trans, trans, trans-[Pt(N3)2(OH)2(NH3)2] and trans, trans, 
trans-[Pt(N3)2(OH)2(pyr)(NH3)].
48
 One advantage offered by such a technique is 
that a minimal amount of sample is required, which makes it ideal when only 
small quantities of sample can be obtained, such as compound 7 studied in this 
chapter (see experimental section 3.2.2.8.8). Liquid chromatography was used to 
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separate the mixture of photoproducts before analysis by high resolution mass 
spectrometry (MaXis) for an accurate assignment of the species.  
3.3.9.1  LC-MS studies of complexes [Pt(N3)2(OH)(Succ)(pyr)2] 4 and 
[Pt(N3)2(OH)(pyr)2(Succ-(RGD)f)] 7 
 
The irradiation of compounds 4 and 7 in the presence of 5’-GMP was carried out 
in H2O (0.5 mM) with 2 mol equiv. 5’-GMP (1 mM), after irradiation with 420 
nm (30510 mJ/cm
2
) at 37 
o
C, using the LuZchem photoreactor. The irradiated 
solutions were analyzed directly without any further dilution. The method 
employed for the separation of the products is described in Chapter 2 (Section 
2.2.2). The characterisation of each peak is given in Table 3.6.  
Figure 3.31: Chromatogram of the complexes 4 and 7 with 5’-GMP (2 mol eq) in 
the dark (black) and after the photoirradiation (red) of A) complex 4 and B) 
Pt(IV)-(RGD)f peptide 7. The numbering corresponds to the various species 
detected, the assignments of which are summarized in Table 3.6.  
Complex 4 
Complex 7 
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The mass spectra of complexes 4 and 7 are shown in Figure 3.32. Compound 4 
elutes as one peak in the chromatograph and the corresponding mass spectrum 
(ESI-MS) contains the molecular ion peaks with low intensity, including a proton 
or sodium ion. The dominant peaks corresponds to the [M-N3]
+
 ion, which 
indicates the ease by which the azide ion dissociates from the complex, under 
electrospray ionisation. Compound 7 gives two peaks (see Figure 3.31 B) 
indicating the presence of another species. The latter was assigned to the Pt(IV)-
(RGD)f conjugate in which the axial –OH has been replaced with trifluoroacetate 
(used in the initial HPLC purification of the compound).  
 
(A) 
 
(B) 
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(C)  
 
Figure 3.32: ESI-MS of dark samples of compound 4 (A) and the Pt(IV)-(RGD)f 
peptide 7 (B and C). The spectrum B corresponds to the main peak of the 
chromatograph (Figure 3.31) whereas spectrum C corresponds to the minor peak. 
Theoretical assignments for peaks: (A) [M-N3]
+
, C14H16N5O5Pt
+
, 529.0799 m/z, 
where M is compound 4. (B) [M-N3+H]
+
, C47H67N15O14Pt
2+
, 630.2314 m/z where 
M is the Pt(IV)-(RGD)f as shown in Figure 3.3. (C) [M-N3+H]
+ 
, 
C49H66F3N15O15Pt
2+
, 678.2227 m/z, where M is the Pt(IV)-(RGD)f-peptide which 
the axial –OH has been substituted with a trifluoreacetate.  
 
 
 
Table 3.6: Assignment of the various species detected after the irradiation of 
compounds 4 and 7. The peak number corresponds to the peak labelling in the 
chromatographs of Figure 3.31. The m/z values given in the assignment column 
correspond to the theoretical values.   
Peak Mass Spectrum Assignment 
Error 
in 
 ppm 
1 
   
[2GMP+H]
+
 
m/z= 727.1246 
 
[GMP+H]
+
 
m/z= 364.0658 
 
 
m/z= 152.0588 
 
 
1.1 
 
 
0.3  
 
 
 
5.3 
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2 
  
 
 
 
 
 
 
 
m/z= 378.5667 
0.3 
3 
 
 
 
 
m/z= 539.5820 
0.2 
4 
 
Unknown 
NA 
5 
  
 
m/z= 758.1164 
0.5 
6 
 
 
Structural isomer of 
mono-GMP adduct 
(above) 
 
m/z= 758.1164 
0.1 
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7 
  
 
 
 
 
 
m/z= 529.0799 
[M-N3-N3]
+
= 487.0707 
 
 
 
1.7 
 
 
 
 
 
1.2 
 
8 
  
 
 
 
 
 
 
 
 
m/z= 474.1006 
1.7 
9 
  
 
 
 
 
 
 
m/z= 1152.1727 
3.5 
10 
 
Unknown 
NA 
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11 
 
[C37H58N10O13]
2+ 
m/z= 425.2087 
[C37H57N10O13]
+ 
m/z= 850.4107 
peptide entity 
 
 
1.6 
 
 
 
3.4 
12 
 
[C47H67N15O14Pt]
+ 
m/z= 630.2316 
(i.e. [M-N3+H]
2+
) 
0.8 
 
Irradiation of 4 (1.5 mM with 463 nm, 40 min) in PBS yielded very similar 
photoproducts to the ones obtained in H2O, as shown in Figure 3.33. The main 
differences lie in the type of 5’-GMP adducts. Irradiation in the absence of PBS 
forms preferably trans-[Pt(ACN)(GMP)(pyr)2], trans-[Pt(GMP)2(pyr)2], and a 
third unknown GMP adduct. However, irradiation in the presence of PBS (which 
contains a total of 0.140 M Cl
-
 concentration), yields a peak at 10 minutes which 
corresponds to the trans- [PtCl(pyr)2(GMP)]
+
 species.  
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Figure 3.33: LC-MS chromatogram of 4 (1.5 mM) irradiated with blue light (463 
nm) in the presence of GMP (2 mol eq) in PBS ([Cl
-
]= 139 mM) (blue line) or in 
H2O (red line). The inset represents the experimental (bottom) and simulated (top) 
peak which corresponds to [Pt(pyr)2(GMP)Cl]
+
. The arrows point out GMP 
photoproducts which are not formed in the presence of PBS. 
 
3.3.9.2 LC-MS study of [Pt(N3)(OH)(N-MI)(pyr)2] 6 
Irradiation of compound 6 (1.5 mM) plus 5’-GMP (2 mol eq) was carried out in a 
mixture of MeOH: H2O (75%: 25%, v/v), to match the NMR experiments. Firstly, 
compound 6 was irradiated at a concentration of 1.5 mM for 45 minutes at 420 
nm, using the photoreactor. The products were injected into the LC-MS system 
without any further dilution. A dark sample was also analyzed as control. Results 
are shown in Figure 3.34 and the assignment of the photoproducts is included in 
Table 3.7.  
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Figure 3.34: HPLC chromatogram of compound 6 in the dark (black line) and 
after irradiation with 420 nm (red line). The peaks were labelled and assigned in 
Table 3.7). 
 
The mass spectrum of the non-irradiated sample (Figure 3.35) shows that the base 
peak corresponds to the molecule minus an azide anion, as in the case of 
compound 4. The intensity of the molecular ion peak was low and corresponded 
to the protonated molecular ion.  
 
Figure 3.35: High resolution ESI-MS of compound 6 in the dark. Theoretical 
assignments are as follows: [M+H]
+
, C18H20N9O3Pt, 605.1337 m/z; [M-N3]
+
, 
C18H19N6O3Pt, 526.1166 m/z; [M-OH]
+
, C18H18N9O2Pt, 587.1231 m/z. 
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Table 3.7: Assignment of the various species detected after the irradiation of 
compound 6 with blue light (420 nm). The peak number corresponds to the peak 
labelling in the chromatograms in Figure 3.34. The m/z ratio reported in the 
assignment column refers to the theoretical values.  
Peak Mass Spectrum Assignment 
Error  
in 
ppm 
1 
 
a= [2GMP+H]
+
 
m/z= 727.1246 
b= [GMP+H]
+ 
m/z= 364.0658 
 
   c= 152.0588 
 
1.5 
 
  2.2 
 
 
 
7.9 
2 
 
 
 
 
 
 
m/z= 758.1164 
0.5 
3 
 
 
 
 
 
 
 
m/z= 436.0849 
 
 
 
m/z= 395.0584 
 
367.0516 unknown 
 
 
 
 
 
1.1 
 
 
 
 
 
0.8 
 
NA 
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4 
 
 
 
 
 
 
 
 
 
m/z= 537.1102 
0.7 
5 
 
 
Unknown 
NA 
6 
 
 
 
 
 
 
 
m/z= 546.1217 
464.0416 unknown 
1.8 
7 
 
 
 
 
 
 
 
m/z= 152.0712 
2.0 
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8 
 
 
 
 
 
 
m/z= 562.1166 
 
[M-N3]
+
= 520.1074  
0.9 
 
 
 
1.3 
9 
 
 
m/z= 460.0574 
 
m/z= 410.0693 
 
m/z= 382.0631 
 
m/z= 303.0209 
 
 
 
0.4 
 
 
 
1.9 
 
 
 
 
0.5 
 
 
 
1.3 
 
3.3.10 DFT and TDDFT calculations 
As demonstrated previously, DFT calculations can provide insights into the 
photochemistry of platinum-azido photoactivatable complexes.
25
 DFT and 
TDDFT calculations were performed as described in section 2.10 (Chapter 2) in 
order to characterise the electronic transitions composing the absorption spectrum 
of complex 4 and rationalize its enhanced photoactivity when compared to 
complex 3. Bond lengths of 4 in the protonated state seem to correlate better with 
the experimental bond distances, as the crystallised complex is in fact in the 
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protonated state (Figure 3.5A). The ground state geometry optimizations were 
performed in both the protonated and deprotonated state, as well as in the lowest 
lying state geometry, as summarized in Table 3.8.  
 
Table 3.8: Selected experimental and calculated bond lengths (in Å) for 
compound 4 in the protonated (trans, trans, trans-[Pt(N3)2(pyr)2(OH)(C4H5O4)]) 
as well as the deprotonated form (trans, trans, trans-
[Pt(N3)2(pyr)2(OH)(C4H4O4)]). The theoretical bond lengths were calculated in 
both the ground as well as in the lowest lying triplet state. 
Bond 
Lengths 
Distance in 
X-ray 
structure (Å) 
Ground-state 
geometry 
(deprot) 
Lowest 
lying 
geometry 
Ground-
state 
geometry 
(prot) 
Lowest 
lying 
geometry 
Pt–Nα 2.050 2.088 2.359 2.085 2.985 
Pt–Nα 2.041 2.069 2.508 2.069 2.326 
Pt–(OH) 1.984 2.015 2.015 1.994 1.992 
Pt–O(CO) 2.021 2.048 2.065 2.061 2.076 
Pt–N(py) 2.039 2.068 2.053 2.043 2.035 
Pt–N(Py) 2.033 2.027 2.040 2.039 2.058 
Nα–Nβ 1.209 1.213 1.200 1.218 1.183 
Nα–Nβ 1.198 1.211 1.189 1.214 1.204 
Nβ–Nγ 1.139 1.149 1.164 1.145 1.173 
Nβ–Nγ 1.133 1.148 1.170 1.146 1.158 
 
As commonly observed for DFT,
49, 50
 the bond lengths of the ground state are 
overestimated, the largest discrepancy being the two Pt-azide bonds, with 
differences of 0.035 and 0.028 Å. This could result from the fact that the 
geometry optimization occurs in the gas phase, or the fact that there are 
intermolecular interactions between the molecules in the crystal structures.  
The excited states of transition metal complexes usually undergo intersystem 
crossing (IC) to triplet states. In particular, the nature of the lowest-lying triplet 
state is crucial, since such a state is significantly populated before the molecule 
relaxes to the ground state. Hence the photochemistry of a metal complex highly 
depends on the lowest lying-triplet state. Elongation of bonds is indicative that 
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they could undergo bond-breaking upon light excitation, and therefore suggestive 
of which ligands are likely to be released. The difference between the lowest lying 
geometry and the ground state in the case of deprotonated and protonated systems 
follows the same trend: both Pt-azide bonds show the biggest elongation. The Pt–
OH bond is either shortened (protonated) or stays intact (deprotonated), the Pt-
succinate bond is elongated, and one of the Pt-pyridine bonds is elongated 
whereas the other is shortened.  
The UV-Vis spectra were simulated by calculation of 32 singlet states using water 
as a solvent (cpcm)
51
 and the TDDFT method. The theoretical UV-Vis maxima 
appear at 286 nm (33748 mol
-1
cm
-1
) in the case of the deprotonated state and 288 
nm (26217 mol
-1
cm
-1
) in the case of the protonated state. The experimental 
maximum is located at 299 nm (ε= 17251 mol-1cm-1). TDDFT calculations 
therefore seemed to slightly underestimate the absorption maximum by ca. 10 nm 
and overestimate the value of the extinction coefficient. The method used for 
these TDDFT calculations is the same as that used for 3, for which a closer match 
between the theoretical and the experimental extinction coefficient was found. 
Therefore the larger difference in the case of 4 can be ascribed to the presence of 
the succinate ligand. Although functional and basis set benchmarking testing 
might improve the agreement between calculated and experimental transitions, the 
results obtained are satisfactory as they help to characterise the nature of the UV-
Vis bands.  
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Figure 3.36: Experimental (pink) and theoretical (purple) UV-Vis spectra of 
compound 4 in the deprotonated (A) and protonated (B) states. The vertical bars 
represent the oscillator strength of the excitated states.  
 
The main focus in the description of the excited states will be on the deprotonated 
state as it has been established before (section 3.3.4) that at physiological pH, 
complex 4 will be deprotonated. The excited states as well as the percentage 
contribution in each case are summarized in Table 3.9. It should be noted that the 
longer wavelength transitions in this complex extend up to 469 nm, whereas in 
trans, trans, trans-[Pt(N3)2(OH)2(pyr)2] 3 they reach to 414 nm. The longer 
wavelength transitions S1, S2 and S3, which occur at wavelengths greater than 
400 nm, show that there is a transfer of electron density from the succinate to the 
platinum centre (
1
LMCT) and also contain 
1
IL (inter-ligand transitions) character. 
In the S1 (LMCT), electron density migrates from the succinate to the Pt centre 
and in the second case (IL) to the hydroxyl and azide groups, but not to the 
pyridines. All these transitions (S1, S2, S3) as well as some of the higher energy 
involve the LUMO, which is antibonding in character with regard to the four 
equatorial ligands but mainly the azides. Interestingly the LUMO+1, to which 
electron density is promoted in the higher wavelength transitions (e.g. S8, S14) is 
orthogonal with respect to the LUMO, making it strongly antibonding mostly 
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towards the pyridines and also the hydroxido and the succinate ligand. This 
suggests that occupation of the LUMO or LUMO+1 could potentially lead to 
dissociation of two out of the six ligands. These two ligands would be in trans to 
each other. The HOMO is mainly ligand-based, with the major contribution from 
the succinate and very little on the pyridine (see Figure 3.37) which explains the 
LMCT character of the low energy transitions. Interestingly, the molecular 
orbitals of complex 4 in the protonated state show that the HOMO involves all the 
equatorial ligands as well as platinum, excluding the pyridines (Figure not 
shown), but the LUMO and LUMO+1 orbitals are very similar in character 
between the two species.  
UV transitions (e.g. S14, S19) occur from lower energy HOMOs and can be 
assigned to 
1
LMCT / 
1
IL transitions. In general all transitions for complex 4 show 
some d-d character, as metal orbitals always contribute to the frontier molecular 
orbitals. Most of the ligands are involved in these transitions, which could suggest 
larger variability in the photoproducts when the complex is irradiated at a short 
wavelength.   
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Table 3.9: Selected calculated (TD-DFT) singlet transitions for complex trans, 
trans, trans-[Pt(N3)2(pyr)2(OH)(Succ)] 4 in the deprotonated state.  
Transition Energy 
(eV) Wavelength (nm) Oscillator Strength Major composition 
S1 2.64 469 0.0004 
HOMO-3 →LUMO (63%) 
HOMO-2 →LUMO (28%) 
S2 3.00 413 0.0005 
HOMO-1→LUMO (80%) 
HOMO→LUMO (17%) 
S3 3.07 404 0.0002 
HOMO-1→LUMO (15%) 
HOMO→LUMO (81%) 
S4 3.13 396 0.0019 HOMO-4 → LUMO (75%) 
S5 3.43 362 0.0019 
HOMO-7→LUMO (28%) 
HOMO-5→LUMO (53%) 
S6 3.48 356 0.0011 
HOMO-3→LUMO (30%) 
HOMO-2→LUMO (64%) 
S8 3.80 326 0.0022 
HOMO-7→LUMO+2 (10%) 
HOMO-5→LUMO+1 (10%) 
HOMO-5→ LUMO+2 (16%) 
HOMO-1→LUMO+1 (13%) 
HOMO-1→LUMO+2 (10%) 
S9 3.84 322 0.0018 
HOMO-7→ LUMO (46%) 
HOMO-6 →LUMO (29%) 
S14 4.19 296 0.0216 
HOMO-3→ LUMO+1 (34%) 
HOMO-3→LUMO+2 (13%) 
HOMO-2→LUMO+1 (12%) 
HOMO-2→LUMO+2 (12%) 
S19 4.31 288 
0.3322 
 
HOMO-7→ LUMO (12%) 
HOMO-6 →LUMO (33%) 
HOMO-5→LUMO (13%) 
S22 4.437 279 0.0543 
HOMO-12→LUMO (10%) 
HOMO-11→LUMO (31%) 
HOMO-10→ LUMO (20%) 
S32 4.77 260 0.0145 
HOMO-5→LUMO+1 (48%) 
HOMO-5→LUMO+2 (31%) 
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LUMO+3 LUMO+2 LUMO+1 
 
LUMO 
 
HOMO 
HOMO-1 HOMO-2 HOMO-3 
 
Figure 3.37: Selected molecular orbitals of compound 4 (deprotonated) in the 
ground-state geometry.  
 
3.3.11 Cytotoxicity and cellular uptake studies 
The determination of IC50 values in the dark and also upon irradiation is important 
to estimate the phototherapeutic window of these novel complexes. The IC50 
values were determined as described in Chapter 2 in collaboration with Dr Julie 
Woods, in A2780 (ovarian cancer cell line) and in one case in A2780cis (A2780 
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cisplatin resistant) cell lines. The complexes were exposed to the drugs for one 
hour in the dark and irradiated with a low light dose of 5 J/cm
2
 at 420 nm. The 
95% confidence interval indicates that the value of IC50 lies between the ranges 
provided. The phototoxic index (PI) is the ratio between the dark and light IC50, 
and a high ratio is more desirable for clinical application. Compounds 4 and 5 
have very similar IC50 values and 6 shows the lowest toxicity. The reported IC50 of 
3 is an average of two independent values: 8.3 μM (CI: 3.4-20.4 μM)52 and 5.1 
μM (CI: 3.7-6.9 μM).  
 
Table 3.10: Summary of phototoxicity and dark toxicity IC50 values of 3, 4, 5 and 
6 on A2780 human ovarian cancer cell line. The irradiation was carried out at 420 
nm.  
Complex 
A2780 A2780cis 
IC50 
420 nm 
(µM) 
95% CI R
2
 
IC50 
Dark 
(µM) 
PI 
IC50 
420 nm 
(µM) 
95% CI R
2
 
IC50 
Dark 
PI 
3 6.7
*
 3.6-13.7 0.890 >200 >45 ND ND ND ND ND 
4 3.6 3.5-3.8 0.984 >175 >48.6 ND ND ND ND ND 
5 3.7 3.0-4.6 0.811 >163 >44.1 ND ND ND ND ND 
6 12.1 7.3-19.9 0.909 >67 >5.5 10.8 7.6-15.3 0.926 >65 >6 
 
Cell uptake studies are highly informative from a pharmacological perspective, 
since they can disclose important information on the mechanism of action of 
anticancer agents. Such studies were performed in A2780 cell line, in the 
conditions used as described in section 3.2.2.6 (Figure 3.38). The concentration 
used for the uptake of all of the drugs was 20 μM, since at this concentration no 
dark toxicity is observed and is above the IC50 for all of them. The uptake of the 
compounds (from highest to lowest) follows the order: 6 (300 ng/10
6
 cells) >> 3 
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(32 ng/10
6
 cells) > CDDP (29 ng/10
6
 cells) > 5 (25 ng/10
6
 cells) > 4 (15 ng/10
6
 
cells).   
Furthermore cell uptake mechanisms have always been important for the 
development of new anticancer drugs, as impaired cellular uptake could be one of 
the reasons which lead to development of resistance.
53
 In general terms, cell 
uptake occurs by either passive (no energy required) or active (involving energy 
consumption) transport. Therefore it is of interest to see how the uptake of these 
metallodrugs is affected by different temperatures and drug concentrations.  
 
 
 
 
 
 
 
 
Figure 3.38: Cell uptake studies (expressed in ng Pt/10
6
 cells) of compounds 3-6 
with cisplatin as comparison. 
 
The temperature-dependence of cell uptake was studied by measuring the uptake 
at 4, 18 and 37 
o
C (Figure 3.39) for 6 and for 3. Both compounds follow the same 
trend, at which the uptake is increasing with increasing temperature. The 
concentration dependence experiment (Figure 3.40) was carried out in order to 
explore whether the system reaches saturation. Uptake of Pt for compound 6 
reaches saturation at 40 μM and for 3 at 20 μM.  
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Figure 3.39: Temperature dependence on the cell uptake of complexes 3 and 6, 
after 1 hour drug incubation in the dark.   
 
 
 
 
 
 
 
 
 
Figure 3.40: Concentration dependence on the cell uptake of complexes 3 and 6, 
after 1 hour drug incubation at 37 
o
C, in a 5% CO2 humidified atmosphere.  
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3.4 Discussion 
3.4.1 Synthesis and characterisation 
The Pt(IV) trans dihydroxo complexes are reactive towards derivatisation. There 
are literature reports which suggest that such functionalisation can be achieved by 
the use of anhydrides or acid chlorides,
54
 pyrocarbonates, and isocyanates to form 
caroboxylates, carbonates and carbamates, respectively.
14,55,56
 
The three novel complexes 4-6 were successfully synthesized, using the 
aforementioned approach, albeit the yield for all of them was relatively low (18-
56%). The succinate and N-methylisatoate axial ligands, in compounds 4 and 6 
respectively, were incorporated by reaction of the precursor 3 with the 
corresponding anhydride through a ring-opening reaction (Figure 3.41). The 
ligand 4-oxo-4-propoxybutanoate in complex 5 was obtained via esterification of 
the succinate ligand in complex 4.  
 
 
Figure 3.41: Synthetic route to compound 6 using N-methylisatoic anhydride and 
compound 3, as starting materials.  
 
The synthesis of compound 6 was attempted in anhydrous reagent grade DMF as 
well as in DMF with the presence of LiOH (1 mol eq) but it was unsuccessful. 
Reaction in DMSO with an excess of the ligand yielded the monosubsituted 
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Pt(IV) complex. This indicates that the polarity of the solvent plays an important 
role in this type of reaction (DMSO more polar than DMF) and also that reaction 
with the second –OH is not favourable.  
Esterification of the carboxylic acid in complex 4 to obtain complex 5 was carried 
out by standard coupling chemistry. The esterification was considered beneficial 
as the cell uptake could potentially be hindered by a negative charge on the 
complex. Furthermore previous reports have shown that different ester derivatives 
influence the cytotoxicity of the complex. Two examples will be mentioned here: 
(a) Keppler and co-workers reported a family complexes of Pt(IV) analogue of 
carboplatin which are axially-derivatised with carboxylic acids, amides or esters. 
The ester derivatives significantly lower IC50 values when compared to the 
carboxylic acids with increased lipophilicity favouring higher cytototoxicity;
5
 (b) 
A similar study was conducted by the axial modification of Pt(IV) analogues of 
oxaliplatin and it was again discovered that the ester length had an effect on the 
IC50 of the compounds. In both cases, the cytotoxicity did not correlate with the 
hydrophobicity trend.
57
 
 
 
 
 
 
 
 
 
Figure 3.42: Synthetic scheme for the synthesis of compound 5, using CDI and 
sodium propionate in DMF.  
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The synthesis of compound 5 was achieved by the use of CDI (1,1'-
carbonyldiimidazole), which is a well known coupling agent used for peptide 
synthesis (Figure 3.42).
58
 The CDI reacts with the carboxylate group to form a 
reactive acylimidazole intermediate, and in the presence of an alcohol the 
esterification takes place with the release of imidazole, as a side product. This 
route can be used for the formation of an amide bond, which can also be exploited 
for the synthesis of peptide conjugates.
58
  
A cRGD peptide was coupled to trans,trans,trans-[Pt(N3)2(OH)2(Succ)(pyr)2], 4 
to yield complex 7 (section 3.2.2.8.8). The RGD sequence is recognized by a 
number of integrins, which are heterodimeric membrane glycoproteins (composed 
of α and β subunits) which recognize extracellular matrix proteins. They are 
involved in angiogenesis, which is an essential step in the metastasis and survival 
of the tumour cells.
59
 There are 24 integrins most of which can recognize an RGD 
segment on the protein sequence, but a strong binder of this sequence is ανβ3. A 
crystal structure representing the complexation of RGD with ανβ3 has been 
published by Arnaout et al.
60
 Besides the involvement of integrins in 
angiogenesis, there are strong evidence of their over expression in cancer cells and 
for this reason RGD peptides can be utilized as tumour targeting peptides, as 
diagnostic tools but also as integrin inhibitors for therapeutic purposes.
59
 
Attachment of a cargo onto an RGD peptide can result in the internalization of the 
cargo via endocytosis, thus enabling increased uptake of the molecule attached to 
the RGD.
59
 Thus, enhanced and targeted uptake can be achieved by the 
incorporation of such moieties. Although light-activation provides a form of 
selective cytotoxicity, the conjugation to a targeting feature should potentiate it. 
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The synthesis of the peptide-Pt(IV) conjugate was carried out using HATU/ DIEA 
(O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate), 
which is another set of commonly used coupling reagents.
58 An interesting finding 
during the synthesis of peptide conjugates was the reactivity of the Pt(IV) 
complex towards TFA, which is commonly used for the deprotection of reactive 
moieties (in this case Boc-protected amino acids). In order to show that the 
hydroxyl groups are reactive towards TFA, compound 3 was allowed to react with 
TFA/DCM (1:1). The product isolated was the bis-triflated adduct, as shown by 
mass spectrometry and 
19
F-NMR.  
195
Pt-NMR spectroscopy was used for the characterisation of compounds 4 and 6; 
although for 6 DMSO-d6 was employed instead of D2O for solubility reasons. The 
chemical shifts of the Pt(IV) signal observed for 4 and 6 fall at 1059 ppm and 990 
ppm, respectively, while for reference compound 3 it was reported to be at 942 
ppm.
26
 Chemical shift comparisons can be made only between 4 and 3 as they 
were measured in the same solvent. The higher chemical shift in the case of 
complex 4 indicates that the 
195
Pt nucleus is more deshielded, even though both 
complexes exhibit a [N4O2] coordination environment around the metal centre. 
Noticeably, lengthening of the Pt–P bond in the case of platinum complexes 
containing phosphine ligands was found to increase the Pt chemical shift.
61
 As 
reported in subsection 3.3.2., the Pt–O bonds with the carboxylate ligands are 
longer than the Pt–OH bond, which might account for the increase in the chemical 
shift.  
As previously stated, the analysis of the UV-Vis spectra of photoactivatable 
complexes is important to understand and exploit their photochemistry. The bands 
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in the spectra of Pt(IV)-diazido compounds can be estimated with the aid of 
theoretical calculations. All complexes discussed in this chapter (3-6) show two 
absorption bands at ca. 260 nm and 300 nm. These are composed mainly of 
transitions with 
1
LMCT character. Since in phototherapy longer wavelength light 
is ideally desirable for greatest penetration into tissues, the longer wavelength 
absorption bands are of great interest for photoactivatable metallodrugs. The 
absorption bands in compounds 4-6 are red-shifted in comparison with those in 
the precursor 3, indicating that modification of the axial bond enhances the 
photolability of Pt(IV)-diazido prodrugs. Figure 3.43 shows the difference in 
colour between compound 4 and compound 3, the former having a more intense 
yellow colour.  
 
 
 
 
 
 
Figure 3.43: Comparison of colour between compound 4 (orange-right) and 
compound 3 (yellow-left). 
 
The largest red shift corresponds to compound 6, which has a visible absorbance 
between 350 nm and 400 nm. This is not surprising since this compound bears a 
benzyl ring and it was predicted by DFT calculations that the replacement of the  
–OH group with  –OPh would result in a red shift, and also more transitions 
appear in the visible region of the spectrum.
62
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3.4.2 Aqueous solubility and stability in the dark 
Regarding the aqueous solubility of complexes 4-6, an evident conclusion is that 
the introduction of carboxylate axial ligands greatly influences in the 
hydrophobicity and hence in their water solubility. Replacing one of the hydroxyl 
groups with a succinate ligand clearly made the complex more hydrophobic as the 
solubility was reduced 17-fold and also the HPLC retention time increased from 
6.3 (compound 3) to 8.8 min (compound 4). The increase in the chain length 
(from trans, trans, trans-[Pt(N3)2(pyr)2(OH)(Succ)] 4 to trans, trans, trans-
[Pt(N3)2(pyr)2(OH)(Succ-Pr)] 5) lead to a slight decrease in the aqueous solubility 
as observed in complex 5. Strikingly the attachment of a phenyl ring in complex 
[Pt(N3)2(OH)(N-MI)(pyr)2] 6 produces a compound which is very poorly soluble 
in water. These results illustrate the effects that derivatisation of these two 
hydroxyl groups can have on water solubility of these Pt(IV) complexes.  
The stability of compound 4 was assessed in the presence of 2 mol eq of GSH, as 
two molecules of GSH would be required to provide 2 electrons to reduce Pt(IV) 
to Pt(II). It is significant to test reactivity with biological reductants, as Pt(IV) 
photoactivatable prodrugs need to be stable in the dark and activated only in the 
presence of light. Biological reducing agents in the cell and in the blood plasma 
include ascorbate, glutathione as well as metallothioneins (small proteins having 
20 cysteines per molecule).
63
 Ascorbic acid has a concentration of ca. 1 mM in the 
cytosol and 50-150 M in the blood plasma, whereas GSH is found at 2-8 mM in 
the cytosol and 850 M in the blood plasma.
63
 It was shown that complexes with 
axial acetates are a lot easier to be reduced than those with hydroxyl groups. For 
example, a recent study by Dabrowiak et al showed that the monocarboxylato 
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Pt(IV) analogue of oxoplatin (i.e. the complex cis, trans, cis-[PtCl2(OH)2(NH3)2]) 
reduces faster in the presence of GSH than oxoplatin.
63
 Also some carboxylato 
complexes e.g. cis, trans, cis-[Pt(NH3)(2-pic)(OAc)2(Cl)2] can be completely 
reduced within 4 hours when co-incubated with GSH.
64
 The fact that these Pt(IV)-
azido monocarboxylato compounds are stable in the presence of GSH (as shown 
in Figure 3.9, section 3.3.3) is significant for their possible development as 
phototherapeutic candidates.  
 
3.4.3 Photoirradiations 
3.4.3.1 UV-Vis studies 
UV-Vis spectroscopy allows the photoreduction of Pt(IV)-diazido compounds to 
be monitored as a decrease of the N3→Pt charge transfer band (at ca. 300 nm) is 
observed due to the loss of an azide. Irradiation of compound 3 results only in a 
decrease in intensity of this LMCT band, whereas for compounds 4 and 5, there is 
an apparent increase in intensity of the band at ca. 250 nm (refer to Figure 3.15 
and Figure 3.16, section 3.3.6). In case of compound 3, similarly to 6, no increase 
of intensity occurs for the band at 250 nm but a slight shift of the maximum 
wavelength is observed. This result could be explained in two ways: either the 
electronic transitions of the attached ligand are not mixing with the transitions of 
the platinum centre therefore absorbance of the former is similar to the free ligand 
or the release of the ligand is very slow in comparison to the release of the azide. 
Most reduction profiles of Pt(IV) complexes,
65
 as found for compounds 3-6, 
follow an exponential decay profile. This is illustrated in Figure 3.18 which shows 
plots of the absorbance of the N3→Pt band, as a function of time. Mechanistic 
Chapter 3: Axial ligand derivatisations 
 
134 
 
studies of the chemical reduction of other Pt(IV) prodrugs in the presence of 
reducing agents such as GSH and L-ascorbate have shown that the reduction is 
second-order and proportional to the concentration of the Pt(IV) complex as well 
as the reducing agent.
66
 In the case of the photoreductions carried out on 3-6, it 
was observed a decrease in the reduction rate when the concentration of the 
sample was increased, upon the same light exposure (Figure 3.44).  
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Figure 3.44: Time dependent photoreduction of complex 6 at 40 μM (t1/2= 192 
min) and 60 μM (214 min) concentration in 5% DMSO/95% H2O. The 
photoirradiation was carried out with green light (517 nm).  
 
The photoreactions proceed at different rates depending on the complex (t1/2= 634 
min for 3, 220 min for 4, 169 min for 5 and 214 min for 6). Evidently, the half 
times of the compounds decrease by up to ~4 times less (e.g. compound 5) as 
compared to the dihydroxo compound 3. This suggests that the carboxylate 
functionality enhances the photoreactivity of these complexes. All three show 
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much faster kinetics in comparison to compound 3. Furthermore compound 5, the 
fastest complex in photodegradation, shows the longest Pt–O (carboxylate) bond, 
which photodissociates upon light exposure. Observing an effect on the reduction 
rate of Pt(IV) prodrugs with an increasing chain length of the functionality on the 
carboxylate ligand is not unusual (although the chain is distant from the Pt centre). 
Ravera et al showed that the reduction potential decreased for a longer carbon 
chain, in cis,trans,cis-[PtCl2(mpy)(NH3)(RCOO)2], where R= CH3(CH2)n, n=0-4.
8
 
The increased rate of photodegradation in the case of compound 4 versus 
compound 3 correlates with the extinction coefficients, higher for 4 at the longer 
wavelengths (Figure 3.13). Compound 4 underwent very little activation with 
yellow light (550 nm, 2.5 mW/cm
2
), as judged by the change in the absorbance of 
the band at ca. 300 nm.  
3.4.3.2 EPR studies 
The formation of azidyl radicals when Pt-diazido compounds are irradiated may 
play a role in the mechanism of action of these prodrugs.
52
 Therefore the amount 
of azidyl radicals produced on photoactivation of the complexes studied here was 
determined.  
The first experiment was carried out with 1 mM solutions of compounds 3, 4, and 
5 in PBS in the presence of DMPO (spin-trap). The results of this study showed 
that no radicals were trapped in the case of 3 whereas 4 and 5 yielded radicals up 
to 68 M and 55 M, respectively (Figure 3.21). The identity of the trapped 
radical was confirmed to be the DMPO-N3 by matching the hyperfine splitting 
constants (HFSC) to the theoretical data reported previously (Figure 3.45).
43, 41
 
Chapter 3: Axial ligand derivatisations 
 
136 
 
Hydroxyl or carboxylate radicals, which could potentially be released from the 
Pt(IV) complex, would give a 1:2:2:1 pattern when trapped by DMPO. This signal 
however, was not detected in the spectrum. Even though compound 4 was found 
to have a slightly lower photodissociation rate than compound 5, the azidyl radical 
yield after 14 minutes of irradiation was in fact slightly higher for the former. 
However the initial production of radicals (e.g. after 7 min of irradiation) was 
lower for 4 than for 5. 
 
Figure 3.45: (A) The structure of the spin-adduct DMPO
.
-N3 adduct formed by 
the addition of N3
. 
to DMPO. (B) The origin of the hyperfine splitting pattern from 
the coupling of the unpaired electron to nitrogen (atom 1), hydrogen (atom 2) and 
nitrogen (atom 3). (C) EPR signal of an irradiated sample of compound 4 in 
DMF/H2O (75 %, 25%, v/v) in the presence of DMPO (2 mol eq) at 20 
o
C.  
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A similar experiment was carried out using DMF as the solvent. Compounds 3, 4, 
and 5 in DMF gave similar results as in PBS, with compound 4 giving the highest 
and compound 3 the lowest azidyl radical yield. Surprisingly, compound 6 
produced a similar amount of radicals as 3 although the rate of photodegradation 
is ~3-fold higher. A plausible explanation for this fact is that the released N-
methylisatoate ligand (axially bound in 6) could act as a radical scavenger. In 
order to confirm this hypothesis, complex 3, trans, trans, trans-
[Pt(N3)2(OH)2(pyr)2], was irradiated (λ= 463 nm, 64 mW/cm
2
) in the presence of 
N-methylisatoic acid (1 or 2 mol eq). The production of azidyl radicals was 
entirely quenched by N-MIA suggesting that upon release, this ligand can readily 
react with N3
·
. The reactivity of similar molecules with reactive oxygen species 
has been established recently where it was shown that methyl anthranilate, 
structurally related to N-methylisatoate ligand, can quench singlet oxygen due to 
the presence of the anilinic moiety.
67
   
3.4.4 NMR and LC-MS studies  
As described in sections 3.3.8, irradiation studies were carried out in the presence 
of 5’-GMP, as DNA is considered to be a possible target site for platinum 
anticancer drugs. 
3.4.4.1 NMR and LC-MS studies of complexes [Pt(N3)2(OH)(Succ)(pyr)2] 4 
and [Pt(N3)2(OH)(Succ-(RGD)f)(pyr)2] 7 
 
The irradiation of complexes 3 and 4 with 5’-GMP (2 mol eq) in PBS yielded the 
mono-GMP Pt(II) adduct in both cases. However 23% of GMP was bound to 
platinum in the case of 4, whereas only 9% was bound in the case of compound 3. 
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This result, along with the UV-Vis and EPR studies shows the enhanced 
photoactivity of the carboxylate versus the dihydroxo complexes. DFT 
calculations gave an insight into the enhanced photoactivity by showing that 
indeed this compound has dissociative transitions which can extent up to 469 nm.  
The photoproducts from the irradiation of compound trans, trans, trans-
[Pt(N3)2(OH)(Succ)(pyr)2)] 4 at 463 nm (blue light) were characterised by 
1
H-
NMR, 
195
Pt-NMR as well as LC-MS. As described previously, the release of 
succinate as well as azidyl radicals was observed (Figure 3.25 and Figure 3.21). 
The reduction of Pt(IV) to Pt(II) requires the gain of two electrons. However, the 
only radical detected by EPR was the azidyl radical. The loss of both azidyl 
radicals is excluded since the major product generated after irradiation is a mono-
azido Pt(II) compound. Therefore, the second electron could originate from either 
the hydroxyl or the carboxylate ligands which could react rapidly with another 
radical or solvent molecule and thus be quenched.  
 
 
 
 
 
The mono-GMP Pt(II) adduct trans-[Pt(N3)(pyr)2(GMP)] is formed in the first 10 
minutes of the irradiation to an extent of 30% (refer to Figure 3.29). The 
assignment was easily confirmed as the 
1
H and 
195
Pt-NMR match those chemical 
Figure 3.46: Scheme for the decomposition pathway of compound 4 leading to the 
major photoproduct which is the mono-azido GMP Pt(II) adduct.  
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shifts assigned previously for trans-[Pt(pyr)2(GMP)(N3)].
26
 Notably, in this 
reaction two products were formed: the first was the mono-azido GMP Pt(II) 
adduct which formed immediately after the light exposure. Further irradiation 
caused the percentage of this adduct to increase but also the appearance of a 
second product. Interestingly the intensity of the mono-azido GMP Pt(II) adduct 
reached a maximum of 30% and then it stayed intact upon further irradiation. This 
suggests that the Pt(II) mono-azido GMP adduct is not photolabile in the presence 
of blue light. This is an important result as it indicates that if DNA is 
photoplatinated in this way, the Pt(II)-DNA adducts will be stable.  
The second photoproduct does not contain GMP, as there were no corresponding 
GMP resonances in the 
1
H-NMR spectra. Moreover, it was observed that further 
irradiation produced an increase in the second photoproduct which was difficult to 
quantify due to the overlap and the broadness of the 
1
H-NMR peaks.  
It should be noted that irradiation with slightly shorter wavelength (420 nm vs 463 
nm) did not result in any significant change in the photoproducts. Similar to the 
results obtained upon excitation at 463 nm, apart from the major GMP adduct, 
only very low intensity signals corresponding to other GMP adducts become 
visible in the 
1
H-NMR spectra. When GMP was irradiated alone under similar 
conditions as a control, no change in its spectrum was observed (results not 
shown).  
In order to aid the identification of the other photoproducts, an LC-MS analysis 
was carried out in the dark and after the irradiation of compound 4 in the presence 
of 2 mol equivalents of GMP. The majority of the HPLC peaks were assigned 
(Figure 3.31), with the exception of the peaks with m/z of 762.1009 (peak 4) and 
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762.1126 (peak 10). The 5’-GMP adducts observed after irradiation are listed 
below and are ordered from high to low peak abundance:  
 trans-[Pt(N3)(GMP)(pyr)2]
+
, m/z 758.1164 (obs.=758.1160) 
 trans-[Pt(ACN)(GMP)(pyr)2]
2+ 
or trans-[Pt(ACN)(GMP-H)(pyr)2]
+
, m/z 
378.5667 and 756.1259, respectively (obs.= 378.5668 and 756.1268). The 
acetonitrile was used as a solvent for the HPLC. In biological medium, this 
position could be occupied by another reactive molecule with affinity for 
platinum.  
 trans-[Pt(GMP)2(pyr)2]
2+
, m/z 539.5820 (obs.= 539.5834)) 
 trans-[Pt2(N3)2(GMP)(pyr)4]
+
, m/z 1152.1727 (obs.= 1152.1686), in which 
GMP bridges between two platinum centres.  
 
A different outcome occurs when the photoirradiation takes place in PBS, which 
contains 139 mM chloride. This prohibited the formation of a bis- GMP adduct 
since upon release of the second azide ligand, a chloride readily binds instead of a 
second 5’-GMP molecule (refer to Figure 3.33). Bednarski et al showed that the 
amount of platinated DNA was significantly reduced when the irradiation of 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)2] was carried out in the presence of 100 
mM of Cl
-
, which reflects the extracellular chloride concentration.
48
 
Interestingly, another product identified by LC-MS was the [Pt(N3)(pyr)3]
+
, which 
can correlate with the presence of a pyridine containing photoproduct in the 
1
H-
NMR spectrum (assigned with rhombus in Figure 3.25). Furthermore, it is worth 
mentioning that after irradiation, the peak with the retention time corresponding to 
the starting complex 4 (at 11.9 min) is depleted. Peak 7 in Figure 3.31 
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corresponds to a [M-N3]
+ 
species with m/z of 529.0750. The formation of such a 
species was observed in the mass spectrum even before irradiation, probably due 
to fragmentation in the mass spectrometer (Figure 3.32 A for the mass spectrum in 
the dark) but the molecular ion [M+H]
+
 was still observed under those conditions. 
The lack of the aforementioned peak ([M+H]
+
) after irradiation suggests that the 
azide was lost as an anion. The detected [M-N3]
+
 species appears at different 
retention time (11.0 min) than that observed in the dark (11.9 min). In this case, it 
may indicate a different coordination mode of the succinate, possibly acting as 
bideprotonated and bidentate chelating ligand to generate a metallacyclic Pt(IV) 
complex which would elute differently on the column. This could suggest that the 
azide is more labile than the axial ligands and its loss would occur before the 
dissociation of an axial ligand.  
Photoirradiation of 7 showed that the peptide tethered to the succinate completely 
dissociates from the Pt(IV) complex after irradiation and elutes at 11.8 min. This 
is a significant result, as it shows that if the compound is delivered to tumour cells 
in the dark, then after irradiation the peptide will be released, allowing the azidyl 
radicals and the platinum centre to exert the cytotoxic mechanism. This result also 
shows that the release of the axial ligand will occur regardless of the type of 
functionality tethered at the end of the carboxylic acid.  
 
3.4.4.2 NMR and LC-MS studies of compound trans, trans, trans-
[Pt(N3)2(OH)(N-MI)(pyr)2] 6 
 
Irradiation of compounds 6 and trans,trans,trans-[Pt(N3)2(OH)2(pyr)2] 3 (section 
3.3.8.2), which were followed by 
1
H-NMR in a mixture of MeOD (75%) and D2O 
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(25%) v/v, gave rise to some unexpected results. Firstly a very small percentage 
of GMP binding was observed and the release of pyridine occurred, especially 
upon irradiation with UVA. Pyridine release was not observed when complex 3 
was irradiated with UVA light in an aqueous solution.
26
 
This stresses the effect of the solvent and the environment on the 
photodecomposition pathways of Pt(IV)-diazido anticancer drugs, suggesting that 
if these drugs accumulate in a hydrophobic, non-aqueous environment within the 
cell (e.g. membrane) different photoproducts can be expected. The release of 
pyridine from these drugs is not unexpected as DFT calculations performed on 
compound 3 had shown that the LUMO and LUMO+1 are strongly antibonding 
towards all ligands.  
Assignment of irradiation photoproducts of 6 was aided by LC-MS, which 
detected as a product a [M-N3]
+ 
species. Taking into account its charge, this can 
be assigned to a Pt(III)
 
complex or to a metallacyclic product in which the N-
methylanthranilate ligand is bideprotonated and coordinates the Pt(IV) ion in a 
bidentate chelating mode. Pt(III) intermediates are not unusual in mass 
spectrometry, but the fact that this complex elutes from the HPLC column 
suggests that it is stable, and therefore may correspond to a metallacyclic Pt(IV) 
complex (as illustrated in Table 3.7). The major photoproducts detected by LC-
MS were assigned to the axial ligand (N-MI) as well as to the [Pt(pyr)2(N3)2]. 
Figure 3.47 summarizes a proposed scheme for the irradiation of compound 6. 
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Figure 3.47: Scheme showing the photoproducts of the irradiation of compound 6 
in MeOH as detected by LC-MS.  
 
 
3.4.4.3 Fluorescence studies  
The attachment of fluorescent tags to platinum compounds is useful to study their 
temporal and spatial distribution in living cells. Furthermore, fluorescent tags can 
act as antennas for light harvesting which can be useful in the development of 
phototherapeutic agents.
68
 Frequently, the attachment of fluorescent tags to Pt(IV) 
occurs on the equatorial position and it results in fluorescence quenching. 
However when reduced to Pt(II), within the cell, fluorescence enhancement 
occurs.
69,70
  
Complex 6 bears a fluorescent tag (N-MI) in the axial position. The fluorescence 
emission spectrum of complex 6 shows a single broad band with maximum at 420 
nm, similar to the maximum emission wavelength of the free ligand N-MIA. This 
band is independent of the excitation monitoring wavelength which suggests a 
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single emissive species in the excited state. These seem to indicate that the 
fluorescence of the ligand is quenched because of its binding to platinum. This 
becomes evident as there is an enhancement in the fluorescence emission at 420 
nm upon repeated excitation at 320 nm due to the release of the ligand (Figure 
3.30).  
3.4.5 Cell studies 
Complexes 4 trans, trans, trans-[Pt(N3)2(OH)2(Succ)(pyr)2] and 5 trans, trans, 
trans-[Pt(N3)2(OH)(Succ-Pr)(pyr)2] showed promising photo-cytotoxicity towards 
ovarian cancer cells (A2780) using a low dose of blue light (420 nm, 5 J/cm
2
). 
The phototoxicity of 4 and 5 increased by 2-fold higher compared to compound 3, 
trans, trans, trans-[Pt(N3)2(OH)2(pyr)2]. This suggests that although the 
photoproducts from complexes 3, 4 and 5 are similar, the enhanced photoactivity 
that the carboxylate confers can result in greater amounts of the active Pt(II) 
products for a given irradiation dose. Complex 6, trans, trans, trans-
[Pt(N3)2(OH)(N-MI)(pyr)2] was the least phototoxic with an IC50 value of 12.1 
μM. This is surprising as complex 6 shows ca. 10-fold greater uptake in 
comparison to the rest of the compounds. The reduced IC50 may be related to the 
low yield of azidyl radicals or to the potential accumulation of the drug in 
hydrophobic environment within the cell (e.g. membranes) which could give rise 
to different photoproducts. In order to confirm the mechanism further, 
experiments would need to be carried out such as determining the subcellular 
distribution of the drug in comparison with a less hydrophobic drug, as well as 
azidyl radical quantification within cells. Cell uptake of 5 is ca. 2-fold higher than 
that of 4 in A2780 cells (from 15 to 25 ng/10
6
), which can be attributed to the 
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increased hydrophobicity from the propyl ester functionality in 5. However an 
improvement in the cytotoxicity is not observed as the IC50 of these compounds is 
very close (3.6 μM for 4 and 3.7 μM for 5). Interestingly, compound 4 produced a 
higher yield of azidyl radicals than 5 as determined by EPR experiments, which 
may compensate for the decreased cell uptake.    
There is some correlation between the hydrophobicity of complexes 4-6 and 
increasing cell uptake. However compound 3 (dihydroxo) is the most hydrophilic-
water-soluble complex in the series and yet its uptake surpasses that of complexes 
4 and 5.  
The transport of molecules across the membrane of a cell can be either active 
(energy dependent) or passive (no energy dependent).
71
 Platinum drugs are 
generally thought to be taken up by both passive and active transport. Extensive 
efforts have been made to discover the uptake mechanisms for cisplatin and it was 
found that a family of copper transporters (Ctr1), which is used for the uptake of 
Cu, plays a major role.
53,72,73
 Organic cation transporters also constitute another 
class of transporters, responsible for the uptake of picoplatin in mice.
74
 The 
importance of passive transport was for example exploited in the case of 
satraplatin, which may be the reason for circumventing cisplatin resistance by 
increased cellular uptake.
53
 
There is very little uptake of cisplatin (0.005 ng of Pt per 10
6
 cells) over the range 
at 4 
o
C which shows that influx is energy-dependent.
75
 However, complexes 3 and 
6 were taken at a low temperature and with increasing temperature (from 4 
o
C to 
18 
o
C), the influx increases. These results demonstrate that the uptake of these 
diazido drugs is a combination of passive and active transport. Passive transport is 
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enhanced greatly by the incorporation of an aromatic ligand in the axial position, 
as shown by complex 6.  
The net cellular accumulation of drugs into cells is a result of equilibrium between 
influx and efflux. Many efflux transporters are involved in the export of drugs. 
These include ATP7A, ATP7B, ES-X (Pt-glutathione conjugates), and the MDR 
efflux pump.
76,
 
77
 In order to estimate the optimum concentration at which 
maximum uptake occurs, concentration-dependent experiments were carried out. 
This can have significant implications in photodynamic therapy since pulsed light 
therapy is considered to be a clinical advantage compared to continuous light 
therapy.
78
 With such a short light exposure, it is important to obtain the highest 
amount of drug within a cell. The optimum concentration for uptake for 
complexes 3 and 4 is 20 μM and 40 μM, respectively.  
3.5 Conclusions  
In this chapter complexes of the type trans, trans, trans-
[Pt(N3)2(OH)(OCOR)(pyr)2] (4, 5 and 6), where OCOR is succinate, 4-oxo-4-
propoxybutanoate and N-methylisatoate ligands have been synthesized and 
characterised by NMR, MS, UV-Vis and X-ray crystallography. Photoactivation 
studies comparing the three novel complexes with respect to the dihydroxo 
precursor trans ,trans, trans-[Pt(N3)2(OH)2(pyr)2] 3 indicate a three-fold faster 
degradation kinetics when irradiated with green light (517 nm). EPR studies 
performed on equimolar aqueous solutions of complexes 3, 4 and 5 showed that 
azidyl radicals were not produced in the case of 3 but produced to a concentration 
up to 69 and 56 μM for 4 and 5, respectively. Complex 4 was also able to bind to 
5’-GMP to an extent of 2.6 times greater than 3 when irradiated with the same 
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dose of 463 nm light (23% vs 9%). Incorporation of the cRGD-peptide moiety 
onto the free carboxylic acid of complex 4 yielded complex 7. LC-MS studies 
undertaken on these two complexes upon blue light irradiation (420 nm) resulted 
in the release of the axial liands (succinate for 4 and succinate-(RGD)f for 7) 
yielding very similar photoproducts, with [Pt(N3)(pyr)2(5’-GMP)] being the 
major.  
Complex 6 bears the fluorescent ligand N-methylisatoate. Continuous fluorescent 
measurements, by exciting aqueous solution at 320 nm, resulted in an increase in 
fluorescence of the band at 420 nm possibly due to the release of the ligand. The 
complex has very low solubility in water (0.065 μM) thus prohibiting NMR or 
EPR studies in aqueous solutions. Irradiation studies (420 nm or UVA) in MeOD 
resulted in a mixture of products. The release of the axial ligand and pyridine 
(especially with UVA irradiation) was observed but no significant 5’-GMP 
binding.  
Cellular uptake studies of complexes 3, 4, 5 and 6 on A2780 cells showed a 
dramatic increase in uptake of complex 6 (10-fold) with respect to 3 and a 1.7-
fold when comparing 4 and 5. Temperature dependence studies on 3 and 6 to 
elucidate whether passive or active transport takes place showed that active 
passport facilitates the influx of the drugs, as there is an increase in uptake upon 
increasing the temperature from 4 to 18 to 37 
o
C.  
Phototoxicity studies with 420 nm irradiation on A2780 cells showed that 
complexes 4 and 5 (IC50= 3.6 and 3.7 μM) were ~2-fold more active than 3 (IC50= 
6.7 μM) but complex 6 was the least active (12.1 μM). The lack of activity of the 
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latter could be attributed a low yield of azidyl radicals, as the N-MI ligand has the 
ability to quench those radicals.  
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4.1 Introduction  
Early structure-activity relationships concluded that cytotoxic Pt(II) drugs should 
contain amines in cis geometry, the  leaving group should be adequately bound 
(but not too strong) and that higher activity could be obtained with complexes 
having amine ligands with fewer substituents (NH3, primary or secondary 
amines).
1
 These rules were revised when it was discovered that the use of 
pyridine-like ligands or substituted amines conferred cytotoxic activity in cisplatin 
resistant cell lines.
1, 2
 Examples of some promising pyridyl Pt(II) complexes are 
illustrated in Figure 4.1.  
 
 
 
 
 
Figure 4.1: Potent Pt(II) compounds (picoplatin, pyriplatin and trans-
(dichloroaminethiazole) platinum (II) with useful cytotoxic properties.  
 
Picoplatin (AMD 473) was designed and synthesized specifically to tackle the 
problem of platinum drug deactivation due to reactions with S-donor molecules, 
such as glutathione, an effect which eventually leads to chemoresistance. A bulky 
2-methylpyridine group close to the platinum centre reduced the rates of side 
reactions which diminish the potency of a drug.
3
 Picoplatin was designated as an 
orphan drug for the treatment of small cell lung cancer carcinoma in 2007.
4
  
Pyriplatin has been studied in recent years by Lippard et al, where it was shown 
that is significantly cytotoxic in a number of tumour cell lines. The 
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monofunctional adducts inhibit transcription and also elude DNA repair. 
Additionally its positive charge confers an uptake mechanism different to cisplatin 
(via organic cation transporters rather than copper transporters).
5
  
Trans-[PtCl2(NH3)(thiazole)] developed by Farrell
6
 has shown the best 
combination of cytotoxicity and aqueous solubility and in vivo activity amongst 
compounds in this general structural family.
7
 
Furthermore, it was shown by Gibson et al. that sterically-hindered complexes 
such as trans-[PtCl2(4-pic)(piperazine)]HCl are very cytotoxic towards cancer 
cells and also have a mechanism of action distinctive from cisplatin.
8
 
The aforementioned compounds illustrate the significance of planar heterocyclic 
ligands in affording Pt(II) drugs with different pharmacological properties (e.g. 
uptake, solubility, type of DNA lesions) and consequent overcoming 
multifactorial cisplatin resistance.  
In the case of Pt(IV)-diazido photoactivatable complexes, it was established that 
the molecules  with the N-donor ligands in trans geometry were more cytotoxic 
than their cis isomers.
9
 Moreover, replacing aliphatic amines with pyridines was 
extremely beneficial for extending the phototoxic activity of the molecule to 
longer -and consequently more clinically relevant- wavelengths of  
activation. Trans, trans, trans-[Pt(pyr)2(N3)2(OH)2] and trans, trans, trans-
[Pt(pyr)(NH3)(N3)2(OH)2] are phototoxic with blue and UVA light, 
respectively.
10,11
 These structure-activity relationships demonstrated that having 
N-heterocyclic amines in a trans geometry is a promising combination that needs 
to be explored for the development and the fine-tuning of this class of compounds. 
Furthermore, upon irradiation (and reduction from Pt(IV) to Pt(II)), the N-
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heterocyclic aromatic ligands remain coordinated to the Pt(II) centre, which is 
thought to be important for retention of the anticancer activity of the Pt(II) 
species. Hence in this present study Pt(IV) diazido complexes were designed with 
N-heterocyclic ligands, which if retained in Pt(II) photoproducts could have 
advantageous cytotoxic properties.  
The aims of this chapter was to synthesize a variety of Pt(IV)-diazido complexes, 
bearing planar N-heterocyclic amine ligands and to study their 
photodecomposition. Some of the planar amines chosen (e.g. pyridine, 2-picoline, 
4-picoline, thiazole and 1-methylimidazole) were inspired by those in known 
cytotoxic Pt(II) compounds. In this chapter, the synthesis, characterisation and 
photodecomposition studies of the following complexes (structures can be found 
in Appendix) will be described: trans,trans,trans-[Pt(N3)2(OH)2(2-
picoline)(pyridine)]-18, trans,trans,trans-[Pt(N3)2(OH)2(3-picoline)(pyridine)]-19, 
trans,trans,trans-[Pt(N3)2(OH)2(4-picoline)(pyridine)]-20, trans,trans,trans-
[Pt(N3)2(OH)2(3-picoline)2]-23, trans,trans,trans-[Pt(N3)2(OH)2(4-picoline)2]-26, 
trans,trans,trans-[Pt(N3)2(OH)2(thiazole)2]-29, trans,trans,trans-[Pt(N3)2(OH)2(1-
methylimidazole)2]-32.  
4.2 Experimental  
Caution! While no problems were encountered during this work, heavy metal 
azides are known to be shock sensitive detonators; therefore it is essential that 
any Pt-azido compound is handled with care. The Pt-diazido complexes were 
handled under dim lighting conditions.  
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4.2.1 Materials 
All materials were used as obtained from commercial sources unless otherwise 
stated. K2PtCl4 was obtained from Precious Metal Online and Alfa Aesar, KI, 
NaCl from Fisher Scientific, AgNO3 from Fluka, NaN3, H2O2 (30%) and all other 
chemicals from Sigma-Aldrich. The solvents used were analytical reagent grade 
from Fisher Scientific and were used as supplied. Inorganic membrane filters were 
purchased from Sartorius stedim biotech.  
4.2.2 Methods 
4.2.2.1 HPLC  
HPLC for purity testing for complexes 18-20, 26 and 29 was carried out using the 
column ZORBAX Eclipse Plus C18 (5 μm pore size, 150 × 4.6 mm dimensions) 
with 1 mL/min flow rate and 45 μl injection volume. The method employed is 
summarized in Table 4.1. The mobile phase was H2O/MeOH with 0.1% TFA. The 
wavelength of detection was 254 nm.  
Purity tests for complexes 23 and 32 were carried out in the same manner as for 4-
6 in Chapter 3. 
 
Table 4.1: HPLC elution gradient for the purity testing of compounds 18-20, 26 
and 29, where B is MeOH (with 0.1% TFA) and the rest is H2O (0.1% TFA).  
Time 
(min) 
%B 
0 7 
5 7 
21 90 
25 90 
25.01 7 
30 7 
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4.2.2.2 Extinction coefficient determination 
Extinction coefficients were determined as outlined in Chapter 2. For the shorter 
wavelengths, solutions of ca. 70 and 50 μM were used whereas for the longer 
wavelengths the concentrations employed were ca 2 mM and 1 mM, except in the 
case of trans, trans, trans-[Pt(N3)2(OH)2(tz)2], where a solution of 0.6 mM was 
used.  
4.2.2.3 X-Ray Diffraction 
The X-ray crystal structures of 20, 23 CH3OH, 26 CH3OH and 32 0.5H2O were 
solved by Dr Guy Clarkson, as described in Chapter 2. 
4.2.2.4 DFT calculations   
The DFT and TDDFT calculations for complex 18 were carried out by Dr Luca 
Salassa, as outlined in Chapter 2.   
4.2.2.5 Synthesis and Characterisation  
Complexes 8-11, 21, 24, 27 and 30 have been synthesized using the Kauffman 
method with the use of concentrated HCl.
12
 Complexes 8-11, 21, 24 have been 
reported previously by Rochon
13
 and complexes 27 and 30 have been synthesized 
and studied by Farrell.
14
 
4.2.2.5.1 Cis-[Pt(I)2(pyridine)2] (8) 
K2PtCl4 (0.500 g, 1.21 mmol) was suspended in H2O (38 mL) and KI (2.0 g, 
12.05 mmol) `was added and allowed to react under stirring for 1 h at room 
temperature. Pyridine (0.194 mL, 2.41 mmol) was added and the mixture was 
stirred under room temperature for 24 h. The dark yellow solid was isolated via 
Chapter 4: Pt(IV)-diazido complexes with aromatic N-heterocyclic ligands 
 
159 
 
filtration under suction and washed with ice cold water, ethanol and diethyl ether. 
Then it was left to dry overnight under vacuum (Yield = 0.724 g, 99 %). 
1
H-NMR (CD2Cl2, 400 MHz, ppm): δ = 8.84 (dd, 
3
J195Pt1H = 39.90 Hz, 
3
J1H1H = 
6.70 Hz, 2H, Ho), δ = 7.82 (t, 
3
J1H1H = 7.61 Hz, 1H, Hp), δ = 7.34 (t, 
3
J1H1H = 6.68 
Hz, 2H, Hm). 
4.2.2.5.2 Cis-[Pt(Cl)2(pyridine)2]) (9) 
Cis-[Pt(I)2(pyr)2] (0.7229 g, 1.19 mmol) was suspended in H2O (143 mL) and 
AgNO3 (0.401 g, 2.36 mmol) was added. The mixture was allowed to react under 
reflux for 24 h at 60 
o
C, to yield a yellow precipitate (AgI). The AgI was removed 
by centrifugation, followed by filtration through celite on frit, then NaCl (0.696 g, 
11.91 mmol) was added and the reaction was carried out for 24 h at room 
temperature. The pale yellow solid was isolated by filtration and washed with cold 
water, ethanol and diethyl ether (Yield= 0.39 g, 77 %). 
1
H-NMR (CDCl3, 400 MHz, ppm): δ = 8.76 (dd, 
3
J195Pt1H = 36.54 Hz,
 3
J1H1H = 6.81 
Hz,
 
2H, Ho), δ = 7.84 (t, 
3
J1H1H =7.69 Hz, 1H, Hp), δ = 7.33 (t, 
3
J1H1H =6.90 Hz, 2H, 
Hm). 
4.2.2.5.3 Cis-[Pt(I)2(2-picoline)2] (10) 
K2PtCl4 (0.200 g, 0.48 mmol) was suspended in H2O (110 mL), KI (0.800 g, 4.82 
mmol) was added and the reaction was left to stir for 40 min at room temperature. 
2-picoline (0.095 mL, 0.96 mmol) was added and the reaction mixture was stirred 
for 24 h at 40 
o
C. The dark yellow solid was collected by filtering under vacuum 
and washed with cold water, ethanol and diethyl ether (Yield=0.268 g, 88%). 
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1
H-NMR (acetone-d6, 600 MHz, ppm), δ = 9.26 (dd, 
3
J195Pt1H =31.5 Hz, 
3
J1H1H = 
6.0 Hz, 1H, H6 or H6’), δ =9.12 (dd, 
3
J195Pt1H =31.40 Hz, 
3
J1H1H =5.9 Hz, 1H,  
H6 or 6’), δ=7.80 (t, 
3
J1H1H = 7.0 Hz,  1H, H4 or 4’ ), δ = 7.79 (t, 
3
J1H1H = 7.0 Hz, 1H, 
H4 or 4’), δ = 7.48 (m, 
3
J1H1H = 6.7 Hz, 2H, H3 and 3’), δ = 7.37 (t, 
3
J1H1H=6.8 Hz, 1H, 
H5 or 5’), δ = 7.33 (t, 
3
J1H1H = 6.6 Hz, 1H, H5 or 5’), δ = 3.34 (s, 3H, CH3), δ = 3.25 
(s, 3H, CH3). 
4.2.2.5.4 Cis-[Pt(Cl)2(2-picoline)2] (11) 
Cis-[Pt(I)2(2-pic)2] (0.212 g, 0.34 mmol) was suspended in H2O (54 mL), AgNO3 
(0.112 g, 0.66 mmol) was added and the reaction was stirred under reflux at 60 
o
C 
for 24 h. The AgCl formed was removed by filtration under suction using celite 
on a frit and also Inorganic Membrane filter to ensure complete removal of traces 
of AgCl. NaCl (0.195 g, 3.34 mmol) was added and the reaction was left to stir for 
24 h at ambient temperature. The pale yellow solid was isolated by filtration under 
suction and washed with cold water, ethanol and diethyl ether (Yield= 0.104 g, 
68%). 
1
H-NMR (acetone-d6, 400 MHz, ppm): δ = 9.1 ppm (broad peak, 2H, H6), δ = 7.8 
(t, 
3
J1H1H = 7.8 Hz, 2H, H4), δ=7.5 (d, 
3
J1H1H = 7.7 Hz, 2H, H3), δ = 7.3 (broad 
peak, 2H, H5), δ = 3.2 (s, 6H, CH3). 
4.2.2.5.5 Synthesis of mixed pyridine complexes 
Trans-[Pt(Cl)2(pyridine)(n-picoline)], where n=2, 3 or 4  
Cis-[Pt(Cl)2(pyr)2] (0.200 g, 0.47 mmol) was suspended in H2O (60 mL) and then 
n-picoline (4 eq, 0.176 g, 1.89 mmol in the case of 2-picoline and 2 eq, 0.044 g, 
0.473 mmol for 3- and 4-picolines) was added and the solution was stirred at  
75 
o
C overnight. When the solution turned colourless (~12 h for 2-picoline and 2 h 
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for 3- and 4-picoline), the water was removed by rotary evaporation. The residual 
white solid was washed with diethyl ether to remove the excess ligand. Then, HCl 
(2 M, 1.3 mL) and H2O (8 mL) were added and the reaction was allowed to 
proceed for 4 days at 70 
o
C. The pale yellow solid was isolated by filtration and 
washed with water, ethanol and diethyl ether.  
 
Trans-[Pt(Cl)2(pyr)(2-pic)] (12) 
Yield = 0.155 g, 75%. 
1
H-NMR (acetone-d6, 600 MHz, ppm): δ = 8.94 (dd,
 3
J195Pt1H= 16.02 Hz 
3
J1H1H= 
5.09 Hz, 2H, H8), δ = 8.87 (d, 
3
J1H1H = 5.53 Hz, 1H, H6), δ = 8.02 (t, 
3
J1H1H = 7.76 
Hz, 1H, H10), δ= 7.84 (t, 
3
J1H1H = 7.67 Hz, 1H, H4), δ = 7.52 (m, 2H, H9, H3), δ= 
7.34 (t, 
3
J1H1H = 6.70 Hz, 1H, H5), δ = 3.25 (s, 3H, CH3). 
13
C-NMR (acetone-d6, 150 MHz, ppm): δ= 161.9 (C2), δ= 154.4 (C6), δ=154.08 
(C8), δ= 139.4 (C10), δ=139.0 (C4), δ= 126.8 (C3), δ=126.0 (C9), δ= 123.2 (C5), δ= 
26.3 ppm (CCH3). 
[ESI-MS]= [M+Na]
+
,[2M+Na]
+
 (m/z) Calc., 461.0, 899.0; Found, 460.9, 898.9 
 
Trans-[Pt(Cl)2(pyr)(3-pic)] (13) 
Yield= 0.135 g, 65%. 
1
H-NMR (acetone-d6, 600 MHz, ppm): δ= 8.89 (d, 
3
J195Pt1H= 13.20 Hz 
3
J1H1H=6.76 
Hz, 2H, H8), δ= 8.70 (d,
 3
J195Pt1H= 13.53 Hz, H2), δ= 8.68 (d, 
3
J1H1H= 5.93 Hz, 1H, 
H6), δ= 8.02 (t, 
3
J1H1H=7.66 Hz, 1H, H10), δ= 7.83 (t, 
3
J1H1H= 7.79 Hz, 1H, H4), δ= 
7.52 (t, 
3
J1H1H= 6.47 Hz, 2H, H9), δ= 7.39 (t, 
3
J1H1H= 6.81 Hz, 1H, H5), δ= 2.41 (s, 
3H, CH3). 
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13
C-NMR (acetone-d6, 150 MHz, ppm): δ =155.3 (C8), δ =155.2 (C2), δ=152.5 
(C6), δ =141.1 (C2), δ =140.5 (C10), δ = 136.22 (C3), δ= 127.1 (C9), δ=126.4 (C5), 
δ =19.0 (CCH3). 
[ESI-MS]= [M+Na]
+
,[2M+Na]
+
 (m/z) Calc., 461.0, 899.0; Found, 460.9, 898.9 
 
Trans-[Pt(Cl)2(pyr)(4-pic)] (14) 
Yield = 0.140 g, 67%. 
1
H-NMR (acetone-d6, 600 MHz, ppm): δ= 8.89 (dd, 
3
J195Pt1H= 15.77 Hz, 
3
J1H1H= 
5.9 Hz, 2H, H6), δ= 8.69 (dd, 
3
J195Pt1H= 15.22 Hz,
 3
J1H1H= 6.5 Hz, 2H, H2), δ= 8.02 
(t, 
3
J1H1H=7.8 Hz, 1H, H8), δ= 7.51 (t, 
3
J1H1H=6.7 Hz, 2H, H7), δ= 7.33 (d, 
3
J1H1H=6.1 Hz, 2H, H3), δ= 2.47 (s, 3H, CH3). 
13
C-NMR (acetone-d6, 150 MHz, ppm): δ= 155.3 (C5), δ= 154.4 (C2), δ= 152.9 
(C4), δ= 140.5 (C7), δ= 127.8 (C3), δ= 127.1 (C6), δ= 21.7 (CCH3). 
[ESI-MS]= [M+Na]
+
,[2M+Na]
+
 (m/z) Calc., 461.0, 899.0; Found, 460.9, 898.9 
4.2.2.5.6 Trans-[Pt(N3)2(pyr)(n-pic)] 
Trans-[Pt(Cl)2(pyr)(n-pic)] (0.155 g, 0.35 mmol; 0.245 g, 0.56 mmol; 0.24 g, 0.55 
mmol for 2-, 3- and 4-picoline, respectively) were suspended in H2O (204 mL per 
1 g). AgNO3 (2 mol eq) was added and the reaction was carried out at 60 
o
C for 24 
h. The AgCl was removed by filtration on celite on frit and also through an Ionic 
Membrane (IM) filter. NaN3 (10 mol eq) was added and the mixture was allowed 
to stir for 24 h at 40 
o
C. The yellow solid was isolated and washed with cold 
water, ethanol and diethyl ether. Recrystallisation of these complexes was carried 
out by dissolving the solid in hot MeOH (50 
o
C, ~0.5 g/L) and then allowing the 
solution to stand at -20 
o
C.  
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Trans-[Pt(N3)2(pyr)(2-pic)] (15) 
Yield = 0.1029 g, 64%. 
1
H-NMR (acetone-d6, 400 MHz, ppm): δ = 9.07 (dd, 
3
J1H1H= 6.0 Hz, 
3
J195Pt1H = 
32.0 Hz, 1H, H4), δ = 8.77 (dd, 
3
J1H1H = 5.5 Hz,
 3
J195Pt1H = 39.0 Hz, 2H, H5), δ= 
8.11 ppm (t, 
3
J1H1H= 7.5 Hz, 1H, H7), δ= 7.96 (t, 
3
J1H1H= 7.8 Hz, 1H, H2), δ= 7. 68 
(d, 
3
J1H1H= 7.8, 1H, H1), δ= 7.60 (t, 
3
J1H1H= 6.8 Hz, 2H, H6), δ= 7.52 (t, 
3
J1H1H= 7.0 
Hz, 1H, H3), δ= 3.31 (s, CH3). 
13
C-NMR (acetone-d6, 150 MHz, ppm): δ= 161.9 (C2), δ= 154.3 (C4), δ= 152.4 
(C8), δ= 140.0 (C10), δ= 139.8 (C4), δ= 127.5 (C3), δ= 126.4 (C9), δ= 124.5 (C5), 
δ= 25.8 (CCH3). 
195
Pt-NMR (acetone-d6, 129 MHz): δ= -2118 ppm. 
[ESI-MS]= [M+Na] 
+ 
(m/z) Calc., 474.0; Found, 473.9. 
Trans-[Pt(N3)2(pyr)(3-pic)] (16) 
Yield= 0.177 g, 70 %. 
1
H-NMR (acetone-d6, 600 MHz, ppm): δ= 8.84 (dd, 
3
J1H1H= 5.1 Hz, 
3
J195Pt1H= 32.0 
Hz, 2H, H8), δ= 8.68 (s, 1H, H2), δ= 8.65 (d, 
3
J1H1H= 5.8 Hz, 1H, H6), δ= 8.12 (t, 
3
J1H1H= 7.4 Hz, 1H, H10), δ= 7.92 (d, 
3
J1H1H= 7.8, 1H, H4), δ= 7.66 (t, 
3
J1H1H= 6.9 
Hz, 2H, H9), δ= 7.54 (t, 
3
J1H1H= 7.1 Hz, 1H, H5), δ= 2.46 (s, 3H, CH3). 
195
Pt-NMR (acetone-d6, 129 MHz): δ= -2120 ppm. 
[ESI-MS]= [M+Na] 
+ 
(m/z) Calc., 474.0; Found, 473.9. 
 
 
Chapter 4: Pt(IV)-diazido complexes with aromatic N-heterocyclic ligands 
 
164 
 
Trans-[Pt(N3)2(pyr)(4-pic)] (17) 
Yield = 0.167 g, 66%. 
1
H-NMR (acetone-d6, 600 MHz, ppm): δ= 8.85 (dd, 
3
J1H1H=5.7 Hz, 
3
J195Pt1H=30.0 
Hz, 2H, H6), δ= 8.66 (dd, 
3
J1H1H=5.8 Hz, 2H, H2), δ= 8.11 (t, 
3
J1H1H=7.77 Hz, 1H, 
H8), δ= 7.65 (t, 
3
J1H1H=6.5 Hz, 2H, H7), δ= 7. 48 (d, 
3
J1H1H= 5.6, 1H, H2), δ= 2.52 
(s, 3H, CH3). 
195
Pt-NMR (acetone-d6, 129 MHz): δ= -2117 ppm. 
[ESI-MS]= [M+Na] 
+ 
(m/z) Calc., 474.0; Found, 473.9. 
4.2.2.5.7 Trans, trans, trans-[Pt(N3)2(OH)2(pyr)(n-pic)] 
Trans-[Pt(N3)2(pyr)(n-pic)] (0.084 g, 0.18 mmol; 0.138 g, 0.30 mmol; 0.108 g, 
0.18 mmol for 2-, 3- and 4-picoline, respectively) was suspended in H2O2 (30% 
v/v, 70 mL per 1 g) and the reaction was allowed to proceed at 45 
o
C for 3 hours. 
A bright yellow solution formed, which was filtered using an Inorganic 
Membrane filter to remove any unreacted starting material or insoluble side 
products. Then, the H2O2 was removed by lyophilization. To isolate the final 
product, the residual yellow precipitate was suspended in the minimum amount of 
warm ethanol (45 
o
C) and then it was allowed to precipitate upon addition of 
diethyl ether (3-fold) at -20 
o
C. Crystals suitable for X-ray diffraction were 
obtained for 20 via this method.  
Trans, trans, trans-[Pt(N3)2(OH)2(pyr)(2-pic)] (18) 
Yield = 0.023 g, 25%. 
1
H-NMR (D2O, 700 MHz, ppm): δ= 8.78 (d, 
3
J1H1H=6.4 Hz, 1H, H6), δ= 8.73 (d, 
3
J1H1H= 6.0 Hz, 2H, H8), δ= 8.26 (t, 
3
J1H1H= 7.1 Hz, 1H, H10), δ= 8.06 (t, 
3
J1H1H= 
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7.6 Hz, 1H, H4), δ= 7. 80 (t, 
3
J1H1H= 6.5, 2H, H9), δ= 7.60 (d, 
3
J1H1H=6.8 Hz, 1H, 
H3), δ= 7.56 (t, 
3
J1H1H=7.0 Hz, 1H, H5), δ= 3.32 (s, 3H, CH3). 
13
C-NMR (D2O, 175 MHz, ppm): δ= 163.3 (C2), δ= 152.8 (C6), δ= 149.8 (C8), δ= 
143.2 (C10), δ= 142.3 (C4), δ=130.1 (C3), δ= 127.6 (C9), δ= 124.8 (C5), δ= 22.9 
(CCH3). 
195
Pt-NMR (D2O, 129 MHz): δ= 1132 ppm. 
[ESI-MS]= [M+Na] 
+ 
(m/z) Calc., 508.0; Found, 508.1. 
HPLC purity= 90%. 
ε 297 nm =20091 M
-1
cm
-1
, ε268 nm =16061 M
-1
cm
-1 
(H2O). 
Trans, trans, trans-[Pt(N3)2(OH)2(pyr)(3-pic)] (19) 
Yield = 0.073 g, 49%. 
1
H-NMR (D2O, 600 MHz, ppm): δ= 8.83 (dd, 
3
J1H1H= 5.9 Hz, 
3
J195Pt1H= 32.0 Hz, 
2H, H8), δ= 8.64 (s, 1H, H2), δ= 8.63 (d, 
3
J1H1H=7.0 Hz, 1H, H6), δ= 8.31 (t, 
3
J1H1H= 7.5 Hz, 1H, H10), δ= 8.14 (d, 
3
J1H1H= 7.8, 1H, H4), δ= 7.85 (t, 
3
J1H1H= 7.0 
Hz, 2H, H9), δ= 7.72 (t, 
3
J1H1H= 7.0 Hz, 1H, H5), δ= 2.56 (s, 3H, CH3). 
13
C-NMR (D2O, 150 MHz, ppm): δ= 150.93 (C8), δ= 150.65 (C2), δ= 148.00 (C6), 
δ= 144.58 (C4), δ= 144.08 (C10), δ= 139.64 (C3), δ= 128.65 (C9), δ= 127.92 (C5), 
δ= 19.32 (CCH3). 
195
Pt-NMR (D2O, 129 MHz): δ= 954 ppm. 
[ESI-MS]= [M+Na] 
+ 
(m/z) Calc., 508.0; Found, 508.0. 
HPLC purity= 88%. 
ε 294 nm =18258 M
-1
cm
-1
, ε268 nm =13467 M
-1
cm
-1 
(H2O). 
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`Trans, trans, trans-[Pt(N3)2(OH)2(pyr)(4-pic)] (20) 
Yield = 0.074 g, 50%. 
1
H-NMR (D2O, 600 MHz, ppm): δ= 8.78 (dd, 
3
J1H1H=5.9 Hz, 
3
J195Pt1H= 48 Hz, 2H, 
H6), δ= 8.59 (d, dd, 
3
J1H1H= 6.1 Hz, 
3
J195Pt1H=52 Hz, 2H, H2), δ= 8.27 (t, 
3
J1H1H= 
6.9 Hz, 1H, H8), δ= 7.81 (t, 
3
J1H1H= 6.4 Hz, 2H, H7), δ= 7.63 (d, 
3
J1H1H= 6.1 Hz, 
2H, H3), δ= 2.60 (s, 3H, CH3). 
13
C-NMR (D2O, 150 MHz, ppm): δ= 158.65 (C4), δ= 149.97 (C6), δ= 148.94 (C2), 
δ=143.14 (C8), δ= 128.48 (C3), δ= 127.71 (C7), δ= 21.14 (CCH3). 
195
Pt-NMR (D2O, 129 MHz): δ= 957 ppm. 
[ESI-MS]= [M+Na] 
+ 
(m/z) Calc., 508.0; Found, 508.1. 
HPLC purity= 91%. 
ε 295 nm = 18955 M
-1
cm
-1
, ε258 nm = 12535 M
-1
cm
-1 
(H2O). 
4.2.2.5.8 Trans-[Pt(Cl)2(3-pic)2] (21) 
K2PtCl4 (0.700 g, 1.69 mmol) was dissolved in H2O (55 mL) and 3-picoline (50 
eq, 7.51 mL) was added. The solution was allowed to react under reflux at 100 
o
C 
for 24 h. The water and excess ligand were evaporated and the white residue was 
washed with diethyl ether. Then HCl (2 M, 24 mL) was added and the reaction 
proceeded for 48 h at 85 
o
C. The yellow precipitate was collected by filtration 
(Yield = 0.706 g, 93%). 
1
H-NMR (CDCl3, 400 MHz, ppm): δ= 8.72 (s, 2H, H2), δ= 8.69 (d,
 3
J1H1H= 5.50 
Hz, 2H, H6), δ= 7.57 (d,
 3
J1H1H= 8.02 Hz, 2H, H4), δ= 7.19 (t,
 3
J1H1H= 6.72 Hz, 2H, 
H5), δ= 2.37 (s, 6H, CH3). 
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4.2.2.5.9 Trans-[Pt(N3)2(3-pic)2] (22) 
Trans-[Pt(Cl)2(3-pic)2] (0.700 g, 1.55 mmol) was dissolved in DMF (30 mL), 
NaN3 (20 eq, 2.013 g) was added and the reaction was stirred for 4 days at 35 
o
C. 
Work up of the reaction was carried out by the addition of diethyl ether (60 mL) 
and precipitation of the solid at -20 
o
C (Yield= 0.400 g, 55%). 
1
H-NMR (CDCl3, 400 MHz, ppm): δ= 8.63 (s, 2H, H2), δ= 8.61 (d,
 3
J1H1H= 6.45 
Hz, 2H, H6), δ= 7.66 (d,
 3
J1H1H= 7.82 Hz, 2H, H4), δ= 7.33 (t,
 3
J1H1H= 6.77 Hz, 2H, 
H5), δ= 2.43 (s, 6H, CH3). 
[ESI-MS]= [M+Na] 
+ 
(m/z) Calc., 488.1; Found, 488.0. 
4.2.2.5.10 Trans, trans, trans-[Pt(N3)2(OH)2(3-pic)2] (23) 
Trans-[Pt(N3)2(3-pic)2] (0.350 g, 0.75 mmol) was suspended in H2O2 (51 mL) and 
the reaction allowed to react at 50 
o
C for 5 h, at which point the solution turned 
transparent. The work up of the reaction was carried out as described in section 
4.2.2.5.7. Crystals suitable for X-ray diffraction were obtained by slow 
evaporation of a solution of the complex in MeOH/DCM at room temperature.  
1
H-NMR (D2O, 500 MHz, ppm): δ= 8.60 (s, 2H, H2), δ= 8.59 (d,
 3
J1H1H= 5.54 Hz, 
2H, H6), δ= 8.10 (d,
 3
J1H1H= 7.76 Hz, 2H, H4), δ= 7.68 (t,
 3
J1H1H= 7.10 Hz, 2H, 
H5), δ= 2.52 (s, 6H, CH3). 
13
C-NMR (D2O, 125 MHz, ppm): δ= 149.74 (C1), δ= 147.04 (C6), δ= 143.62 (C4), 
δ= 138.68 (C3), δ= 126.98 (C5), δ= 18.38 (CCH3). 
195
Pt-NMR (D2O, 107 MHz): δ= 971 ppm. 
[ESI-MS]= [M+Na] 
+ 
(m/z) Calc., 522.1; Found, 521.9. 
HPLC purity= 97%. 
ε 295 nm =19025 M
-1
cm
-1
, ε267 nm =13766 M
-1
cm
-1 
(H2O). 
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4.2.2.5.11 Trans-[Pt(Cl)2(4-pic)2] (24) 
K2PtCl4 (0.800 g, 1.93 mmol) was completely dissolved in H2O (24 mL), 4-
picoline (20 eq, 3.75 mL) was added and the solution allowed to react at 95 
o
C for 
1 h, at which point the mixture turned into a colourless solution. The solvent was 
rotary evaporated to dryness and the residual white solid was suspended in HCl (2 
M, 27 mL) and allowed to react for 12 h. The yellow precipitate was filtered out 
and washed with water, ethanol and diethyl ether (Yield = 0.697 g, 80%). 
1
H-NMR (CDCl3, 400 MHz, ppm): δ= 8.71 (d,
 3
J1H1H= 6.87 Hz, 4H, H2), δ= 7.11 
(d,
 3
J1H1H= 6.87 Hz, 4H, H3), δ= 2.41 (s, 6H, CH3). 
4.2.2.5.12 Trans-[Pt(N3)2(4-pic)2] (25) 
Trans-[Pt(Cl)2(4-pic)2] (0.690 g, 1.53 mmol) was dissolved in DMF (35 mL), then 
NaN3 (20 eq, 1.282 g) was added and the mixture was allowed to react for 4 days 
at room temperature in the dark. The solution was then placed at -20 
o
C, for the 
precipitation of the first crop. A second crop was collected by the addition of 
diethyl ether to the filtrate and then allowing further precipitation at -20 
o
C. Both 
batches were washed with excess water for removal of sodium azide (Yield = 
0.605 g, 85%). 
1
H-NMR (acetone-d6, 400 MHz, ppm): δ= 8.65 (dd,
 3
J195Pt1H= 34 Hz,
 3
J1H1H= 6.60 
Hz, 4H, H2), δ= 7.47 (d,
 3
J1H1H= 6.03 Hz, 4H, H3), δ= 2.51 (s, 6H, CH3). 
[ESI-MS]= [M+Na] 
+ 
(m/z) Calc., 488.1; Found, 488.0. 
4.2.2.5.13 Trans-[Pt(N3)2(OH)2(4-pic)2] (26) 
Trans-[Pt(N3)2(4-pic)2] (0.600 g, 1.29 mmol) was suspended in H2O2 and the 
mixture was stirred for 20 h at 50 
o
C, to give a yellow solution which was 
lyophilized. Recrystallisation was carried out by dissolving the solid in warm 
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methanol (2 mL, 55 
o
C) and then adding diethyl ether (20 mL). The mixture was 
placed at -20 
o
C to yield the title compound. Crystals suitable for X-ray diffraction 
were obtained by the slow evaporation at ambient temperature of a methanol 
solution (Yield= 0.193 g, 30%). 
1
H-NMR (D2O, 400 MHz, ppm): δ= 8.57 (dd,
 3
J195Pt1H= 26.80 Hz,
 3
J1H1H= 6.81 
Hz, 4H, H2), δ= 7.62 (d,
 3
J1H1H= 6.16 Hz, 4H, H3), δ= 2.60 (s, 6H, CH3). 
13
C-NMR (D2O, 150 MHz, ppm): δ= 156.63 (C4), δ= 148.95 (C2), δ= 128.46 (C3), 
δ= 21.36 (CCH3). 
195
Pt-NMR (D2O, 129 MHz): δ= 964 ppm. 
[ESI-MS]= [M+Na] 
+ 
(m/z) Calc., 522.1; Found, 522.1. 
HPLC purity= 90%. 
ε 293 nm =15815 M
-1
cm
-1
, ε256  nm =12689 M
-1
cm
-1
 (H2O). 
4.2.2.5.14 Trans-[Pt(Cl)2(thiazole)2] (27) 
K2PtCl4 (0.800 g, 1.93 mmol) was completely dissolved in H2O (16 mL) and 
thiazole (14 eq, 2.29 mL) was added. The solution was allowed to react, under 
reflux, at 100 
o
C for three hours until the mixture turned into a transparent yellow 
solution. The reaction passes through an orange precipitate. The solvent was 
rotary evaporated to dryness and the residual yellow solid was suspended in HCl 
(2 M, 24 mL) and allowed to react overnight (14 hours) at 85 
o
C. The yellow 
precipitate was filtered off and washed with water, ethanol and diethyl ether 
(Yield = 0.750 g, 89%). 
1
H-NMR (acetone-d6, 400 MHz, ppm): δ = 9.58 (dd, 
3
J1H1H= 2.36 Hz, 
3
J195Pt1H= 27 
Hz, 2H, H2), 8.32 (d, 
3
J1H1H= 3.44 Hz, 2H, H4), 7.88 (t, 
3
J1H1H= 2.96 Hz, 2H, H5). 
[ESI-MS]= [M+Na]
+
, [2M+Na]
+
 (m/z) Calc., 458.9, 894.8; Found, 458.8, 894.7 
Chapter 4: Pt(IV)-diazido complexes with aromatic N-heterocyclic ligands 
 
170 
 
4.2.2.5.15 Trans-[Pt(N3)2(thiazole)2] (28) 
Trans-[Pt(Cl)2(tz)2] (0.700 g, 1.61 mmol) was completely dissolved in DMF (30 
mL) and NaN3 (20 eq, 2.087 g) was added. The reaction mixture was allowed to 
react for 6 days at room temperature in the dark. Work up of the reaction was 
carried out as described in section 4.2.2.5.9 (Yield= 0.411 g, 57%). 
1
H-NMR (acetone-d6, 400 MHz, ppm): δ = 9.57 (dd, 
3
J1H1H= 2.05 Hz, 
3
J195Pt1H= 29 
Hz, 2H, H2), 8.26 (d, 
3
J1H1H= 3.68 Hz, 2H, H4), 8.04 (t, 
3
J1H1H= 2.85 Hz, 2H, H5). 
[ESI-MS]= [M+Na] 
+ 
(m/z) Calc., 488.0; Found, 488.0. 
4.2.2.5.16 Trans, trans, trans-[Pt(N3)2(OH)2(thiazole)2] (29) 
Trans-[Pt(N3)2(tz)2] (0.400 g, 0.89 mmol) was suspended in H2O2 (30% v/v, 45 
mL) and allowed to react at 50 
o
C for 5 hours. The yellow solution was IM 
filtered and then the H2O2 removed by freeze drying. The resulting residual solid 
of the title compound was washed with ethanol and acetone, as well as cold water 
(Yield= 0.215 g, 50%). 
1
H-NMR (D2O, 400MHz, ppm): δ = 9.58 (dd, 
3
J1H1H= 1.97 Hz, 
3
J195Pt1H= 20.30 
Hz, 2H, H2), 8.30 (dd, 
3
J1H1H= 3.85 Hz, 
3
J195Pt1H= 15.71 Hz, 2H, H4), 8.07 (t, 
3
J1H1H= 2.93 Hz, 2H, H5). 
13
C-NMR (D2O, 150 MHz, ppm): δ= 157.8 (C2), δ= 140.3 (C4), δ= 123.8 (C5). 
195
Pt-NMR (D2O, 129 MHz): δ= 977 ppm. 
[ESI-MS]= [M+Na] 
+ 
(m/z) Calc., 506.0; Found, 505.8. 
HPLC purity= 94 %. 
ε 295 nm =16750 M
-1
cm
-1 
(H2O). 
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4.2.2.5.17 Trans-[Pt(Cl)2(1-methylimidazole)2] (30) 
K2PtCl4 (0.5 g, 1.21 mmol) was dissolved in H2O (15 mL), 1-methylimidazole (7 
eq, 0.672 mL, 8.43 mmol) was added and the solution was allowed to react under 
reflux at 90 
o
C. The precipitation of a yellow intermediate was observed and the 
solution turned colourless after 120 min. Water was removed by rotary 
evaporation to leave a yellow solid and excess ligand. HCl (2 M, 15 mL) was then 
added and the reaction was allowed to proceed for 48 h at 85 
o
C, to yield a yellow 
solid which was isolated by filtration and washed with water, ethanol and diethyl 
ether (Yield= 0.366 g, 71%). 
1
H-NMR (acetone-d6, 400 MHz, ppm): δ= 8.13 (s, 2H, H2), δ= 7.38 (t, 
3
J1H1H = 
1.32 Hz, 2H, H4), δ= 7.11 (t, 
3
J1H1H= 1.56Hz, 2H, H5), δ= 3.86 (s, 6H, CH3). 
[ESI-MS]= [M+Na]
+
, [2M+Na]
+
 (m/z) Calc., 453.0, 883.0; Found, 452.9, 882.9 
4.2.2.5.18 Trans-[Pt(N3)2(1-methylimidazole)2] (31) 
Trans-[Pt(Cl)2(mim)2] (0.350 g, 0.82 mmol) was dissolved in DMF (7 mL) and 
NaN3 (20 eq,1.057 g) was suspended in the solution. The reaction was allowed to 
proceed for 4 days at 35 
o
C. Work up of the reaction was executed as described in 
section 4.2.2.5.9 (Yield= 0.110 g, 30%). 
1
H-NMR (methanol-d4, 400 MHz, ppm): δ= 8.03 (s, 2H, H2), δ= 7.19 (s, 4H, H4, 
H5), δ= 3.82 (s, 6H, CH3). 
[ESI-MS]= [M+Na] 
+ 
(m/z) Calc., 466.1; Found, 465.9. 
4.2.2.5.19 Trans-[Pt(OH)2(N3)2(1-methylimidazole)2] (32) 
Trans-[Pt(N3)2(mim)2] (0.106 g, 0.24 mmol) was suspended in H2O2 (30%, 9.2 
mL) and the reaction was heated to 50 
o
C, until the yellow solution became 
transparent (1.5 h). Removal of the solvent was carried out via lyophilisation after 
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the solution was IM-filtered. Recrystallisation in a methanol/ DCM solution 
allowed the growth of crystals suitable for their study by X-ray diffraction (Yield= 
0.050 g, 44%). 
1
H-NMR (D2O, 500 MHz, ppm): δ= 8.22 (s, 2H, H1), δ= 7.35 (t,
 3
J1H1H= 1.54 Hz, 
2H, H2), δ= 7.32 (t, 3J1H1H= 1.62 Hz, 2H, H3), δ= 3.92 (s, 6H, CH3). 
13
C-NMR (D2O, 125 MHz, ppm): δ= 137.48 (C2), δ= 125.54 (C4), δ= 123.05 (C5), 
δ= 35.59 (CCH3). 
195
Pt-NMR (D2O, 107 MHz): δ= 987 ppm. 
[ESI-MS]= [M+Na] 
+ 
(m/z) Calc., 500.0; Found, 499.9. 
HPLC purity= 88 %. 
ε 290 nm =18307 M
-1
cm
-1 
(H2O). 
4.3 Results  
4.3.1 Characterisation and purity test 
The Pt(IV)-diazido complexes were characterised by 
1
H, 
13
C, 
195
Pt-NMR, ESI-MS 
and the purity assessed by HPLC (see section 4.2.2.5).  
4.3.2 X-ray diffraction 
Single crystals suitable for X-ray diffraction studies were obtained for the novel 
complexes trans, trans, trans-[Pt(N3)2(OH)2(pyr)(4-pic)] 20, trans, trans, trans-
[Pt(N3)2(OH)2(3-pic)2] 23, trans, trans, trans-[Pt(N3)2(OH)2(4-pic)2] 26 and trans, 
trans, trans-[Pt(N3)2(OH)2(mim)2] 32, as described in section 4.2.2.5. The ORTEP 
diagrams of the molecular structures are shown in Figure 4.2. Crystallographic 
data of complexes 20, 26, 23 and 32 are summarized in Table 4.2 and selected 
bond distances and angles in Table 4.3 and Table 4.4.  
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Compounds 20 and 23 crystallized in the monoclinic space group P2(1)/n, 
whereas 26 and 32 in a triclinic space group P-1. All the complexes show an 
octahedral geometry with an [N4O2] coordination sphere around the metal center. 
Complexes 23, 26 and 32 are completely symmetrical, therefore the two halves of 
the molecule are identical. The O–Pt–O angle is 180o indicating a perfect 
octahedral geometry, whereas complex 20 has a slight distortion with a N3–Pt–N6 
bond angle of 178.0(3)
o
. The crystal structures of 23 and 26 consist of a molecule 
of complex solvated by one methanol molecule. The unit cell of complex 32 
contains two crystallographically-independent molecules of complex and a water 
molecule.  
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Table 4.2: Crystallographic data for complexes 20, 23 CH3OH, 26 CH3OH and 
32 0.5H2O.  
Complex 20 23 CH3OH 26 CH3OH 32 0.5H2O 
Empirical formula C11H14N8O2Pt C13H20N8O3Pt C13H20 N8O3Pt C8H15N10O2.5Pt 
Formula weight 485.39 531.44 531.44 486.36 
Crystal description Colourless  
block 
Colourless  
block 
Yellow block Yellow block 
Crystal system Monoclinic Monoclinic Triclinic Triclinic 
Crystal size/ mm 0.24×0.20× 
0.18 
0.26×0.26× 
0.06 
0.40×0.20× 
0.16 
0.20×0.20× 
0.06 
Space group P2(1)/n P2(1)/n P-1 P-1 
a/ Å 9.5981(5) 7.09413(13) 9.4526(2) 8.4781(6) 
b/ Å 9.2035(5) 11.18048(20) 9.5894(2) 8.7226(7) 
c/ Å 17.2119(8) 12.3270(2) 12.0611(2) 10.9694(5) 
α / (°) 90 90 97.810(2) 71.064(5) 
β/ (°) 92.640(5) 90.6038(17) 105.402(2) 79.820(5) 
γ/ (°) 90 90 114.181(2) 84.869(6) 
Volume/ Å
3 1518.82(13) 977.67(3) 923.57(3) 754.77(8) 
Z 4 2 2 2 
Dcalc/gcm
-3 2.123 1.914 2.026 2.180 
F(000) 920 548 548 472 
µcalcd /mm
-1
 9.259 7.214 7.636 9.326 
T/ K 100(2) 150(2) 100(2) 150(2) 
Max θ /° 29.75 31.45 32.26 29.77 
Reflections 
collected/unique  
[Rint] 
8340/ 3732 
[0.0710] 
10712 /3001  
[0.0268] 
19091/ 6074 
[0.0320] 
6604, 3714 
[0.0498] 
Goodness-of-fit 
 on F
2
 
1.034 1.050 1.098 1.032 
Data/restraints/ 
parameters 
3732/ 0/ 200 3001/ 0/ 132 6074/ 2/ 254 3714/ 0/ 211 
Final R indices 
[I>2σ(I)] 
R1= 0.050 
wR2=0.1172 
R1= 0.0184 
wR2=0.0405 
R1= 0.0240 
wR2=0.0577 
R1= 0.0450 
wR2=0.1159 
R indices 
 (all data) 
R1= 0.064 
wR2=0.1235 
R1= 0.0263 
wR2=0.0451 
R1= 0.0311 
wR2=0.0614 
R1= 0.0588 
wR2=0.1312 
Largest diff. peak  
and hole (eÅ
-3
) 
6.803 and  
-1.988 
0.829 and  
-1.015 
2.811 and  
-1.263 
4.383 and  
-2.786 
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 (A) 
 (B) 
 
(C) 
 (D) 
Figure 4.2: ORTEP diagrams of the complexes reported in this chapter: A) trans, 
trans, trans-[Pt(N3)2(OH)2(pyr)(4-pic)] 20; B) trans, trans, trans-[Pt(N3)2(OH)2(3-
pic)2] 23; C) trans, trans, trans-[Pt(N3)2(OH)2(4-pic)2] 26; D) trans, trans, trans-
[Pt(N3)2(OH)2(mim)2] 32. The ellipsoids are set to 50% probability level.  
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Table 4.3: Selected bond distances (Å) and angles (
o
) for complex 20. 
Bond  (Å) Angle (
o
) 
Pt–O1 2.003(6) N6–Pt–N3 178.0(3) 
Pt–O2 2.014(6) N7–N6–Pt 118.0(6) 
Pt–N1 2.013(7) N4–N3–Pt 116.1(6) 
Pt–N2 2.033(7) N1–Pt–N2 179.2(3) 
Pt–N3 2.052(6) O2–Pt–O1 176.7(2) 
Pt–N6 2.043(7) N3–N4–N5 174.8(9) 
N6–N7 1.197(10) N6–N7–N8 175.6(9) 
N7–N8 1.141(11) - - 
N3–N4 1.225(10) - - 
N4–N5 1.136(11) - - 
 
Table 4.4: Selected bond distances (Å) and angles (
o
) for complexes 23 CH3OH, 
26 CH3OH and 32 0.5H2O. For the latter, two independent platinum centres were 
found and they are represented as A and B.  
Bond (Å)/ Angle (
o
) 23 26 32 
A 
32 
B 
Pt–O1 2.0046(19) 1.998(2) 1.997(4) 2.003(3) 
Pt–N1 2.033(2) 2.036(3) 2.000(5) 2.005(5) 
Pt–N2 2.048(2) 2.048(3) 2.058(5) 2.062(5) 
N2–N3 1.218(3) 1.210(4) 1.198(8) 1.198(7) 
N3–N4 1.147(3) 1.144(4) 1.155(10) 1.134(8) 
N2–Pt–N2 180.0 180.0 180.00(19) 180.0(1) 
N3–N2–Pt 115.51(15) 115.6(2) 118.7(4) 115.4(4) 
N1–Pt–N1 180.0(1) 180.0(1) 180.0 180.000(1) 
O1–Pt–O1 180.0 180.0 180.0(3) 180.000(1) 
N2–N3–N4 174.5(2) 174.6(4) 174.2(8) 175.3(7) 
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4.3.3 Solubility and Stability 
All compounds were stable in water in the dark at ambient temperature (20-25 
o
C) 
for at least two weeks, as examined by 
1
H-NMR experiments. The solubility of 
the compounds in water is summarized in Table 4.5.  
 
Table 4.5: Maximum solubility in water at ca 20 
o
C of the Pt(IV)-diazido 
complexes reported in this chapter.  
Complex Max 
Solubility 
(mM) 
18 20.0 
19 20.0 
20 20.0 
23 3.0 
26 4.0 
29 82.0 
32 0.9 
 
4.3.4 Extinction coefficient determinations 
The extinction coefficients for the novel Pt(IV)-diazido complexes were 
determined in water and the UV-Vis spectra are depicted in the same graph for 
comparison (Figure 4.3).  
The longest wavelength absorption maximum in these set of complexes was found 
for complex trans, trans, trans-[Pt(N3)2(OH)2(pyr)(2-pic)] 18 at 297 nm, whereas 
the shortest absorption maximum is for compound trans, trans, trans-
[Pt(N3)2(OH)2(mim)2] 32 with a λmax of 290 nm. The absorption maxima of all 
other complexes, including the previously reported complex trans, trans, trans-
[Pt(N3)2(OH)2(pyr)2],
11
 lie between 293-295 nm. The complexes containing 
pyridine and/or pyridine-derivative ligands had two main absorption bands 
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whereas the complexes with thiazole or 1-methylimidazole showed one main 
band.  
 
Figure 4.3: UV-Vis spectra of the Pt(IV)-diazido complexes in water. The inset in 
the graph shows an extension for the 400-600 nm range.  
 
4.3.5 Photoirradiation of complexes followed by UV-Vis 
Aqueous solutions of the complexes (60 μM) were irradiated with blue light (463 
nm, 57 mW/cm
2
), under identical conditions, and their photodegradation was 
followed by UV-Vis spectroscopy, at frequent time points (Figure 4.4). Although 
the complexes can also be activated with green light (λ= 517 nm), a comparative 
study was carried out with blue light activation, as the time required for the green 
light for substantial photodecomposition is greater than 6 hours (e.g. see 
Appendix). As pointed out in Chapter 3, a decrease in intensity of the N3→Pt 
band is observed upon irradiation. This exponential decrease was followed until 
ca 78% decrease for all complexes and plotted against time. The data were fitted 
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to the function y= y0+Ae
Rox, with an r
2
> 0.98 in all of the cases (Figure 4.5). The 
half lives of the complexes are depicted in Table 4.6. The fastest half life was 
found for complex 18 (Pt
IV
-(pyr)(2-pic)) whereas the slowest was for complexes 
23 and 26 (Pt
IV
-(3-pic)2 and Pt
IV
-(4-pic)2, respectively). 
 
 
 
 
 
 
 
 
 
3 18 
19 20 
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Figure 4.4: Changes in UV-Vis spectra of the complexes (60 μM in H2O) upon 
irradiation with 463 nm light.  
 
 
23 26 
29 32 
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Figure 4.5: Plot of decrease of the normalised absorbance corresponding to the 
change of the N3→Pt band to an extent of ca. 22%. Irradiation was carried out 
with blue light (463 nm, 57 mW/cm
2
).  
 
Table 4.6: Decomposition half-lives of complexes (60 μM) when irradiated with 
blue (463 nm) light, as measured by UV-Vis spectroscopy.  
 
Complex t1/2 (min) 
18 9.2 
19 20.7 
20 20.1 
23 25.8 
26 25.1 
29 16.8 
32 21.8 
3 21.6 
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4.3.6 1H-NMR of complexes cis-[Pt(I)2(2-pic)2]-10 and  
cis-[Pt(Cl)2(2-pic)2]-11 
 
The synthesis of trans-[Pt(Cl)2(2-pic)(pyr)] was attempted by the addition of 2 
mol equivalents of pyridine to cis-[Pt(Cl)2(2-pic)2] 11. The steric strain in this 
molecule as well as in the precursor cis-[Pt(I)2(2-pic)2] 10 was studied via 
1
H-
NMR. The iodido complex gives rise to a set of two peaks for each picoline 
ligand. Increase in temperature resulted in the peaks approaching together (Figure 
4.6), especially H5 and H3. In the chlorido complex, broad peaks are generated 
for the H5 and H6 protons.  
 
Figure 4.6:  
1
H-NMR spectrum (600 MHz) of cis-[Pt(I)2(2-pic)2] 10 at (A) T= 25 
o
C  and (B) T= 45 
o
C; (C) 
1
H-NMR spectrum (400 MHz) of cis-[Pt(Cl)2(2-pic)2] 
11 at T= 25 
o
C . All NMR spectra were recorded in acetone-d6.  
6 
6 
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4.3.7 DFT-TDDFT calculations for complex 18 
Complex 18, trans, trans, trans-[Pt(N3)2(OH)2(pyr)(2-pic)], was found to be the 
most photosensitive complex in this series, with a half life decreased by 2.5, when 
compared to complexes from the same family. Ground-state and lowest-lying-
triplet-state optimizations were performed. Furthermore, TDDFT calculations 
were carried out in order to simulate the electronic transitions and rationalize the 
photoactivity of metal complexes. A crystal structure for complex 18 was not 
obtained and therefore direct comparison of bond lengths in the ground state was 
not possible. However the theoretical UV-Vis spectrum, as shown in Figure 4.7, 
matches well with the experimental, with the absorption maximum 
underestimated by only 9 nm (experimental: 297 nm, 20091 M
-1
cm
-1
, theoretical 
288 nm, 19282 M
-1
cm
-1
) and the shoulder with only 1 nm difference (theoretical: 
267 nm, 13520 M
-1
cm
-1
 and experimental: 268 nm, 16061 M
-1
cm
-1
). The UV-Vis 
spectra were simulated by the calculation of 32 singlet states using water as a 
solvent (cpcm)
15
 and the TDDFT method. The singlet excited states as well as the 
percentage contribution are presented in Table 4.8, whereas in  
Figure 4.8, a representation of the contributions of each of the ligands in the most 
relevant molecular orbitals is provided which can help with the characterisation of 
the transitions. The main band is composed by ligand-to-metal charge transfer 
(LMCT) dissociative transitions with N3
-→Pt character. The transitions 
composing the shoulder of the spectrum contain mixed LMCT/ IL character 
involving the OH
- → Pt, pyridines.  
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Table 4.7: Selected bond distances for 18, the Nα, Nβ and Nγ labels denote the 
azide atoms.   
Bond length Ground-state 
(Å) 
Lowest-lying 
excited state(Å) 
Pt–Nα 2.075 2.435 
Pt–Nα 2.075 2.526 
Pt–OH 2.054 2.025 
Pt–OH 2.031 2.010 
Pt–N(Py) 2.055 2.062 
Pt–N(Py-CH3) 2.068 2.063 
Nα–Nβ 1.217 1.200 
Nα–Nβ 1.217 1.192 
Nβ–Nγ 1.147 1.162 
Nβ–Nγ 1.147 1.167 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Calculated and experimental absorption spectra of 18. The excited 
states are shown as vertical bars with heights equal to the extinction coefficients. 
The theoretical graph was obtained using GAUSSUM 2.2.  
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Table 4.8: Calculated singlet transitions for complex 18, in H2O.  
 
Energy 
(eV) 
Wavelength 
(nm) 
Oscillator 
Strength 
Major contributions 
1 2.96 419 0.004 H-1→LUMO (88%) 
2 2.97 417 0.0003 HOMO→LUMO (94%) 
3 3.03 409 0.0023 H-2→LUMO (88%) 
5 4.08 304 0.0094 
H-5→LUMO (57%) 
H-4→LUMO (26%) 
8 4.25 291 0.067 
H-3→LUMO (17%) 
H-2→L+3 (56%) 
9 4.30 288 0.127 
H-3→LUMO (30%) 
H-2→L+3 (21%) 
H-1→L+3 (25%) 
13 4.51 275 0.0359 
H-5→LUMO (32%) 
H-4→LUMO (54%) 
17 4.76 261 0.1032 
H-7→LUMO (38%) 
H-2→L+2 (21%) 
22 5.01 248 0.0379 
H-9→LUMO (18%) 
H-8→LUMO (47%) 
30 5.39 230 0.0803 
H-5→L+2 (15%) 
H-4→L+1 (16%) 
H-4→L+2 (17%) 
H-1→L+5 (17%) 
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LUMO+3 
 
LUMO+2 
 
LUMO+1 
 
 
 
 
 
 
 
 
LUMO 
 
HOMO 
 
HOMO-1 
 
HOMO-2 
 
HOMO-3 
 
Figure 4.8: Selected molecular orbitals of complex 18, with purple and green 
representing the two signs of the wavefunctions (+ and -).  
4.4 Discussion  
The design of novel platinum-diazido complexes with different planar-aromatic 
ligands, is important for the development of the Pt(IV)-diazido family of 
complexes, since these ligands can have an effect on the photolability as well as 
the phototoxicity of the complexes. Previous research
11, 16
 showed that after 
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photoactivation, these aromatic ligands are retained on the platinum, upon 
reduction to Pt(II) and therefore play a vital role in the cytotoxic properties of 
these complexes. Furthermore studies by Bednarski et al.
17
 showed that the bulk 
of the ligand also plays a vital role in the photolability of the complex. 
Comparative studies between piperidine and pyridine containing complexes 
showed that with the piperidine ligand, a faster rate of cellular death under light 
activation was achieved.  
4.4.1 Synthesis, characterization and solubility 
 
Cis-dichlorido compounds 
In general, the synthesis of the cis-dichlorido diammine Pt(II) compounds, can be 
achieved by direct replacement of chlorides on K2PtCl4, upon addition of two 
equivalents of the amine ligand.
12
 Although this method is appealing, the purity of 
the products was not reproducible and also the yield was low. Previous reports 
also showed that contamination with the “Magnus” green salt, [PtL4][PtCl4], is 
common in these procedures.
18
 Therefore, the method by Dhara
19
 for cisplatin 
synthesis was adopted, as illustrated in Figure 4.9.  
 
 
 
Figure 4.9:.Method for the synthesis of cis-dichloro complexes, as developed by 
Dhara.
19
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Replacement of the chlorides with iodides (i.e. formation of K2PtI4) is necessary 
to ensure the cis geometry of the complex. This is promoted by the high trans 
effect of iodido ligands. In general, square-planar Pt(II) substitution chemistry is 
highly dependent on the trans effect: the effect of a ligand on the rate of 
substitution of the ligand trans to it.
20
 Ligands with a large trans effect can be 
strong σ-donors or π-acceptors, the former characteristic affecting the ground state 
of the molecule and the latter influencing the transition state geometry of the 
ligand substitution intermediate. The order of common ligands with decreasing 
trans effect is the following
21
:  
CN
- 
, C2H4, CO
 
> PR3, H
- 
> CH3
-
, SC(NH2)2 > C6H5
-
, I
-
, SCN
-
> Br
-
 > Cl
-
 > py, 
NH3, OH
-
, H2O 
Upon obtaining the cis-diiodido compound, conversion to the dichlorido Pt(II) 
complex can be easily achieved via the use of AgNO3 and then addition of NaCl 
to the di-aqua intermediate.  
 
Trans-Dichlorido compounds 
The synthesis of the titled compounds is based on the method of Kauffman and 
Thompson,
12
 which involves the use of HCl in an aqueous solution of 
[Pt(L)2(L’)2]
2+
. It was used previously for the synthesis of trans-Pt(II) complexes 
with substituted pyridines or diamines as ligands.
22, 23
 The stronger trans effect of 
Cl
-
 compared to the pyridine ligands ensures the formation of the trans isomer. 
When L and L’ are the same ligand, then it is a two-step process (Figure 4.10 A). 
Ligand substitution in Pt(II) complexes normally goes through an associative 
mechanism,
24
 via a pentacoordinate transition state, as illustrated in Figure 4.10 B. 
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Compounds 21, 24, 27 and 30 which contain the same planar aromatic ligand, 
were reported previously.
13, 14
 The synthesis of 13, [Pt(Cl)2(pyr)(3-pic)], and 14, 
[Pt(Cl)2(pyr)(4-pic)], was more challenging due to the formation of the respective 
trans-[Pt(Cl)2(n-pic)2] as side product. This complication was avoided by the use 
of exactly 2 molar equivalents of the second ligand. If a slight excess is employed 
then the formation of trans-[Pt(Cl)2(n-pic)2] occurs, which due to its similarity to 
the target compound, is difficult to purify by crystallisation (e.g. from 0.1 M HCl).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: (A) Synthetic scheme and reaction mechanism for the synthesis of 
trans-[Pt(Cl)2(L)2], and (B) reaction mechanism for the synthesis of trans-
[Pt(Cl)2(L)(L’)], where L and L’ are nitrogen monodentate ligands.  
 
In the case of complex 12, the side product was trans-[Pt(Cl)2(pyr)2]. Since the 2-
picoline ligand is bulky, it does not enter easily the coordination sphere of the 
platinum, leaving some of the starting material unreacted. In the presence of HCl 
(under heat), it isomerizes from cis to trans
25
 which then is carried as an impurity 
(A) 
(B) 
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through the rest of the steps. Attempts to generate this compound starting from 
cis-[Pt(Cl)2(2-pic)2], 11, and subsequent addition of pyridine were unsuccessful. 
This can be attributed to the steric hindrance created by the 2-picoline ligands, 
making the platinum centre inaccessible to the pyridine. The restricted rotation of 
the 2-picoline ligands is evident from the 
1
H-NMR spectra of cis-[Pt(I)2(2-pic)2] 
10 and cis-[Pt(Cl)2(2-pic)2] 11. In the former, two sets of peaks are featured for 
each proton indicating the inequivalence of the picolines due to the presence of 
rotamers and in the latter the broadness of peaks proves the restricted rotation 
(Figure 4.6). The crystal structure of cis-[Pt(Cl)2(2-pic)2] was reported previously 
by Rochon et al.
13
 
An increase in the amount of the picoline ligand in the reaction mixture (to 4 mol 
equivalents) diminished the side product but the use of these experimental 
conditions was not reproducibly successful. Nevertheless, the evidence suggests 
that the reaction could be successful, if an even greater proportion of picoline 
ligand is used.  
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Trans-Diazido Pt(II) compounds 
 
 
 
 
 
 
 
Replacement of the chlorido ligands with azidos can be achieved by the use of 
AgNO3 to form the diaqua complex and then subsequent addition of NaN3 (Figure 
4.11). Care must be taken during this reaction to use stoichiometric amount of 
AgNO3, as excess amount of Ag
+ 
could lead to the formation of AgN3, which is a 
well-known explosive. Another method that can be employed is the direct 
replacement of the chlorides in a solution of the precursor in DMF with excess 
sodium azide.
26
 This route, although less time efficient, resulted in a superior 
quality product, as the precipitation of the solid was in the form of crystalline 
material. Furthermore, the synthesis of trans-[Pt(N3)2(mim)2] 31, via the first 
route was unsuccessful.  
 
Trans-diazido Pt(IV) compounds 
The hydroxido ligands were added in the axial positions via oxidation of the Pt(II) 
precursor with hydrogen peroxide. Recrystallisation of the Pt(II)-diazido 
precursor in general has a beneficial effect on the oxidation step, as the production 
Figure 4.11: Scheme for the synthesis of trans-[Pt(N3)2(L)(L’)] complexes.  
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of side products is minimized. In the case of trans, trans, trans-
[Pt(N3)2(OH)2(pyr)(3-pic)] 19, isolation and analysis of the side product at the 
oxidation step indicated the production of [Pt(N3)3(OH)(pyr)(3-pic)], which 
demonstrated the importance of the complete removal of excess azide before 
oxidation.  
All the novel Pt(IV)-diazido complexes (including trans, trans, trans-
[Pt(N3)2(OH)2(4-pic)2] 26 and trans, trans, trans-[Pt(N3)2(OH)2(tz)2] 29 which 
have been synthesized before in our group but without any full characterization 
data)
27
 were characterised by 
1
H, 
13
C, 
195
Pt-NMR, ESI-MS and HPLC.  
The 
195
Pt NMR peaks of all the complexes were found to lie in the range of 954-
987 ppm. The only exception was complex trans, trans, trans-
[Pt(N3)2(OH)2(pyr)(2-pic)] 18, with a δPt of 1132 ppm, showing the platinum 
nucleus in this case is greatly deshielded. A systematic study has been carried out 
previously by Marzilli et al.
28
 on the 
195
Pt chemical shift of cis-
[Pt(Xpy)(Me2SO)Cl2], trans-[Pt(Xpy)(Me2SO)Cl2], cis-[Pt(Xpy)2(Me2SO)Cl]+ 
and cis-[Pt(Xpy)(Me2SO)2Cl]
+
, where Xpy is a pyridine related compound. It was 
shown that the chemical shift is influenced not only by the basicity of the ligand 
but also by the ortho substituent. The ortho ligands influence δPt from low 
(shielding) to high (deshielding) chemical shift values as follows: O
- 
> NHR > 
CH3O ~ HOCH2 ~ CH3 ~ C2H5 ~ n-C3H7 > HC(O) > (C6H5)C(O) ~ 3-thienyl > 
C6H5. Therefore it is not surprising that a deshielding effect is observed for 
complex trans, trans, trans-[Pt(N3)2(OH)2(pyr)(2-pic)] 18, although the pKa 
values of all the picoline ligands are similar (5.97, 5.68 and 6.02 for 2-, 3- and 4- 
picoline, respectively).
29
 Furthermore, the theoretical calculations on complex 18 
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predicted that the Pt–N (2-picoline) distance is 2.068 Å and Pt–N(pyridine) is 
2.055 Å, which could suggest that the sterically hindered 2-picoline forms a 
longer σ-bond and therefore the platinum centre has less electron density.  
 
The solubility results (Table 4.5) indicate the effect that the planar aromatic ligand 
has on the lipophilicity of the complex. A striking difference exists between 
complexes 29 and 32 with 1-methylimidazole and thiazole ligands, respectively, 
for which the solubility decreases 91-fold. Good aqueous solubility is a desirable 
attribute for platinum anticancer complexes as they tend to have a longer half life 
in the blood and they are excreted efficiently via the kidneys, avoiding systemic 
toxicity.
30
 For example in the case of cisplatin, with an aqueous solubility of ~ 8 
mM, excretion occurs 50% through kidneys and 50% through the bile which 
might require 2 months before complete excretion.
31
 As shown in Chapter 3, a 
significant proportion of this class of complexes enters the cell through passive 
diffusion. Although measurement of lipophilicity via logP was not carried out, it 
can be assumed that the highly soluble complexes (e.g. 29) will be more 
hydrophilic and hence passive uptake will be hindered. This agrees with a recent 
work by Gao et al in which they showed that blocking active transport of their 
extremely soluble Pt(II) complex (aqueous solubility of 1.5 M), decreases the 
cytotoxicity.
32
  
 
4.4.2 X-Ray crystallography 
The Pt–Nα bond lengths and the Nβ–Nα–Pt bond angle were found to compare 
well with other Pt(IV)-diazido complexes reported previously.
33,34,35
 Complexes 
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23 and 26 have no significant differences in bond distances or angles indicating 
that sterically and electronically are very similar. The Pt–N (aromatic ligand) 
bond length is significantly shorter in complex 32, an effect which might be 
attributed to the higher pKa of 1-methylimidazole (7.06) compared to the picoline 
ligands (5.68-6.02).  
The intermolecular interactions in these complexes are dominated by H-bonding 
(Figure 4.12), frequently between the hydroxyl group and the Nα of the azide (e.g. 
in the case of 20, 26 and 32). The strength of these H-bonds is moderate (refer to 
Chapter 3), the strongest being in the case of 32, for O1’–H1’···N2 (2.066 Å). In 
complex 20 some weak C–H···π interactions (Ct1–H10A, 3.044 Å) also occur. In 
the case of 23, H-bond bridges are formed between methanol molecules and 
neighbouring complexes using the -OHs on each face of the complex (Figure 
4.12) to form an infinite chain along one crystal packing axis.  
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(A) (B) 
(C) (D) 
Figure 4.12: Intermolecular interactions for complexes 20 (A), 23 (B), 26 (C) and 
32 (D). The pink lines denote H-bond interactions, and in the case of 20 the green 
lines illustrate C–H··· π interaction.  
 
Chapter 4: Pt(IV)-diazido complexes with aromatic N-heterocyclic ligands 
 
196 
 
4.4.3 Photoirradiations monitored by UV-Vis  
The complexes were irradiated with blue light (λ= 463 nm) and the decrease in the 
absorbance of the main UV band, which corresponds to the N3→Pt LMCT was 
followed until 78% decrease. This decrease occurs because of the loss of an azide, 
which has been documented before in these systems.
36, 33
 The decay fits an 
exponential function (Figure 4.5) suggesting an irreversible first order 
photoreaction, from which a half-life was obtained and compared for the various 
complexes, given that the irradiation conditions were the same. The complexes 
listed from the highest to the lowest half-lives have the following order (Table 
4.6) : Pt(4-pic)2 ~ Pt(3-pic)2 > Pt(1-mim)2 ~ Pt(pyr)2 ~ Pt(pyr)(4-pic) ~ Pt(pyr)(3-
pic) > Pt(tz)2 > > Pt(pyr)(2-pic).  
In photoreaction kinetics, the rate of the disappearance of a product is 
proportional to the quantum yield and the energy absorbed in unit time by unit 
volume.
37
 This relationship is described by the equation: d[X]/dt = Iabs × ф, where 
Iabs is the absorbed energy and ф, the primary quantum yield. A primary quantum 
yield is defined as the number of molecules undergoing the process of interest per 
number photons absorbed. The energy absorbed depends on the intensity of the 
light and the extinction coefficient of the molecule at that particular wavelength.  
The extinction coefficient of the compounds at 463 nm was found to be very 
similar and lying within a narrow range of 32 to 36 M
-1
cm
-1
. The only exception is 
for compound 18, trans, trans, trans-[Pt(N3)2(OH)2(pyr)(2-pic)], which was found 
to be 64 M
-1
cm
-1
, double than the dipyridine compound trans, trans, trans-
[Pt(N3)2(OH)2(pyr)2] 3 (ε = 32 M
-1
cm
-1
), Figure 4.3. This fact can explain its 
Chapter 4: Pt(IV)-diazido complexes with aromatic N-heterocyclic ligands 
 
197 
 
increased rate of photodecomposition when irradiated with blue light (half-life of 
9.1 min versus 21.6 min). Although the trans, trans, trans-[Pt(N3)2(OH)2(pyr)(3-
pic)] and trans, trans, trans-[Pt(N3)2(OH)2(pyr)(4-pic)] complexes have a half-life 
of 20 min, for the bis-picoline complexes (e.g. [Pt(N3)2(OH)2(3-pic)2], the half life 
increases to ~25 min. This increase cannot be accounted by a significant decrease 
in the extinction coefficient, suggesting that it might lie in the different quantum 
yields for these compounds. The same observation applies to comparison of the 
two complexes with 5-membered planar aromatic ligands (i.e. thiazole and 1-
methylimidazole), trans, trans, trans-[Pt(N3)2(OH)2(tz)2] 29 and trans, trans, 
trans-[Pt(N3)2(OH)2(mim)2] 32, with half lives of 21.7 and 16.7 min, respectively.  
Interestingly, DFT and TDDFT calculations performed on complex 18, showed 
the presence of transitions at 419 nm and 417 nm with oscillator strengths of 
0.004 and 0.0003, respectively (Table 4.8). Calculations on trans, trans, trans-
[Pt(pyr)2(OH)2(N3)2] resulted in transitions at lower wavelengths (414 nm, 404 
nm) with smaller oscillator strengths (0.0027 and 0.0001).
11
 As with most of 
trans-Pt(IV)-diazido complexes, the transitions are highly dissociative and 
occupation of the LUMO (Table 4.8 and Figure 4.8) would lead to dissociation of 
the azide and/or the hydroxide ligands. The facile chemical reduction of a Pt(IV) 
complex incorporating a 2-picoline ligand was noted by Hambley et al who 
showed that the reduction potential increases by 56 mV by replacing pyridine with 
2-picoline in the complex cis, trans, cis-[PtCl2(OH)2(NH3)(X)], where X is 2-
picoline or pyridine. This was attributed to the steric clash between the N-ligand 
and the platinum which destabilizes the Pt–O bond facilitating reduction to 
Pt(II).
38
 This destabilization proves to be beneficial for the photochemical 
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reduction of Pt(IV)-diazido complexes suggesting that steric hindrance is more 
important for photolability rather than the electronic effects caused through 
inductive effects of the methyl group.  
It is worth mentioning that a theoretical study on Pt(IV)-diazido complexes 
showed that electron-donating substituents on the pyridine can have an effect on 
the absorption properties of Pt(IV)-diazido complexes by increasing the 
contribution of the frontier orbitals that are closer to the HOMO and LUMO.
39
 
The present work has shown that the position of the substituent may play a more 
crucial role.  
4.5 Conclusions 
In this Chapter, the first family of Pt(IV)-diazido complexes, with the general 
formula of trans, trans, trans-[Pt(N3)2(OH)2(L1)(L2)], where L1 and L2 are N-
heterocyclic ligands (pyridine, picolines, thiazole, 1-methylimidazole) has been 
constructed. The synthesis, characterisation (
1
H, 
13
C, 
195
Pt-NMR, ESI-MS) and X-
ray crystal structures (in four cases) of seven novel complexes are described and 
discussed.  
The planar ligands have an effect on the solubility, with thiazole and 1-
methylimidazole producing the least and most water soluble complexes, 
respectively (0.9 mM and 84 mM). Also the use of picoline instead of pyridine 
ligands diminished the solubility by 5-fold.  
Studying the photosensitivity of the compounds showed that incorporation of a 
sterically demanding 2-pic ligand as in the case for trans, trans, trans-
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[Pt(N3)2(OH)2(2-pic)(pyr)] can greatly enhance the photoactivity of the complex, 
as the half-life decreases to 9 minutes on irradiation with 463 nm, whereas the 
other complexes had half-lives in the range of 20-25 min. DFT-TTDFT 
calculations on complex trans, trans, trans-[Pt(N3)2(OH)2(pyr)(2-pic)] 18, showed 
that indeed this complex has higher intensity transitions at longer wavelength 
which are in agreement with its enhanced photoactivity. In the next chapter, 
phototoxicity data of these complexes will be presented.  
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5.1 Introduction  
Irradiation of Pt(IV)-diazido, dihydroxo complexes in the presence of nucleotides 
has shown to form monofunctional as well as bifunctional Pt(II) adducts, 
following the loss of one or both azides.
1
 Furthermore, CT-DNA binding studies 
have indicated that these complexes bind irreversibly to DNA. The rate at which 
this occurs depends greatly on the presence or absence of the pyridine ligand (for 
example the trans, trans, trans-[Pt(N3)2(OH)2(NH3)2] binding faster than the 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(pyridine)] complex) and the extent of the 
binding is dependent upon the irradiation conditions: the presence of the DNA in 
situ (as opposed to mixing the irradiated complex with DNA) and the absence of 
competing nucleophiles, (e.g. chloride and GSH) enhance the binding yield.
2, 3
 
Characterization of DNA adducts by plasmid transcription studies using trans, 
trans, trans-[Pt(N3)2(OH)2(NH3)(pyr)] showed that the preferred binding sites are 
mainly guanines and cytosines and less frequently adenines (similarly to 
transplatin).
3
  Studies with ethidium bromide, thiourea and gel electrophoresis 
illustrated that the Pt(IV)-azido complexes can potentially form monofunctional 
adducts which rapidly close to form bifunctional adducts. Only 6% of these 
adducts are interstrand, suggesting a potential majority of 1,3-intrastrand lesions.
3
 
Similar studies with trans,trans,trans-[Pt(N3)2(OH)2(pyr)2] resulted in an 
analogous outcome in which monofunctional and intrastrand crosslinks are the 
major DNA adducts (51% and 37%, respectively) upon irradiation with either 
UVA or visible light.
4
 These lesions are able to stall RNA polymeraseII thus 
inhibiting RNA synthesis.
4
 DNA isolated from treated cells with aforementioned 
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complex (trans,trans,trans-[Pt(N3)2(OH)2(pyr)2]) provide direct evidence that it 
enters cells and binds to nuclear DNA after photoactivation.
4
  
In order to determine whether the mechanism of cell death involves an apoptotic 
pathway, the caspase activity as well as the phosphatidylserine (PS) redistribution 
(both hallmarks of apoptosis) have been studied in cells treated with trans, trans, 
trans-[Pt(N3)2(OH)2(pyridine)(NH3)].
5
 Neither activation of caspase 3 or 7 nor the 
significant translocation of PS from the inner to the outer leaflet of the plasma 
membrane were observed. In contrast, cisplatin gave positive results in these 
tests.
3, 5
 Staining of nuclei of A2780 cells treated with trans, trans, trans-
[Pt(N3)2(OH)2(pyr)2] with Hoechst dye showed that the nuclei did not fragment or 
condense, as opposed to the cisplatin-treated cells. Chromatin condensation and 
fragmentation is generally associated with a cell undergoing apoptosis.
6
 Overall 
these results indicated a non-apoptotic mechanism of cell death, which is distinct 
from cisplatin. Furthermore, morphological studies carried out on cells treated 
with cis, cis, trans-[Pt(N3)2(NH3)2(OH)2] showed rounding of the cells, cellular 
shrinkage and loss of contact with neighbouring cells had occurred. In addition an 
excessive nuclear packing but no budding or formation of apoptotic bodies, 
expected for apoptosis, was seen.
7
 
In the search for a possible mechanism of cell death, autophagy became a 
reasonable possibility due to the expected alteration of key autophagic proteins 
(e.g. LC3, p62) when HL60 cells were irradiated in the presence of trans, trans, 
trans-[Pt(NH3)(pyr)(N3)2(OH)2]. However this  still needs to be confirmed.
5
 
The work described in this chapter assesses the binding of the photoactivatable 
complexes, described in Chapter 4, to the nucleotide 5’-GMP; since the 
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preferential binding of platinum complexes to guanines is well established. Of 
specific interest is the complex trans, trans, trans-[Pt(N3)2(OH)2(2-pic)(pyr)] as it 
is sterically hindered, showing fast photodegradation kinetics (refer to Chapter 4).  
Furthermore, the phototoxicity of the complexes in different cell lines A2780, 
A2780cis (ovarian cancer cell line) and OE19 (oesophageal cancer cell line) will 
be presented and discussed. The incidence of oesophageal cancer is increasing in 
the UK. Currently it is the ninth most common cancer and it is one of the most 
difficult cancers to treat.
8, 9
 Therefore novel anticancer drugs which can tackle this 
serious problem are required. Moreover, both organs, the ovaries and the 
oesophagus, are accessible for PDT treatment.
10, 11
  
The mechanism of cell death and the cellular targets of the Pt(IV)-diazido 
complexes have only recently been studied and further research is required for a 
better understanding. Herein, methods which have been employed for the first 
time in the study of photoactivatable Pt(IV)-diazido complexes will be presented 
and discussed.  
5.2 Materials  
Yeast strains for the S. pomble cell survival experiments were provided by Dr 
Jacob Dalgaard, University of Warwick (Life Sciences). The optical densities of 
the yeast cultures were determined on a NanoDrop 2000 spectrophotometer 
(Thermo Scientific). The microscopy slides for the confocal microscopy were 
sterile 15 μ-slide 8 well, purchased from Ibidi (Thistle Scientific). The fluorescent 
dyes (LIVE/DEAD Cell-mediated cytotoxicity kit (L7010) and the MitoTracker 
(Mitochondrion-Selective Probes)) were bought from Molecular Probes and 
Invitrogen, respectively.  
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5.3 Methods 
5.3.1 5’-GMP binding studies 
5’-GMP binding studies were carried out by irradiating the complexes (2 mM, 
except in case of 29, trans, trans, trans-[Pt(N3)2(OH)2(tz)2] where 1 mM was 
used) in the presence of 5’-GMP (2 mol eq) with 420 nm light source 
(photoreactor, 1 h, 14 mW/cm
2
) and recording 
1
H-NMR spectra immediately after 
the irradiation on a 500 MHz NMR spectrometer. The binding was quantified by 
integrating the peaks of the C1H’ bound protons for bound GMP (numbering 
scheme for 5’-GMP can be seen in the Appendix). Extensive irradiation studies 
for complex 18 (trans, trans, trans-[Pt(N3)2(OH)2(pyr)(2-pic)] were carried out (9 
mM, PBS/ D2O) in the presence of 2 mol eq of 5’-GMP at 420 nm light (7 
mW/cm
2
, 45 minutes). The 
1
H-NMR spectra were recorded on a 600 MHz NMR 
spectrometer. The LC-MS analysis was undertaken on the HTC-Ultra mass 
spectrometer (Bruker) by diluting 50-fold the NMR samples in H2O. An aliquot of 
20 μL was injected into a ZORBAX Eclipse Plus C18 (4.6×150 mm, 5-Micron) 
column and eluted with H2O (A)/ MeOH (B), both containing 0.1% formic acid. 
The gradient used was the following: 0 min- 7% B, 5 min-7% B, 25 min-70% B, 
29 min- 70% B, 29.01-7%  B, 30 min-7% B. The detection wavelength was 254 
nm.  
5.3.2 Phototoxicity testing  
The phototoxicity testing was carried out in collaboration with Dr Julie Woods, 
University of Dundee, as outlined in Chapter 2.  
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5.3.3 Light dose dependence on cell survival (Action spectra) 
Cells (A2780, OE19, HT1197) were seeded at a density of 1×10
6
 in Petri dishes 
(diameter 53.5 mm) 24 hours before treatment, in order to adhere to the plate. The 
medium was removed and the cells were washed with PBS (2 × 5 mL) prior to the 
addition of the drug (15 μM, 5 mL). The cells were incubated with the drug for 1 
hour at 37 
o
C, 5% CO2 atmosphere in the dark. Following this step, removal of the 
cells from the plate surface was carried out by gentle scraping and then broken 
apart by pipetting and release. Irradiations at 430 nm or 515 nm were carried in 
sterilized quartz cuvettes (2.5 mL) equipped with a magnetic stirrer. For each dose 
of irradiation 3 aliquots (3×30 μL) of the irradiated or sham irradiated sample 
were taken and placed in a 96-well plate containing pre-warmed media at 37 
o
C. 
The monochromator used (Figure 5.1) was a Bentham 450 W Xenon Light 
Sources (IL 450 Xe), the output of which was measured before any experiment. 
The slit widths were set to 9 mm. Depending on the wavelength, the appropriate 
filter type was used: for 430 nm and 515 nm, GG375 and GG475, respectively. 
The cells were allowed to recover for 72 hours (in the case of A2780 and OE19) 
or 96 hours (for HT1197). Then cell viability was determined using the MTT 
assay as outlined in Chapter 2.  
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5.3.4 Yeast studies 
Colonies from two strains of Schizosaccharomyces pombe (h
90
leu 1-32, ade 6-
210, ura4-Δ18 and h90, ade 6-210, ura4-Δ18, Δrad3:: ura4)  were collected and 
allowed to grow overnight in ~ 5 mL of complete yeast extract medium 
supplemented with adenine (YEA, 5 g/L yeast extract, 30 g/L dextrose, 0.075 g/L 
adenine) at 33 
o
C with shaking. Then, they were inoculated in 5 mL of pre-
warmed medium at an OD600 nm of ~0.5 and were allowed to grow for a further 2 
hours. The cells were then spun down for the removal of the medium, 
resuspended in PBS and kept on ice during the experiment to prohibit further 
growth. A stock solution with an OD600 nm 0.02 was prepared and used to plate the 
cells in a 96-well plate with ODs of 0.01, 0.005, 0.0025 and 0.00125 (OD600 nm 
0.01 corresponds to ~100000 cells). Complex 3 (trans, trans, trans-
[Pt(N3)2(OH)2(pyr)2]) was then added at different concentrations (300, 200, 100 
and 0 μM) and the plate was placed on the shaker for 5 minutes. The drug was 
Figure 5.1: The monochromator (Bentham 450 W) employed for the action 
spectra, which is normally used for PDT on patients at the Photobiology Unit of 
Ninewells Hospital (Dundee, UK).  
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allowed to be taken up for 1 hour on ice in the dark and then the cells were 
irradiated with 420 nm light (45 min, 12 mW/cm
2
), using the photoreactor. 
Following this step, the plate was placed on a plate centrifuge (10 minutes, 5000 
g). The supernatant was removed and the cells resuspended in YEA media (100 
μL). The contents of each well were spread on YEA agar plates and were allowed 
to grow for 3 days at 33 
o
C. The survival was estimated by colony counting which 
was plotted against the non-treated controls. A modified protocol was also 
applied, where the number of cells plated was equivalent to OD600 nm= 0.1 in 2 
mL. Following irradiation under the same experimental conditions as described 
above, the cells were counted using a cellometer (Nexcelom Biosceince) and 
diluted to a concentration of 4000 cells/mL before spreading onto the YEA agar 
plates.  
5.3.5 Confocal Microscopy 
A2780 cells were seeded on a microscopy chamber (Figure 5.2) at densities of 
2×10
5
 and 1×10
5 
and were allowed to adhere for 24 or 48 hours, for the contrast 
and confocal microscopy experiments, respectively. The walls of the empty 
middle wells of the microscopy chamber were blacked out using a black 
permanent marker pen to avoid leakage of light to the control wells.  
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Figure 5.2: The chamber used for the live-cell confocal microscopy experiment, 
showing the setup of each well. The thick middle line represents the blackened out 
walls.  
After the adhesion period, cells were washed with PBS (300 μL) prior to addition 
of the drug in PBS (50 μM) and mitotracker (213 nM) and incubated in the dark 
for 1 hour. Cells were irradiated for 5 min (64 mW/cm
2
, 17 J/cm
2
) resulting in a 
comparable dosage, according to number of cells and irradiation time used for the 
phototoxicity studies of complex 3 reported previously
6
 (5 J/cm
2 
for 6 × 10
4
 cells/ 
cm
2
). Following irradiation, media was replaced with fresh RPMI-1640 (300 μL) 
and propidium iodide (10 μL of 7.5 μM stock solution) was added. Cells were 
then incubated for 5 minutes at 37 
o
C and viewed using a SP5 Leica confocal 
microscope equipped with a temperature control chamber set to 37 
o
C. Focusing 
of the cells was carried out by visualizing the mitotracker using a 633 nm laser, 
therefore prohibiting exposure to white light, which can photoactivate the 
complex. Cells were imaged using a 594 nm (HeNe) laser during 12-15 hours 
using a 40 X oil immersed objective. The first image was captured ca 30 minutes 
after the photoactivation of the cells. Images were taken every 15 minutes.  
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5.4 Results  
5.4.1 5’-GMP binding studies 
Irradiation of the trans-diazido diamine complexes (2 mM) (Figure 5.3) at 420 nm 
(1 hour, 24.7 mW/cm
2
, 88920 mJ/cm
2) in the presence of 5’-GMP (2 mol 
equivalents) in PBS/ D2O (pH* 7.4) resulted in binding of all the complexes to 
form two adducts which can be assigned by analogy with previous studies to the 
mono and bis GMP adducts.
6
 The extent of binding of individual complexes to 5’-
GMP is depicted in Table 5.1. Release of the N-heterocyclic ligand was not 
observed in any of the cases.  
 
Figure 5.3: Structures of complexes studied in this chapter.  
 
In order to examine the photoproducts of the sterically hindered trans, trans, 
trans-[Pt(N3)2(OH)2(pyr)(2-pic)] (18), the irradiation was carried out using the 
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same concentration and irradiation conditions as published previously for trans, 
trans, trans-[Pt(N3)2(OH)2(pyr)2] (9 mM, 420 nm, 7 mW/cm
2
).
6
 Upon irradiation, 
the solution turned cloudy and the appearance of bubbles was observed. 
Precipitation was not observed when the irradiations are carried out at lower 
concentrations (e.g. 2 mM).  
Table 5.1: 5’-GMP binding of Pt(IV)-diazido complexes upon blue light 
irradiation (420 nm, 1 hour, 14 mW/cm
2
). The error is approximated to 5-10% due 
to errors in integration of NMR peaks.  
 
Complex %Binding 
18 52 
19 58 
20 64 
23 68 
26 64 
29
* 80 
32 48 
 
Irradiation of complex 18 (9 mM) in PBS with a low dose of 420 nm resulted in 
the formation of only one major 5’-GMP photoproduct as illustrated by the 1H-
NMR (Figure 5.4 B). 
195
Pt: 129 MHz NMR spectrum showing the Pt(IV) region 
proved the almost complete disappearance of the Pt(IV) peak suggesting a nearly 
complete reduction to Pt(II) had occurred (Figure 5.5 A). In the Pt(II) region the 
formation of a major and minor products, (X) and (Z) respectively, is shown 
(Figure 5.5 B). The major peak (X) can be assigned to the mono-GMP adduct, 
trans-[Pt(N3)(2-pic)(pyr)(5’-GMP)], as confirmed by the LC-MS studies (Figure 
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5.6). Over time (2 weeks in the dark) it was shown that a second 5’-GMP product 
is formed and its appearance was evident as early as 3 days after the irradiation 
(Figure 5.4 C and Figure 5.6 B). The LC-MS chromatogram indicated that this 
photoproduct is the bis-5’-GMP adduct (Y). It can be deduced that the minor 
Pt(II) product, Z shown in the 
195
Pt-NMR spectrum, had formed immediately after 
irradiation and is slowly being converted into the bis-GMP adduct. This species 
can be tentatively assigned to the species [Pt(2-pic)(pyr)(OH)(5’-GMP)]+ 
(theoretical M
+
= 747.1 m/z)
 
as in the LC-MS chromatogram, there is a minor peak 
with the corresponding mass spectrum containing a peak with m/z= 747.0.  
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Figure 5.4: 600 MHz 
1
H-NMR of complex 18 (9 mM) in the presence of 5’-GMP 
(2 mol eq) in PBS/ D2O (pH* 7.4) of: (A) In the dark. (B) Immediately after 
irradiation (420 nm, 45 min, 7 mW/cm
2
). The formation of the mono-GMP adduct 
is shown, with the assignment of the peaks corresponding to the pyridine ligands 
on the platinum. The assignment was aided by 2D 
1
H correlation spectroscopy 
(COSY). The circle and the triangle represent free and bound 5’-GMP, 
respectively. (C) Two weeks after the irradiation, where the evolution of a second 
5’-GMP adduct is observed, as shown by the arrows. The spectrum on the right 
hand side is zoomed in, on the C1 proton of the sugar ring to illustrate the 
evolution of the second product 3 days after irradiation.  
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Figure 5.5: 
195
Pt-NMR spectra of the Pt(IV) and Pt(II) regions after irradiation 
(420 nm, 45 min, 7 mW/cm
2
) of complex 18 (9 mM) in the presence of 5’-GMP . 
Spectra A and B were obtained immediately after irradiation whereas spectrum C 
was recorded 2 weeks after the sample was allowed to stand in the dark at ambient 
temperature. Products X and Y have been assigned to the mono-GMP and bis-
GMP adducts, respectively whereas product Z was tentatively assigned to trans-
[Pt(2-pic)(pyr)(OH)(5’-GMP).  
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Figure 5.6: LC-MS of the irradiated sample of complex 18 a day after irradiation 
(black) and two weeks (red). Product X (major) corresponds to [Pt(N3)(2-
pic)(pyr)(5’-GMP)]+ (theoretical M= 772.1 m/z, [M-H2PO3
-
+H
+
]= 692.2 m/z). 
Product Y evolves over time and is assigned as [Pt(5’-GMP)(2-
pic)(pyr)]
2+
(theoretical [M]
2+
= 546.6 m/z, [M-H+Na]
2+
= 557.6 m/z, [M-
H+K]
2+
=565.6 m/z).   
 
5.4.2 Phototoxicity studies  
The phototoxicity studies were performed on ovarian cell lines (A2780 and 
A2780 cisplatin resistant cells A2780cis) and oesophageal cancer cells (OE19). 
The results are depicted in Table 5.2. Activity in cisplatin resistant cell lines is 
usually indicative of a cell death mechanism distinct of that from cisplatin which 
is a favourable feature for potential anticancer therapeutics.  
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Table 5.2: Phototoxicity of the complexes reported in Chapter 4, with the general 
structure of trans, trans, trans-[Pt(N3)2(OH)2(L1)(L2)] where L1 and L2 are defined 
in Figure 5.3. Irradiation of the complexes was carried out with 420 nm (5 J/cm
2
, 
TL03), filtered below 400 nm. 
*PI= phototoxic index, 
** 
ND= not determined, ***FM165= trans, trans, trans-
[Pt(N3)2(OH)2(NH3)(pyr)]
 
 
Complex 
A2780 A2780cis OE19 
IC50 95% CI 
*
PI IC50 95% CI PI IC50 95% CI PI 
18 14.5 12.7-16.7 7.3 15.5 11.2-21.5 5.3 ND ND ND 
19 4.0 3.0-5.4 >51.5 3.3 1.9-5.9 >71.0 5.5 3.2-9.4 >38 
20 5.4 4.3-6.8 >38 4.6 3.8-5.6 >45 12.3 7.9-19.1 >17 
23 7.2 6.0-8.7 >27.8 10.4 8.7-12.2 >19.3 ND ND ND 
26 2.1 1.6-2.7 >95 4.1 3.3-5.1 >48.8 8.2 5.5-12.0 >24 
29 2.4 2.2-2.7 48 2.9 1.6-5.2 >71.0 7.6 5.4-10.7 >27 
32 56.3 40.2-78.9 >3.7 164.2 wide >1.3 ND ND ND 
FM165
*** 25.4 22.2-29.1 >9.6 
**
ND ND ND ND ND ND 
3 6.7 3.6-13.7 >45 ND ND ND 8.4 ND >45 
 
Photofrin (a known PDT agent) has an IC50 of 46.8 ng/mL. This is in the 
nanomolar range but photofrin is a mixture of oligomers, so an IC50 in molar units 
cannot be accurately provided. Nevertheless, it is significantly more active than 
the current Pt(IV)-diazido complexes. 
The dose-response of the activity of complex 20 ([Pt(N3)2(OH)2(pyr)(4-pic)]) 
upon irradiation at 430 nm and 515 nm in A2780 and OE19 cells was also 
assessed (Figure 5.7). The complex showed no phototoxicity on activation at 515 
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nm in either A2780 or OE19 cells. Upon use of 430 nm irradiation, there was 8% 
and 57% survival with a dose of 100 J/cm
2
 in A2780 and OE19 cells, respectively.  
 
Figure 5.7: Survival of A2780 (A and B) and OE19 (C and D) cells treated with 
complex 20, upon irradiation with different doses (in J/cm
2
) of 430 nm and 515 
nm light. Sham cells were not exposed to any light.  
 
5.4.3 Cell survival in Schizosaccharomyces pombe in response to Pt(IV)-
diazido drug 
Two strains of S. pombe were used, a wild-type strain and a Δrad3 (i.e. deletion of 
the Rad3 kinase which is responsible for DNA repair) to study the effects of the 
complex trans, trans, trans-[Pt(N3)2(pyr)2(OH)2], 3.  
When the experiment was carried out under conditions of a low drug 
concentration (2 μM and 0.04 μM), no apparent difference between the two strains 
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was observed and when 400 μM drug concentrations was used there was no 
colony growth for either WT or ΔRad3 cells. However with Pt concentrations of 
300 and 200 μM, the difference between the two strains became obvious. No 
difference in cell survival was observed for the non-treated cells, indicating that 
the light alone did not cause any cell death (Figure 5.8 and Figure 5.9).  
 
Figure 5.8: Images of colony growth of S. pombe cells. The arrow shows the 
decreasing amount of cells in each plate (OD 0.01, 0.005, 0.0025, 0.00125). (A) 
300 μM of complex 3 (B) 200 μM (C) 100 μM and (D) 0 μM. The cells were 
irradiated with 420 nm (45 min, 12 mW/cm
2
, 45 min). The top row of dishes in 
each of the images consists of WT cells whereas the bottom the Δrad3 mutant. 
The image shows the difference in survival between the two strains.  
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Figure 5.9: Effect of complex 3 concentration on the % survival of S. pombe cells 
as measured by colony counting between the two strains. The data were plotted 
with the initial concentration of seeded cells as an OD = 0.005. The error bars 
were produced from two experimental repeats.  
 
5.4.4 Live-cell confocal microscopy 
 
The aim of this experiment was to establish a protocol to allow changes in cells 
after the photoactivation of a Pt(IV)-diazido drug such as trans, trans, trans-
[Pt(N3)2(OH)2(pyr)2] to be monitored. The concentration chosen was low enough 
to avoid any dark toxicity (20 μM) although it was unknown whether the 
prolonged exposure to the confocal microscope’s laser would cause any complex 
activation and subsequent cell death. Finding the appropriate focus was achieved 
using the purple dye, mitotracker (λex= 644 nm), a specific dye which targets 
mitochondria only, to avoid exposure to white light. However some non-specific 
binding was observed and the cytoplasm was also partially stained (Figure 5.10). 
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Cell death was assessed by following the uptake of propidium iodide (red dye) 
which binds to nucleic acids only when the integrity of the cell membrane is 
compromised. Activation of the drug using LED light source (463 nm, 5 min) 
allowed phototoxicity to be obtained for treated cells without unwanted death of 
control cells (Figure 5.11). The first indication of cell staining with propidium 
iodide occured as early as 1 h 45 min after the activation, suggesting that the 
membranes may have been compromised very early on. This represents the first 
example of live imaging of cell death caused by a Pt(IV)-diazido complex.  
Morphological changes of the treated cells with phase contrast images captured 16 
hours after activation showed rounding of the cells, loss of contact with the 
neighbouring cells as well as detachment from the surface of the chamber. No 
such changes were observed when the cells were treated with the complex alone 
without irradiation or for untreated irradiated controls (Figure 5.12).  
Figure 5.10: Confocal microscopy images of A2780 cells treated with complex 3 
and irradiated with blue light (463 nm) at t= 0 (A), 2 h 30min (B) and 5h 30 
min(C) post-irradiation. The blue and the red fluorescent dyes are a result of the 
mitotracker and propidium iodide, respectively. The colour of the mitotracker was 
changed from purple to blue using ImageJ in order for clarity.  
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Figure 5.11: Confocal microscopy images obtained at t=0, 2 h 30 min and 5 h 30 
min during the live cell experiment of A2780 cells treated with complex 3 and 
irradiated with blue light (463 nm) (t=0 corresponds to ca 30 min after the 
photoactivation of the cells). A, B and C represent the different conditions, under 
which the cells were exposed. The red staining (Propidium Iodide) illustrates the 
nuclei of the dead cells. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12: Phase-contrast images of A2780 cells after exposure to complex 3 
(trans, trans, trans-[Pt(N3)2(OH)2(pyr)2] for 1 hour in the dark (left) or irradiated 
with 463 nm light (right). The images were obtained 16 hours after the exposure 
to the drug alone (left) or the drug plus light (right). 
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5.5 Discussion 
5.5.1 5’-GMP binding studies 
Irradiation of the trans-Pt(IV)-diazido complexes reported in the previous chapter 
was shown to lead to formation of 5’-GMP adducts with an average extent of 59% 
conversion with respect to the platinum complex. Similar reactions for complexes 
with (pyr)(3-pic), (3-pic)2 and (4-pic)2 as the N-heterocyclic ligands resulted in 
almost identical binding yields, between 64-68%. A lower extent of binding was 
observed for the (1-methylimidazole)2 complex, 48% (Table 5.1). Although no 
excessive photoproduct analysis was undertaken for all these complexes, it can be 
reasonably assumed that the photoproducts are the mono [Pt(N3)(GMP)(n-
heterocycle)2]
+
 and bis [Pt(GMP)2(n-heterocycle)2]
2+
adducts.  
Complex 18, Pt
IV
(2-pic)(pyr), irradiated at 420 nm as a 9 mM solution in PBS 
(D2O) was studied more extensively with 
1
H, 
195
Pt- NMR and LC-MS. The mono-
GMP adduct is the only adduct formed first and the bis-GMP is generated when 
the irradiated sample is allowed to stand over time in the dark at room temperature 
(Figure 5.4 and Figure 5.6). The methyl group creates steric constraint on the 
platinum centre which can reduce the substitution kinetics of the Pt(II) 
photoproduct. In fact, the restricted rotation about the Pt
II
-2-picoline bond of the 
[Pt(N3)(2-pic)(pyr)(5’-GMP)] product is evident from the broadening of the 6 and 
5 protons (Figure 5.4 B). The analogous protons exhibited most of the broadening 
observed for cis-[Pt(2-pic)2Cl2] (Chapter 4, Figure 4.6).  
The evolution of various DNA adducts over time is commonly observed amongst 
platinum compounds. For example transplatin shows a few interstrand crosslinks 
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in cells and this was accounted by the slow conversion of the monofunctional to 
bifunctional adducts.
12
 
In studies performed with the trans, trans, trans-[Pt(N3)2(OH)2(pyr)2], re-
oxidation of the Pt(II) product was observed over time,
6
 a result which was not 
obtained in this work for complex 18. This difference could be attributed to the 
fact that in this work PBS (0.01 M phosphate, 0.0027 M KCl, 0.137 M NaCl) was 
employed instead of D2O only. 
5.5.2 Phototoxicity and structure-activity relationships 
The N-heterocyclic ligand appears to play an important role in the biological 
properties of the trans, trans, trans-Pt(IV)-diazido-dihydroxo complexes. 
Comparing the compounds with pyridine as one ligand and n-picoline as the 
second ammine ligand, it is evident that the complex 18 containing 2-picoline is 
the least phototoxic (λ= 420 nm, IC50= 14.5 μM). Along with the findings from 
the [Pt(N3)2(OH)2(NH3)(n-picoline)] family of compounds, which were 
photoactivated with UVA light, it is confirmed that steric hindrance close to the 
platinum centre does not favour phototoxicity.
13
 A possible explanation for this 
could be the slow formation of bifunctional adducts, as in the case of picoplatin. It 
was shown that picoplatin forms interstrand DNA crosslinks and binds plasma 
proteins more slowly than cisplatin.
14
 The phototoxicity and dark toxicity IC50 
values are tabulated in Table 5.2. The difference in IC50 values between the 
Pt
IV
(pyridine)(3-picoline) (19) and Pt
IV
(pyridine)(4-picoline) (20) complexes is 
minimal (4.0 vs 5.4 μM in A2780) however in OE19 cells the PtIV(pyr)(3-pic) 
complex is 2-fold more active (5.5 μM vs 12.3 μM). In the PtIV(n-picoline)2 
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family of complexes, there is almost a 2-fold decrease in cytotoxicity between the 
Pt
IV
(3-picoline)2 (23) and Pt
IV
(4-picoline)2 (26) complexes. Variations in 
cytotoxicity between picoline analogues is not unusual, as it has been reported 
that in complexes trans-[Pt
II
X2(3-pic)2] and trans-[Pt
II
X2(4-pic)2], where X is Cl
-
 
or OAc
-
, the 4-picoline complexes were more cytotoxic in Pam 212 and Pam 212-
ras cell lines (murine keratinocytes).
15
 Furthermore, it was shown by Rakic et al. 
that changing the position of substituent on the pyridine has a significant effect on 
the cytotoxic properties of the complexes, as studying the cytotoxicity of trans-
[PtCl2(3-acetylpyridine)2] and trans-[PtCl2(4-acetylpyridine)2] in a range of cell 
lines showed that the para-subsitituted complex was more cytotoxic.
16
 The results 
in the present work show that for the bis-picoline complexes, a para substitution 
enhances the cytotoxicity but in the (pyridine)(n-picoline) complexes the meta 
substitution is slightly favoured. None of the complexes in this series was found to 
be dark-toxic with the exception of the Pt
IV
(pyridine)(2-picoline) complex, with a 
PI of 7.3 (i.e. IC50 ~ 106 μM in the dark).  
The trans-Pt
IV
(thiazole)2 (complex 29) is a very potent compound (2.4 μM in 
A2780), constituting another example of a compound with bis-aromatic ligands 
more phototoxic than having only one aromatic amine, as the IC50 of the complex 
trans, trans, trans-[Pt(N3)2(OH)2(NH2CH3)(thiazole)] was 28.2 μM.
17
 However 
this complex exhibited some dark toxicity in the A2780, although it was the most 
toxic compound in the A2780cis cell line. The least phototoxic compound from 
the family was that bearing 1-methylimidazole ligands (complex 32). This lack of 
activity might be attributable to its high hydrophilicity, as shown by the high 
aqueous solubility, leading to low cellular uptake.  
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In order to test cell viability with different doses of light at 430 nm, and 515 nm, 
action spectra were recorded for the A2780 and OE19 cell lines (Figure 5.7). They 
were also attempted with the HT1197 bladder cell line but these cells were highly 
sensitive to the blue light as well as the conditions under which the experiment 
was conducted (e.g. stirring, scraping, pipetting to form a single cell suspension). 
The light sensitivity of these cells can be attributed to the high intracellular 
porphyrin content (twice as high as OE19) causing phototoxicity.
18
 It is also 
evident from the action spectra as well as the phototoxicity values for A2780 and 
OE19 cells that there is a resistance factor in the oesophageal cancer cell line. This 
effect might involve antioxidant defence, drug uptake, drug efflux, drug 
localisation or DNA repair, for example.  
5.5.3 Cell survival assessed in S. pombe  
During the cell cycle of eukaryotes, accurate DNA replication is crucial for 
genomic stability and thus the survival of the organism. DNA lesions can be 
caused endogenously, for example by base-pair mismatch or strand breaks 
occurring during replication, and exogenously by UV exposure, DNA damaging 
agents (e.g. hydroxyurea, methyl methanesulfonate) making cells non-viable or 
susceptible to mutation.
19, 20
 For these reasons, eukaryotic cells have developed 
sophisticated mechanisms to control responses to DNA damage which happen at 
checkpoints at different times of the cell cycle.
11, 21
 When damage is detected, the 
appropriate signalling is triggered to delay the cell mitosis and for DNA repair to 
take place. Checkpoint sensor proteins are responsible for detecting the DNA 
damage and then activating the mediator proteins, which in turn promote protein-
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protein interactions between sensors and effectors, thus mediating signal 
transduction to the effectors. Once these become activated, most of the biological 
effects take place in the cell which can lead to procession to the next stage of the 
cell cycle, to DNA repair, remodelling or to cell death.
19
 Most of the proteins 
involved in the repair pathways have been identified in budding and fission yeast 
and loss of function in these (by mutation) can result in significant cell death in 
the presence of a damaging agent.
22
 In Schizosaccharomyces pombe there are two 
known checkpoint pathways: the first one is controlled by the effector Cds1 
(acting in the S-phase) and the second by the Chk1 (acting in the G2 phase and in 
the G2 phase in the absence of Chk1). Both of these are activated (by 
phosphorylation) by the upstream sensor protein Rad3
23
 that detects replication 
blocks as well as DNA damage (e.g. double strand breaks) (Figure 5.13).
24
 The 
orthlogous protein in mammals is the ATR kinase.  Disruption or mutation of 
Rad3 can lead to serious inhibition of the DNA checkpoint signalling. Due to the 
functional overlap of the two signalling pathways (Cds1 and Chk1), deletion of 
either one of them does not lead to a striking effect in the replication pathway but 
a Rad3 deletion has a profound effect in cell survival, when exposed to a DNA 
damaging agent.
25, 26
  
Yeast is a widely used model to study the effects of drugs due to the fact that it is 
a eukaryotic organism with many of the cellular processes conserved in 
mammals.
27
 S. cerevisiae has been used previously to study cisplatin toxicity, 
drug transport, DNA repair and also genes involved in drug resistance and 
sensitivity.
24, 28, 29
 Nevertheless, best to the author’s knowledge, this work 
represents their first use to study the mechanism of action of light activated drugs. 
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Figure 5.13: Schematic illustration of the S-phase checkpoint in fission yeast, 
where the Rad3 is recruited on the ssDNA region through the binding partner 
Rad26. Then Rad3 phosphorylates Mrc1 which is required for the efficient 
phosophorylation of Cds1 by Rad3. Cds1 switches on DNA repair. Taken from 
reference.
30
  
 
The sensitivity of the Rad3 mutant towards the Pt(IV)-diazido complex (Figure 
5.8) indicates that the DNA is a target for this kind of compound. However, the 
WT strain also showed toxicity especially at high drug concentrations (>200 μM), 
suggesting the existence of multiple mechanisms of action (e.g. oxidative stress 
caused by the complex). For the 100 and 200 μM concentrations, the difference in 
survival between the two strains is significant, suggesting that the DNA damage 
triggered can be repaired, thus enhancing the survival of the WT cells (Figure 
5.9). The Pt(IV)-diazido complexes can damage DNA through the release of 
radicals or through DNA platination (Figure 1.15, Chapter 1). Reactive oxygen 
species can produce DNA lesions via base modification, induction of inter and 
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intrastrand crosslinks, promotion of DNA-portein crosslinks or creating strand 
breaks.
31
 However the ROS can cause oxidation of other vital cellular components 
such as proteins and membrane lipids, therefore triggering a DNA-independent 
cell death. These results suggest a concentration-dependent mechanism of action, 
where DNA damage can potentially play a major role.  
Notably the amount of complex 3 that is required to cause an effect is ca 20-fold 
higher than in mammalian cells. A similar result was observed for the cisplatin 
studies although in that case it was attributed to the reactivity and subsequent 
deactivation of the drug with the sulphur-rich culture media.
27
 In this case 
however, the inertness of Pt(IV) drugs, especially in PBS, could not account for 
this effect. A reasonable explanation can be the poor cell uptake of the Pt(IV) 
drugs, which is likely due to the presence of a cell wall, that can impede the 
uptake of some agents.
32
  
The assay was carried out by diluting first the yeast cells and then treating them 
with the drug, in this way only a small amount of compound is required. The 
experiment was also attempted with a different protocol, in which the cells were 
seeded in larger numbers and counted, diluted, photoactivated and then plated on 
YEA media. The distinction between the cell survival of the two strains was then 
less obvious, leading to complete cell death in most of the cases. This can be due 
to the fact that the time between activation and plating into the YEA culture media 
was longer (ca 2 hours), allowing longer exposure to the irradiated medium and 
also a longer time before cells were allowed to recover, making this approach less 
suitable for this assay.  
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5.5.4 Live-cell confocal microscopy  
The determination of the cell death pathway for a drug is not straight forward 
requiring the use of multiple markers. The application of real-time techniques can 
lead to significant improvements.
33
 Morphological changes can usually provide 
initial information about the cell death mechanism triggered. For example, in 
apoptosis cell shrinkage, nuclear condensation, blebbing and formation of 
apoptotic bodies usually take place. Necrosis on the other hand is usually 
manifested by an increasing translucent cytoplasm, organelle swelling and cell 
volume expansion.
33
 In autophagy, the appearance of autophagosomes within the 
cytoplasm can become evident.
34
  
Live cell imaging is a useful technique that can be used to visualize cells with 
minimal artefacts, as opposed to fixed cell microscopy. Furthermore, it is the best 
method for following kinetic events and it also gives the opportunity to study 
whole cells rather than looking at organelle-specific techniques which can lead to 
erroneous results.
35
 Nevertheless, challenges in performing live cell experiments 
include the difficulty of maintaining the cells healthy for prolonged periods of 
time outside the incubator, the focal drift due to cell movement, as well as 
potential phototoxicity induced by the continuous exposure to the laser of the 
microscope.
35
 
The original idea was to activate the drug in cells in situ using the microscope’s 
laser. This proved to be difficult, as control cells which were exposed for long 
times to the laser light underwent cell death. This was attributed to components 
within the cell media that cause oxidative stress via radical production when 
exposed to light. Studies reported in the literature confirmed that the riboflavin 
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contained in the media (e.g. 0.2 mg/ L in RPMI-1640) is likely to be the main 
component responsible for such effects, although L-tryptophan (5 mg/ L) 
enhances the effects of riboflavin.
36, 37, 38
 Therefore for this method to be 
successful more optimization is required (e.g. potential addition of antioxidants).  
Irradiation of the complex in PBS with a blue LED (463 nm, 5 min) resulted in a 
better survival of the untreated controls, allowing imaging of the uptake of 
propidium iodide (PI), a marker of cell death without artefacts. PI-related 
fluorescence was only observed in the drug-treated plus irradiated cells 
approximately 2 h 30 min post activation (Figure 5.11), indicating a relatively fast 
process. 
In comparison, morphological changes for cisplatin treated ASTC-a-1 cells 
(human lung adenocarcinoma) showed the typical hallmarks of apoptotis 16 hours 
post-treatment.
39
 A similar result was also reported with 5637 cells,
7
 suggesting 
that the DNA-damaging effect of cisplatin -which eventually leads to apoptosis- is 
a relatively slow process. Also, time-lapse analysis of actinomycin D (a strong 
apoptosis inducer) has shown propidium iodide uptake 5 hours 48 min after drug 
exposure.
35
  
The morphological images captured after 16 hours following photoactivation 
resemble those reported for the autophagic cell death of HL60 cells treated with 
trans, trans, trans-[Pt(N3)2(OH)2(pyr)(NH3)] and activated by UVA (image in 
Chapter 1).
5
 Although morphological changes cannot be used as a stand-alone 
method for identifying cell death, the absence of the typical apoptosis markers 
along with the timing of cell death (Figure 5.12), can lead to the conclusion that 
also in the case of trans, trans, trans-[Pt(N3)2(OH)2(pyr)2], apoptosis is not 
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induced. However it must be noted that the pathway which a cell uses to die upon 
exposure to an agent is dose-dependent. It was shown that at low and high 
concentrations of a drug apoptosis or necrosis respectively can be triggered.
40
 In 
photodynamic therapy all three types of cell death have been identified.
11
 
5.6 Conclusions 
Complexes of the general formula trans, trans, trans-[Pt(N3)2(OH)2(L1)(L2)], 
where L1 and L2 are ligands such as pyridine, 2, 3, 4-picoline, thiazole or 1-
methylimidazole, synthesized and characterized in the previous chapter, were 
irradiated in the presence of 5’-GMP and showed to form adducts with an average 
yield of 59% with respect to the platinum centre.  
Irradiation studies of the sterically hindered 2-picoline complex, trans, trans, 
trans-[Pt(N3)2(OH)2(2-pic)(pyr)], followed by 
1
H, 
195
Pt-NMR and LC-MS showed 
the formation of the [Pt(N3)(2-pic)(pyr)(5’-GMP)] whereas the bis-GMP adduct 
([Pt(2-pic)(pyr)(5’-GMP2)] only formed slowly over time in the dark. 
In phototoxicity studies (λ= 420 nm) on A2780, A2780cis and OE19 cell lines 
with the (pyridine)(n-picoline) family, the 2-picoline complex was the least toxic 
with an IC50 3.6 μM, 2.7 fold higher than that of 3-picoline and 4-picoline, 
respectively. This suggests that steric hindrance close to the platinum centre does 
not favour phototoxicity, possibly due to the slow formation of bifunctional 
adducts. The most active complexes were the trans,trans,trans-[Pt(N3)2(OH)2(4-
pic)2]  (IC50 = 2.1 μM) and trans,trans,trans-[Pt(N3)2(OH)2(thiazole)2] complexes 
(IC50 = 2.4 μM), although the latter showed some dark toxicity (PI (phototoxic 
index) = 48). Most of the complexes studied here were equally potent in cisplatin 
resistance ovarian cancer cell line (A2780cis), except trans,trans,trans-
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[Pt(N3)2(OH)2(3-pic)2] and trans,trans,trans-[Pt(N3)2(OH)2(4-pic)2] which 
exhibited some cross resistance. All of the complexes tested in both A2780 and 
oesophageal (OE19) cell lines showed less sensitivity to OE19 cancer cells 
(average IC50 in A2780 and OE19, 3.5 μM and 8.4 μM, respectively). 
Studies of trans,trans,trans-[Pt(N3)2(OH)2(pyr)2] in S. pombe yeast strains (WT 
and ΔRad3) to probe the role of DNA in photocytotoxicity resulted in a decrease 
in the survival of the Rad3 mutant (e.g. with the use of 200 μM complex, survival 
reduced from 57% to 0.4%) due to impaired DNA repair in ΔRad3, suggesting 
that DNA is potentially an important target for this class of compounds. However 
the fact that there is significant cell death in the WT (with 200 and 300 μM) also 
suggests that these complexes are multi-targeting.  
Live-cell confocal microscopy performed on A2780 cells treated with the 
aforementioned complex (3) and irradiated with a low dose of blue light (463 nm, 
17 J/cm
2
) resulted in cell death 2 h 30 min post-activation. The phase-contrast 
images did not illustrate the morphological changes typical of apoptosis, 
suggesting that the cell death mechanism could be either via necrosis or 
autophagy. This work appears to be the first example of a real-time study of 
photoactivation of a Pt(IV)-diazido complex in cells and it shows that with the use 
of appropriate conditions and lasers, these photoactivatable complexes can be 
studied with confocal microscopy.  
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6.1 Conclusions 
This thesis describes the synthesis, characterisation as well as chemical and 
biological photochemical studies of trans-diazido Pt(IV) complexes with the 
prospect of being used as anticancer agents for photoactivated chemotherapy. A 
variety of techniques have been employed such as NMR, HPLC, LC-MS, UV-
Vis, mammalian and yeast cell studies and confocal microscopy.  
Functionalization of an axial hydroxido group to obtain Pt(IV)- azido complexes 
with general formula trans, trans, trans-[Pt(N3)2(OH)(OCOR)(pyr)2], reported in 
Chapter 3, was achieved by reaction of the dihydroxido precursor trans, trans, 
trans-[Pt(N3)2(OH)2(pyr)2] with anhydrides (succinic anhydride and N-
methylisatoic anhydride). Further derivatisations of the trans, trans, trans-
[Pt(N3)2(OH)(Succ)(pyr)2] were carried out via coupling to 1-propanol, in order to 
afford a neutral and more lipophilic complex, as well as to the (RGD)f peptide (a 
tumour targeting peptide) to increase the selectivity of the complex towards 
cancer cells. The synthesis of the seven trans, trans, trans-[Pt(N3)2(OH)2(L1)(L2)] 
complexes reported in Chapter 4, where L1 and L2 can be pyridine, picoline, 
thiazole or 1-methylimidazole ligands, was achieved by oxidation of the Pt(II)-
diazido precursors trans-[Pt(N3)2(L1)(L2)]. 
The X-ray crystal structures of seven Pt(IV)-diazido complexes have been 
obtained in this work, including the first examples of mono-carboxylato diazido 
Pt(IV) complexes reported up to date. All complexes show an octahedral 
geometry with [N4O2] coordination environment around the platinum centre. 
Slight distortions from the ideal geometry were observed in the complexes 
bearing two different ligands in trans position, as indicated by deviations from the 
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o 
angle between ligands. In the case of the monocarboxylato complexes the 
average lengths of the Pt–O(H) and Pt–O(COR) bonds were 1.978 Å and 2.035 Å, 
respectively, indicating a potential lability of the carboxylate with respect to the 
hydroxido ligand. The intermolecular forces in all of the cases are dominated by 
moderately strong H-bonding between the hydroxido and the Pt-bound Nα of the 
azide.  
The photodegradation kinetics were studied by UV-Vis spectroscopy and the 
exponential decrease in intensity of the N3→Pt LMCT band was followed to 
determine the half-lives of the complexes. For trans, trans, trans-
[Pt(N3)2(OH)2(L1)(L2)] family of complexes, the steric hindrance created by the 
methyl group in the ortho position of the 2-picoline ligand, favoured an increased 
rate of photodegradation upon irradiation with blue light (463 nm) as the half-life 
decreased by 2.5-fold when compared to the average half-life of the other 
complexes (20-25 minutes). A 3-fold decrease in the half-lives of the trans, trans, 
trans-[Pt(N3)2(OH)(OCOR)(pyr)2] complexes was observed in comparison to the 
dihydroxido complex when irradiated with green light (517 nm). Therefore it can 
be concluded that axial ligand modifications with the carboxylato functionality as 
well as the steric effect induced by the methyl substitution on the pyridine ligand 
are beneficial in the photolability of the complexes.  
DFT and TDDFT calculations on the complexes of [Pt(N3)2(OH)(Succ)(pyr)2] 4 
and [Pt(N3)2(OH)2(pyr)(2-pic)] 18 show higher and longer intensity transitions in 
the 410-470 nm region when compared to complex trans, trans, trans-
[Pt(N3)2(OH)2(pyr)2], which support the experimental data of improved 
photoactivity at the longer wavelengths.  
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1
H and 
195
Pt-NMR were used for photoproduct analysis from irradiations of 
selected complexes with 2 mol eq of 5’-GMP in order to follow the 
photochemical behaviour of these complexes in the presence of biomolecules. 
Irradiation of complex trans, trans, trans-[Pt(N3)2(OH)(Succ)(pyr)2] resulted in 
the formation of the mono-GMP adduct in a 2.6-fold greater proportion than for 
[Pt(N3)2(pyr)2(OH)2] 3 when irradiated with the same dose of 463 nm light. 
Studies of complex [Pt(N3)2(OH)(N-MI)(pyr)2] 6 were carried out in MeOD due 
to the poor solubility of the complex in water. The release of the axial ligand N-
MI was observed, but no significant 5’-GMP binding was found. Furthermore, the 
release of pyridine was observed, especially when the irradiation was carried out 
with a low dose of UVA which is a result similar to that obtained when the 
dihydroxido complex [Pt(N3)2(OH)2(pyr)2] 3 was irradiated under the same 
conditions, indicating the effect of the solvent on the type of photoproducts 
formed. However, the release of the axial N-methylisatoate (N-MI) ligand in an 
aqueous environment was confirmed by fluorescence emission studies where an 
increase in the intensity of the fluorescence band at 420 nm was observed upon 
continuous irradiation. This fluorescence band matches the emission wavelength 
of the free ligand (N-MIA), which was synthesized independently for comparison 
purposes. 
Irradiation of complex [Pt(N3)2(OH)2(pyr)(2-pic)] 18 at a high concentration (9 
mM) in the presence of 5´-GMP (2 mol eq) showed the production of the mono-
GMP adduct. The presence of the bulky 5’-GMP ligand caused restricted rotation 
of the 2-picoline ligand, as shown by the broadness of H6 and H5 
1
H-NMR 
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resonances (Figure 5.4, Chapter 5). Slow formation of the bis-GMP adduct was 
observed over time after keeping the solution in the dark at room temperature. 
To obtain further information with regard to the photoproducts upon irradiation 
with 420 nm of the complexes trans, trans, trans-[Pt(N3)2(OH)(Succ)(pyr)2] 4 and 
trans, trans, trans-[Pt(N3)2(OH)(Succ-(RGD)f)(pyr)2] 7 in the presence of 5’-
GMP (2 mol eq), LC-MS studies were undertaken. The photoproducts in this case 
were shown to be identical with a major product, the mono-GMP Pt(II) adduct. 
The release of the intact peptide moiety from trans, trans, trans-
[Pt(N3)2(OH)(Succ-(RGD)f)(pyr)2] 7 was observed, showing that in a cellular 
environment, as soon as the complex selectively enters the tumour cells, light 
activation will liberate the active Pt(II) moiety.  
The pathway of the photoreduction of these complexes, regardless of the nature of 
the axial ligand (OH or OCOR) involves the release of azidyl radicals, which were 
shown by previous reports to play an important role in the phototoxicity of this 
type of complexes. The fact that the carboxylato complexes trans, trans, trans-
[Pt(N3)2(OH)(Succ) (pyr)2] 4 and trans, trans, trans-[Pt(N3)2(OH)(Succ-Pr)(pyr)2] 
5 (at 1 mM concentration) show release of azidyl radicals in water upon green 
light (517 nm) activation constitutes an important advantage of this class of 
complexes. The highest yield of trapped radicals [DMPO-N3] was observed for 
the complex [Pt(N3)2(OH)(Succ-Pr)(pyr)2] at a concentration 68 μM, whereas the 
dihydroxido complex [Pt(N3)2(OH)2(pyr)2] 3 did not generate any radicals at this 
wavelength.  
Cellular uptake studies in A2780 cells after 1 hour incubation in the dark, were 
performed on the complexes reported in Chapter 3: trans, trans, trans-[(Pt(N3)2 
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(OH)2(pyr)2] 3, trans, trans, trans-[Pt(N3)2(pyr)2(OH)(Succ)] 4, 
[Pt(N3)2(pyr)2(OH)(Succ-Pr)]  5 and trans, trans, trans-[Pt(N3)2(pyr)2(OH)(N-
MI)] 6. The uptake increased by 1.7-fold when comparing 4 and 5 and 
interestingly by 10-fold when comparing complexes 3 and 6. Temperature 
dependence studies on complexes 3 and 6 showed that the uptake is greatly 
facilitated by active transport as there is an increase in uptake when the 
temperature increases from 4 
o
C to 37
 o
C (5-fold and 2-fold in the cases of 3 and 
6, respectively). However the fact that there is still uptake even at 4
o
C shows that 
passive uptake is also involved.  
The phototoxicity of the complexes reported in this thesis was tested in the dark 
and with a low dose of blue light (420 nm, 5 J/cm
2
) against ovarian (A2780 and 
A2780cis) and also oesophageal (OE19) cancer cell lines. The only complexes 
that showed dark toxicity towards A2780 were complex [Pt(N3)2(OH)2(thiazole)2] 
29 (Phototoxic Index (PI)= 48) and [Pt(N3)2(OH)2(pyr)(2-pic)] 18 (PI= 7.3). The 
least phototoxic complexes were [Pt(N3)2(OH)2(1-methylimidazole)2] 32 (IC50 
56.3 μM) and [Pt(N3)2(OH)2(2-pic)(pyr)] 18 (IC50 14.5 μM). The lack of activity 
of the former could be attributed to low cellular uptake as the high solubility of 
the complex (82 mM) implies high hydrophilicity. The steric hindrance close to 
the platinum centre created by the 2-picoline ligand in the latter could hinder the 
formation of bifunctional DNA adducts.  
Complexes [Pt(N3)2(OH)(Succ)(pyr)2] 4 and [Pt(N3)2(OH)(Succ-Pr)(pyr)2] 5 also 
showed an improved activity (IC50 values of 3.6 μM and 3.7 μM) when compared 
to [Pt(N3)2(OH)2(pyr)2] 3 (IC50= 6.7 μM) although all of them gave rise to the 
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same Pt(II) photoproducts. This suggests that the enhanced photoactivity is 
beneficial for obtaining more active complexes. 
Finally, yeast and confocal microscopy studies carried out on complex 3 provided 
new tools for the study of Pt(IV)-diazido photoactivatable complexes. Survival 
studies with WT and ΔRad3 mutants of S. pombe showed a decrease in survival 
(from 57% to 0.4%) when the complex was irradiated with blue light (420 nm). 
Since the mutant is unable to repair DNA, these results suggest that the DNA can 
be a significant target for this class of complexes. Live cell confocal microscopy 
performed on A2780 cells with the same complex captured for the first time the 
live-cell death triggered only by photoactivation with blue light (463 nm). The 
uptake of propidium iodide was monitored over time and the first signs of cell 
death were captured 2h 30 min post activation. 
6.2 Future Work 
This section will explore possible future work which can be carried on based in 
the results described in the previous chapters.  
6.2.1 Axial ligand modifications  
Several axial ligand modifications could be carried out by derivatising an already 
existing axial ligand or by substitution of the hydroxide ligands in the precursor 
Pt(IV)-dihydroxido complexes.  
Complex [Pt(N3)2(OH)(succ)(pyr)2], 4 described in Chapter 3, provides the 
potential for coupling with moieties which can confer imaging or targeting 
capabilities to the Pt(IV)-diazido prodrugs. A chromophore attachment can 
enhance the light harvesting capabilities of the complex. For example Ford et al
1
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have shown that attachment of RSE chromophore to Roussin’s red salt ester 
([Fe2(μ-RS)2(NO)4]) resulted in efficient energy transfer from the chromophore to 
the metal centre enabling the release of NO at longer wavelength.  
Attachment of L-tryptophan (Figure 6.1 A) onto complex 4 is also an interesting 
possibility to explore the effect on the phototoxicity since L-tryptophan is a 
radical quencher. A preliminary synthesis was carried out through a CDI-
mediated (carbonyldiimidazole) coupling reaction to the monocarboxylato 
complex 4. However, further purification is required since two tryptophans were 
found to be coupled to the platinum complex: potentially one through the 
carboxylic acid and the second through the axial hydroxide ligand.   
Other functional groups (e.g. various alcohol or ammines) can be incorporated 
onto the carboxyl group of complex 4 to enable the study of structure-activity 
relationship with regards to the axial group. Furthermore, a potential correlation 
between photoreactivity with electrode potentials is an interesting avenue to be 
explored.  
Different molecules can also be incorporated as axial ligands, such as TFA 
(trifluoroacetate) or DCA (dichloroacetate), as shown in Figure 6.1 B and C. 
Incorporation of TFA ligands in the Pt(dach)(L)(L’), where L= acetate or TFA 
and L’=oxalate showed that the TFA bearing complexes had superior in vivo 
activity due to increased cellular accumulation.
2
 The facile reaction of the 
hydroxide ligands of the Pt(IV)-diazido complexes with TFA (trifluoroacetic acid) 
has already been shown in the present work (Chapter 3) therefore it will be 
interesting to demonstrate the effect of the TFA ligands on the photolability of the 
Pt(IV) complexes. Another ligand which would be interesting to attach instead of 
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the axial hydroxides is dichloroacetate (DCA), a pyruvate dehydrogenase 
inhibitor. The incorporation of DCA in mitaplatin, cis ,trans, cis-
[Pt(NH3)2(dca)2Cl2] led to the formation of a potent complex with dual mode of 
action.
3
 
 
Figure 6.1: Proposed complexes to be explored. A and B have been synthesized 
in preliminary attempts but their synthesis requires further optimization.  
 
Complex [Pt(N3)2(OH)(N-MI)(pyr)2] 6, has two important features which provide 
beneficial application for imaging experiments in cells: its high cellular 
accumulation and a fluorophore ligand that could be released for confocal 
microscopy studies. IR-mapping of the azides within cells (collaboration with 
Prof Clotilde Policar) was attempted in MCF-7 cells treated with complex 3 after 
fixing them onto ZnS and CaF2 windows but no signals were observed under 
these conditions. However, the high cellular uptake of the complex 
[Pt(N3)2(OH)(N-MI)(pyr)2] 6, could lead to successful Pt-azide IR mapping.  
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6.2.2 Further work on equatorial ligand modifications  
Firstly, cell uptake studies are important to be carried out for the 
[Pt(N3)2(OH)2(L1)(L2)] (Chapter 4) family of complexes which can provide an 
insight to explain the lack of activity of [Pt(N3)2(OH)2(1-mim)2], 32.   
Furthermore the lower photototoxicity of [Pt(N3)2(OH)2(2-pic)(pyr)] compared to 
the [Pt(N3)2(OH)2(n-pic)(pyr)] or [Pt(N3)2(OH)2(n-pic)2] family of complexes, 
despite its fast photoreduction kinetics, could be explained by the mode of 
interaction of Pt(II) photoproducts with DNA. Therefore characterisation studies 
of adducts with plasmid DNA interactions analysed by electrophoresis, similar to 
those reported by Pracharova et al 
4
 are proposed future experiments.  
The survival studies with S. pombe reported in Chapter 5 can be utilized to 
explore other cellular targets and modes of action of Pt(IV)-diazido complexes. 
For example, it has been shown by Farrell et al., that trans planar amine Pt(II) 
complexes have the ability to form crosslinks with DNA and topoisomerase I, 
suggesting that topoisomerases can be a potential target for the Pt(IV)-diazido 
complexes.
5, 6
 Studies comparing the survival of TopI mutant versus WT in the 
presence of a Pt(IV)-diazido drug should show an increase of survival in the TopI 
mutant if enzyme inhibition takes place.  
Further modifications of the eqatorial ligands can also involve modifications via 
the azide. The azide-alkyne cycloadditions have long been known in the literature 
but a great majority require Cu(I) catalysts.
7
 Preliminary work within our group 
(Farrer et al, unpublished data) on complex trans, trans, trans-
[Pt(N3)2(OH)2(pyr)2] 3 has shown that the azides can react with only electron-
withdrawing acetylenes (dimethyl acetylenedicarboxylate, DMAD and diethyl 
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acetylenedicarboxylate, DEACD) on one or both azides to produce 
monofunctional and bifunctional adducts. A pure product was obtained by the 
reaction (Figure 6.2) of complex trans-[Pt(N3)2(pyr)2] 2, with DMAD. The azides 
coordinated to Pt(II) are more electron rich
8
 thus facilitating the cycloaddition 
reaction. The presence of the two different resonances corresponding to methyl 
groups in the 
1
H-NMR spectra (Appendix) suggested that the triazole is 
coordinated to the Pt through the Nα.  
 
Figure 6.2: Synthetic scheme for reaction between complex trans-[Pt(N3)2(pyr)2] 
2, and DMAD.  
 
The controlled functionalization of the azides via cycloaddition can provide an 
easy method for the derivatisation of the complexes with fluorescent tags or 
peptides. 
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APPENDIX 
 
Table A1: Compounds and atom numbering. Ligands are denoted as: Pyr= 
pyridine; Succ= succinate; Succ-Pr= 4-oxo-4-propoxybutanoate; N-MI= N-
methylisatoate; Succ-(RGD)f= succinate coupled with (RGD)f peptide; pic= 
picoline; tz= thiazole; mim= 1-methylimidazole. 
 
Name N
o
 Structure 
trans-[Pt(Cl)2(pyr)2] 1 
 
trans-[Pt(N3)2(pyr)2]  2 
 
trans, trans, trans-
[Pt(N3)2(OH)2(pyr)2] 
3 
 
trans, trans, trans-
[Pt(N3)2(OH)(Succ)(pyr)2] 
4 
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trans, trans, trans-
[Pt(N3)2(OH)(Succ-Pr)(pyr)2] 
5 
 
trans, trans, trans-
[Pt(N3)2(pyr)2(OH)(N-MI)] 
6 
 
trans, trans, trans-
[Pt(N3)2(OH)(pyr)2(Succ-
(RGD)f)] 
7 
 
N-methylisatoic acid  
(N-MIA) 
L1 
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cis-[Pt(I)2(pyr)2] 8 
 
cis-[Pt(Cl)2(pyr)2] 9 
 
cis-[Pt(I)2(2-pic)2] 10 
 
cis-[Pt(Cl)2(2-pic)2] 11 
 
trans-[Pt(Cl)2(pyr)(2-pic)] 12 
 
trans-[Pt(Cl)2(pyr)(3-pic)] 13 
 
trans-[Pt(Cl)2(pyr)(4-pic)] 14 
 
Appendix 
 
252 
 
trans-[Pt(N3)2(pyr)(2-pic)] 15 
 
trans-[Pt(N3)2(pyr)(3-pic)] 16 
 
trans-[Pt(N3)2(pyr)(4-pic)] 17 
 
trans, trans, trans-
[Pt(N3)2(OH)2(pyr)(2-pic)] 
18 
 
trans, trans, trans-
[Pt(N3)2(OH)2(pyr)(3-pic)] 
19 
 
trans, trans, trans-
[Pt(N3)2(OH)2(pyr)(4-pic)] 
20 
 
trans-[Pt(Cl)2(3-pic)2] 21 
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trans-[Pt(N3)2(3-pic)2] 22 
 
trans, trans, trans-
[Pt(N3)2(OH)2(3-pic)2] 
23 
 
trans-[Pt(Cl)2(4-pic)2] 24 
 
trans-[Pt(N3)2(4-pic)2] 25 
 
trans, trans, trans-
[Pt(N3)2(OH)2(4-pic)2] 
26 
 
trans-[Pt(Cl)2(tz)2] 27 
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trans-[Pt(N3)2(tz)2] 28 
 
trans, trans, trans-
[Pt(N3)2(OH)2(tz)2] 
29 
 
trans-[Pt(Cl)2(mim)2] 30 
 
trans-[Pt(N3)2(mim)2] 31 
 
trans, trans, trans-
[Pt(N3)2(OH)2(mim)2] 
32 
 
5’-Guanosine 
Monophosphate 
(5´-GMP) 
33 
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Figure A1: Output of Light Sources. (a) UVA lamps (Hitachi) fitted in the LZC-
ICH2 photoreactor; (b) 420 nm lamps (Luzchem) fitted in the LZC-ICH2 
photoreactor; (c) 463 nm, LED; (d) 517 nm, LED; (e) 550 nm KiloArc, fitted 
with GG530 filter, 4 nm slit widths. 
200 250 300 350 400 450 500 550 600 
Wavelength (nm) 
(d) 
200 250 300 350 400 450 500 550 600 
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(a) 
 
 
(b) 
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(c) 
 
Figure A2: UV-Vis spectra of some complexes presented in Chapter 4 upon 
photoirradiation with 517 nm (30 mW/cm
2
): (a) complex trans, trans, trans-
[Pt(N3)2(OH)2(pyr)(2-pic)] 18, (b) complex trans, trans, trans-
[Pt(N3)2(OH)2(pyr)(3-pic)] 19 and (c) complex trans, trans, trans-
[Pt(N3)2(OH)2(pyr)(4-pic)] 20, respectively. The graphs show the decrease in 
intensity of the N3→Pt LMCT absorption band upon continuous irradiation at ca. 
20 
o
C. 
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Figure A3: 
1
H-COSY NMR spectrum (600 MHz) of complex trans, trans, trans-
[Pt(N3)2(OH)2(pyr)(2-pic)] 18 upon photoirradiation (420 nm, 7 mW/cm
2
, 45 min) 
in the presence of 5’-GMP (2 mol equiv). The correlated signals correspond to the 
trans-[Pt(N3)(5’-GMP)(pyr)(2-pic)] adduct.  
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Figure A4: 
1
H-NMR (600 MHz) of the [Pt
II
(4,5-dicarbamethoxy-1,2,3-
triazole)2(pyr)2] produced by the click reaction of DMAD to [Pt(N3)2(pyr)2]. The 
peaks at 3.9 and 3.7 ppm are assigned to the two methyl groups on the triazole.  
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